Advancing Opportunity
Kraton Performance Polymers
2013 Annual Report
K
r
a
t
o
n
P
e
r
f
o
r
m
a
n
c
e
P
o
y
m
e
r
s
l
2
0
1
3
A
n
n
u
a
l
R
e
p
o
r
t
Kraton Performance Polymers, Inc.
15710 John F. Kennedy Boulevard
Suite 300
Houston, Texas 77032
Phone: 281-504-4700
Kraton At A Glance
Financial Highlights
(In thousands, except per share data)
2013
2012
2011
Year Ended December 31,
Operating revenues
Income from operations
Net income (loss) attributable to Kraton
EBITDA(1)
Adjusted EBITDA(1)
Adjusted EBITDA at ECRC(1)
Earnings (loss) per common share – diluted
Cash flows from operating activities
Capital expenditures
Working capital
Long-term debt, net of current portion
Total stockholders’ equity
$ 1,292,121
$ 25,078
$ (618)
$ 88,790
$ 110,169
$ 140,906
$ (0.02)
$ 105,456
$ 86,205
$ 478,148
$ 350,989
$ 554,398
$ 1,423,122
$ 31,888
$ (16,191)
$ 96,972
$ 113,309
$ 143,842
$ (0.50)
$ 146,333
$ 69,609
$ 552,875
$ 432,943
$ 492,215
$ 1,437,479
$ 123,849
$ 90,925
$ 184,128
$ 194,327
$ 127,995
2.81
$
$ 64,775
$ 64,440
$ 504,445
$ 385,000
$ 517,794
(1) EBITDA represents net income before interest, taxes, depreciation and amortization. Adjusted EBITDA at estimated current replacement cost (ECRC) is Adjusted EBITDA net of
the impact of the spread between the FIFO basis of accounting and ECRC. A reconciliation of net income or loss attributable to Kraton to EBITDA, Adjusted EBITDA and Adjusted
EBITDA at ECRC is presented in Item 6 of the Annual Report on Form 10-K for the year ended December 31, 2013 included in this annual report.
Corporate Profile
Kraton Performance Polymers, Inc. (NYSE: KRA) is a leading global producer of engineered polymers used to enhance
the performance of products that touch virtually every aspect of our lives. The original inventor of styrenic block copolymer
(SBC) chemistry in the 1960s, Kraton has a history of innovation dating back almost 50 years that drives growth for its
customers. The company has a broad portfolio of value-enhancing polymers that are used in a wide variety of appli cations
including consumer and personal care items, adhesives and coatings, electronics, medical supplies, automotive com-
ponents, and paving and roofing materials. Kraton offers its products to a diverse group of more than 800 customers
in over 60 countries worldwide and collaborates with customers on custom solutions to meet specific needs.
Our Mission
Our Vision
Our Core Values
Create exceptional value
by “Giving Innovators Their
Edge®” better than all others
in the industry we lead.
Guided by our Core Values,
we will be an admired
Fortune 500 specialty
chemical company with
consistent earnings per
share growth, a sustaining
Vitality Index, industry-
leading margins, delivering
returns above our cost
of capital.
The health of our people
Compliant, respectful and ethical behavior
Talented people, enthusiastic teams
Safety:
Integrity:
Verve:
Relationships: Our customers and all other stakeholders
Innovation:
Results:
Creative solutions
Making it happen...Safely!
Shareholder Information
Investor Relations, Form 10-K
and Other Information
We will furnish without charge to each
person whose proxy is being solicited,
upon request of any such person, a
copy of our Annual Report on Form
10-K for the year ended December 31,
2013, as filed with the Securities and
Exchange Commission, including the
consolidated financial statements and
schedules thereto, but not the exhibits.
Our Annual Report on Form 10-K as
filed with the Securities and Exchange
Commission is also available on our
website under the “Investor Relations”
tab at www.kraton.com. Information
on our website or any other website
is not incorporated by reference into
or otherwise made a part of this report.
Please contact:
Investor Relations
Kraton Performance Polymers, Inc.
15710 John F. Kennedy Boulevard
Suite 300
Houston, Texas 77032
Phone: 281-504-4700
E-mail: Investor.Relations@Kraton.com
Transfer Agent and Registrar
If you have any questions regarding
your stock certificate or changes
to your address, please contact:
Computershare Investor Services
250 Royall Street
Canton, Massachusetts 02021
Phone: 303-262-0678
Directors and Officers
Board of Directors
Dan F. Smith 2, 3*
Chairman,
Former Chairman, President
and Chief Executive Officer,
Lyondell Chemical Company
Richard C. Brown 2*, 3
Managing Director,
Sun Capital Partners, Inc.
Anna C. Catalano 2
Former Group Vice President, BP plc
Steven J. Demetriou 4*
Chairman and Chief Executive Officer,
Aleris International, Inc.
Kevin M. Fogarty 3
President and Chief Executive Officer,
Kraton Performance Polymers, Inc.
Dominique Fournier 4
Former Chief Executive Officer,
Infineum International, Limited
John J. Gallagher, III 1, 4
Chief Executive Officer,
Stellar CJS Holdings, LLC
Barry J. Goldstein 1*, 4
Retired Executive Vice President
and Chief Financial Officer,
Office Depot, Inc.
Francis S. Kalman 1
Former Executive Vice President,
McDermott International, Inc.
Karen A. Twitchell 1, 2
Former Executive Vice President
and Chief Financial Officer,
Landmark Aviation
Committees
1 Audit
2 Compensation
3 Executive
4 Nominating and Corporate Governance
* Denotes Chairperson
Corporate Officers
Kevin M. Fogarty
President and Chief Executive Officer
Thomas A. Abrey
Vice President, Health, Safety,
Environmental and Security
Damian T. Burke
Vice President, Corporate Development
Melinda S. Conley
Vice President, Human Resources
Stephen W. Duffy
Vice President, General Counsel
and Secretary
Lothar P.F. Freund
Vice President, Technology
Holger R. Jung
Vice President, Sales and Marketing
G. Scott Lee
Vice President, Operations
Stephen E. Tremblay
Vice President, Chief Financial Officer
Independent Auditors
KPMG
Suite 4500
811 Main Street
Houston, Texas 77002
Stock Exchange Listing
Kraton Performance Polymers, Inc.
Common Stock is listed on the
New York Stock Exchange under
the symbol KRA.
Annual Meeting
The company’s annual meeting
of shareholders is scheduled
for Tuesday, June 3, 2014, at
1:00 p.m. at:
Sheraton North Houston
15700 John F. Kennedy Boulevard
Houston, Texas 77032
X
T
,
N
O
T
S
U
O
H
,
S
D
N
A
R
B
E
G
A
V
A
S
:
I
N
G
S
E
D
Forward-looking Statements
Some of the statements in this annual report to stockholders contain forward-looking statements within the meaning of the Private Securities Litigation
Reform Act of 1995, including, without limitation, discussions of strategy, plans or intentions; anticipated benefits of or performance of our products;
beliefs regarding opportunities for new, high-margin applications and other innovations; our investment in the joint venture with Formosa Petrochemical
Corporation; our proposed combination with the Styrenic Block Copolymer (“SBC”) business of LCY Chemical Corp. (“LCY”), the expectation that such
combination will close in the fourth quarter of 2014 and expected synergies and other benefits therefrom and costs associated therewith; expectations
regarding high-margin applications; our plans and expectations regarding our planned Asia expansion project; and our expectations regarding the
startup of our semi-works facility in Belpre, Ohio, during the first quarter of 2014. Such forward-looking statements involve known and unknown risks,
uncertainties, assumptions and other important factors that could cause the actual results, performance or our achievements, or industry results, to differ
materially from historical results, any future results, or performance or achievements expressed or implied by such forward-looking statements. Please refer
to our Annual Report on Form 10-K included herewith for further identification of forward-looking statements, and discussion of associated risks and
important factors that could cause our actual results to differ materially from those expressed as forward-looking statements. Forward-looking statements
are based on current plans, estimates and projections, and, therefore, you should not place undue reliance on them. Forward-looking statements speak
only as of the date they are made, and we undertake no obligation to update them publicly in light of new information or future events.
DO
NOT
USE
Adhesives, Sealants
and Coatings
Kraton™ polymers impart flexibility,
improved adhesion, toughness, and
water and chemical resistance to a
variety of products in the adhesives,
sealants and coatings markets.
Advanced Materials
Paving and Roofing
Cariflex™
Isoprene Rubber
Kraton pioneered soft-touch
applications, compounds and other
advanced material solutions that
have a myriad of applications from
consumer products and packaging
to wire and cable jacketing.
Kraton’s innovative, recyclable and
cost-effective asphalt-modification
polymers deliver superior durability
and elasticity over a broad range
of temperatures in paving and
roofing applications.
Available in solid or water-based
latex form, Cariflex isoprene rubber
(IR) offers a high-performance,
non-allergenic alternative to natural
rubber for applications that demand
extreme purity and performance.
2013 Overview
2013 Overview
2013 Overview
2013 Overview
The Adhesives, Sealants and Coatings
end use generated $478 million, or
37 percent of our total revenue in 2013,
on sales volume that was flat with
2012. The 6 percent revenue decrease
reflects lower average selling prices
associated with reductions in raw
material costs and a $5 million
adverse impact of foreign currency
exchange rates. Sales volume rose
in South America and Europe,
declined in North America and was
flat in Asia. Innovation sales volume
decreased compared to 2012, primarily
due to a shift in designation of
innovation products that have
been commercialized for more than
five years.
The Advanced Materials end use
generated $346 million, or 27 per-
cent of Kraton's 2013 revenue.
With sales volume essentially flat
compared to 2012, the 10 percent
revenue decrease largely reflects
lower average selling prices
associated with reductions in raw
material costs and a $2 million
adverse impact of changes in foreign
currency exchange rates. Increased
sales volume in Europe, Asia and
South America offset lower volume
in North America. Innovation sales
volume increased nearly 20 percent,
with higher sales of USBC innovation
grades more than offsetting lower
sales into wire and cable applications.
The Paving and Roofing end use
generated $351 million, or 27 per-
cent of Kraton’s 2013 revenue.
Sales volume decreased one percent
compared to 2012, with strong
volume in the second half of the
year offsetting the impact of adverse
weather in the first half, but sales
revenue declined 17 percent. In
addition to lower sales volume, the
revenue decrease reflects lower
average selling prices associated
with reductions in raw material
costs. Changes in foreign currency
exchange rates had a $2 million
favorable revenue impact compared
to 2012. Innovation sales volume
increased 32 percent.
Cariflex isoprene rubber (IR) sales
accounted for 9 percent of Kraton’s
total revenue in 2013. Sales revenue
was $116 million, up 10 percent
compared to 2012. Revenue growth
was driven by a 13 percent increase
in sales volume, reflecting strong
growth in surgical glove applications
partially offset by a $5 million
negative impact from changes in
foreign currency exchange rates.
Innovation sales volume increased
13 percent, led by higher sales of
isoprene rubber latex. During 2013,
we expanded our customer base
for Cariflex IR and IR latex, and
we continued to diversify our
sales geographically.
Applications
• Tapes and labels
• Non-woven and
industrial adhesives
• Clear sealants and
industrial coatings
• Protective films for industrial
and consumer applications
• Lubricant additives, consumer
and industrial gels
durable soft-touch products
• Engineering thermoplastics
• Personal care items
• PVC alternatives for medical
packaging, wire and cable,
automotive interiors, coated
fabrics and flooring
• Disposable food packaging
and closures
• Highly engineered polymer
modification
Applications
Applications
Applications
• Consumer disposable and consumer
• Asphalt modification for
performance roadways, bridges
and airports
• Asphalt modification for roofing
• Surgical gloves
• Condoms
• Catheters
• Medical stoppers and needle
felts and shingles
shield covers
• Consumer products
• Cold-seal adhesives for
food products
• Electronic industry applications
37% of 2013 Sales
27% of 2013 Sales
27% of 2013 Sales
9% of 2013 Sales
Advancing Opportunity 1
Fellow Shareholders
Two thousand thirteen was a year of
growing momentum for Kraton. We
made significant strides in advancing
our opportunities for growth and value
creation on several fronts. We continued
to increase our presence and participation
in Asia’s thriving markets, and we made
good progress with a number of innovation
platforms that set our company apart
from competitors.
“ Our investments in Asia reflect
our commitment to the region
and the opportunity for growth
it represents.”
In terms of our financial results, 2013
paralleled 2012. After a slow start, sales
volumes recovered in the second half on
strong business momentum leading to
full-year sales of 314 kilotons; essentially
unchanged from the previous year.
Lingering macro-economic weakness
in many parts of the world limited growth
in both our Advanced Materials and our
Adhesives, Sealants and Coatings end
uses. In contrast, our Cariflex™ end use
demonstrated continued growth, driven
by market demand for its differentiated
product offering.
One very positive change in 2013 was a
more stable price environment for raw
materials, particularly butadiene. After two
years of managing through extreme price
volatility, we welcomed the relative stability
of raw material prices that prevailed
through much of 2013, lessening volatility
in customer order patterns and in our
reported financial results. The 9 percent
decline in our revenue during 2013 was
largely due to a reduction in sales prices
associated with lower average raw
material costs.
Beyond the Numbers
Adjusted EBITDA on a current-cost basis
(ECRC) was $141 million, or nearly 11 per-
cent of revenue, for 2013. This compares
with $144 million of Adjusted EBITDA at
ECRC in 2012 when the associated margin
was 10 percent. Given that our sales
volume was essentially flat year-on-year,
the slight decrease in Adjusted EBITDA
at ECRC is largely due to incremental
operating costs as well as minor changes
in our sales mix. The incremental costs
included the initial expenses toward the full
replacement of coal-fired boilers at our
Belpre, Ohio, site to ensure compliance
with the Environmental Protection
Agency’s “MACT” legislation, and costs
associated with our proposed combination
with the styrenic block copolymer (SBC)
business of LCY Chemical Corp. (LCY).
A look beyond the overall numbers reveals
significant areas of strength. Our Paving
and Roofing end use, which was negatively
impacted by adverse weather through
April of 2013, rebounded sharply during
Additional Information and Where to Find It
THIS COMMUNICATION DOES NOT CONSTITUTE AN OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO BUY SECURITIES OF KRATON OR THE COMBINED COMPANY. KRATON WILL FILE A PROXY
STATEMENT/PROSPECTUS (AND RELATED REGISTRATION STATEMENT) AND OTHER DOCUMENTS WITH THE SEC. INVESTORS AND SECURITY HOLDERS ARE URGED TO CAREFULLY READ THE PROXY
STATEMENT/PROSPECTUS AND THE REGISTRATION STATEMENT (INCLUDING ANY AMENDMENT OR SUPPLEMENTS THERETO) WHEN THEY BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT
INFORMATION REGARDING KRATON, LCY AND THE COMBINATION. A DEFINITIVE PROXY STATEMENT/PROSPECTUS WILL BE SENT TO THE SECURITY HOLDERS OF KRATON SEEKING THEIR APPROVAL
OF THE COMBINATION. INVESTORS AND SECURITY HOLDERS MAY OBTAIN A FREE COPY OF THE PROXY STATEMENT/PROSPECTUS AND THE REGISTRATION STATEMENT (WHEN AVAILABLE) AND OTHER
DOCUMENTS FILED BY KRATON WITH THE SEC AT THE SEC’S WEBSITE AT WWW.SEC.GOV. THE PROXY STATEMENT/PROSPECTUS AND THE REGISTRATION STATEMENT AND OTHER SUCH DOCUMENTS
(RELATING TO KRATON) MAY ALSO BE OBTAINED FOR FREE FROM KRATON BY ACCESSING KRATON’S WEBSITE AT WWW.KRATON.COM.
2 2013 Annual Re po r t
2 2013 Annua l Re p or t
the second half of the year. We also saw
continued growth in demand for Cariflex
isoprene rubber and isoprene rubber latex.
Cariflex sales volumes grew 14 percent in
2013, and Cariflex now accounts for 9 per-
cent of Kraton’s total revenue.
We continue working to reshape
our portfolio, shifting its composition
to include more of the high-value
differentiated and innovation products
that set us apart. During 2013, we made
good progress with commercializing
and growing several of our innovation
platforms, and we closed the year with
a Vitality Index, which is the percentage
of total revenue coming from innovation
products, of 15 percent.
Winning Combinations
Asia is rapidly becoming the center of the
world for our industry. In addition to strong
GDP growth and substantial infrastructure
spending, Asia is a global hub for the
manufacturing and exportation of finished
products, and we believe it will account for
80 percent of future growth in worldwide
demand for SBCs. It is an area that
continues to produce attractive sales
growth for Kraton with robust demand for
our more profitable Cariflex and HSBC-
based products. In recent years, we have
made significant investments in increased
staffing, research and development
capabilities, and manufacturing
expansions to better serve our customers
and capture opportunities in this high-
potential region.
In moving to enhance our position in
Asia, we have forged mutually beneficial
relationships with key regional players.
We are building a 30 kiloton HSBC
manufacturing facility through a joint
venture with Formosa Petrochemical
Company (FPCC) and, in early 2014, we
announced an agreement to combine
Kraton with the SBC operations of
Taiwan-based LCY.
The proposed combination with LCY’s
SBC business, which remains subject
to various shareholder and regulatory
approvals, will create an industry leader
with more than $2 billion in annual
pro forma revenue, an improved
manufacturing cost position and a
diversified product portfolio. We expect
the transaction to be accretive to Kraton's
operating earnings starting in the first full
year of combined operations, which we
believe will be 2015. We expect substantial
cost synergies to be fully realized by
2017. In addition, we anticipate that the
combined company’s strong pro forma
capital structure and cash flow profile will
provide a solid foundation for continued
investment in innovation and other
avenues of growth.
Advancing our Opportunities
Two thousand thirteen was a year of
progress in executing the strategy on
which we are building Kraton’s future.
We continued enhancing our position
and participation in fast-growing Asian
markets and we made additional market
inroads with several of our innovation
products and strengthened our ability
for continued growth through innovation.
We greatly appreciate the continued
support of our investors and customers
and the contributions of our employees
whose talent and dedication drive our
success. We are committed to creating
superior value for all of our stakeholders,
and I am confident that our actions and
achievements over the past year have
advanced our opportunities for attractive
growth and profitability.
Sincerely,
Kevin M. Fogarty
President and Chief Executive Officer
Participants in the Solicitation
Kraton, its directors, executive officers and certain members of management and employees may be considered “participants in the solicitation” of proxies from Kraton’s stockholders in connection with the
combination. Information regarding such persons and a description of their interest in the combination will be contained in the proxy statement/prospectus when it is filed. Information concerning beneficial ownership
of Kraton common stock by its directors and certain executive officers is included in its proxy statement dated April 15, 2013 and subsequent statements of changes in beneficial ownership on file with the SEC.
Advancing Opp ortunity 3
Investing in Opportunity
Looking forward, we expect the
Asia Pacific region to account
for approximately 80 percent
of future growth in global
SBC consumption.
Vitality Index
16%
14%
12%
10%
8%
6%
4%
2%
0%
2006
2007
2008
2009
2010
2011
2012
2013
Percentage of total revenue derived from sales of innovation
product grades.
4 2013 Annua l Re p or t
Asia represents a significant opportunity for Kraton by virtue of its growing economies,
attractive markets and its position as a hub for the manufacture and export of finished
products. China alone has experienced average GDP growth of 9.2 percent over the
past four years, outpacing most other regions of the world. In addition, manufacturers across
the region are driving robust growth in demand for SBCs. Looking forward, we expect the
Asia Pacific region to account for approximately 80 percent of future growth in global
SBC consumption.
Kraton’s sales in Asia reflect the vibrant nature of its economies as evidenced by increasing
demand for our more profitable CariflexTM and HSBC-based products. In 2013, our sales in
the Asia Pacific region represented 22 percent of our total revenue. HSBC-based products
accounted for 40 percent of our 2013 Asia Pacific sales, compared to 32 percent for the
company as a whole, and nearly 90 percent of our Cariflex sales occurred in this region.
Expanding our Capabilities
Capturing opportunity in this high-potential region by getting closer to customers, collaborating
on product innovations and focusing on customer service is a key element of Kraton’s growth
strategy. In recent years, we have made significant investments to enhance our position and
participation in Asian markets. Since 2010, we have grown our staffing by 64 percent to
include 102 employees at R&D, manufacturing, sales and service facilities across the region.
Two years ago, we opened our state-of-the-art, 3,000 square meter Shanghai Innovation
Center, bringing our sophisticated R&D capabilities to Asia. The Center has helped to
accelerate the development and commercialization of new products while fostering increased
collaboration and closer ties with customers in the region. New technologies, such as
PVC alternative materials used in cap liners and medical tubing, coextruded protective film
compounds and thermoplastic elastomer medical closure compounds, have been developed
as a result of close collaboration with regional customers.
Adding Manufacturing Capacity
We also are expanding our manufacturing footprint in Asia. Shortly after expanding our IR latex
production capacity in Japan several years ago, we began planning for the establishment of
HSBC manufacturing capabilities in the region. Our state-of-the-art, 30 kiloton production
facility being built through a 50/50 joint venture with Formosa Petrochemical Company (FPCC)
at an existing FPCC site in Mailiao, Taiwan, is currently expected to be mechanically complete
in the fourth quarter 2015, with production beginning in early 2016. The plant will support
sales of our innovation grade products as well as overall growth in the region and throughout
the world.
316
314
312
310
308
306
304
302
300
298
296
In addition to serving target markets in the region as well as customers in other parts of the
world, our expanded manufacturing footprint in Asia will operate as part of our global supply
chain. Other strategic benefits from the new facility include an efficient cost structure, plentiful
and competitively priced on-site raw materials, as well as the expertise and resources of our
joint venture partner.
A Bridge from Lab to Market
While a great deal of our focus has been on Asia in recent years, we are making investments
in other locations that will benefit our customers and operations across the globe. A new
semi-works plant located at our existing manufacturing site in Belpre, Ohio, reached
mechanical completion in late 2013 and is expected to be fully operational by the end
of the first quarter of 2014.
Designed to bridge the gap between laboratory quantities and full-scale production, the
facility will enable faster, more effective scale-up of production to accelerate our innovation
and product development processes. With these capabilities, this leading-edge facility
has garnered significant interest on the part of our innovative customers and development
partners, and it will play a key role in our future innovation programs.
A revolutionary technology that has a num-
ber of highly attractive properties including
unique cooling qualities, selective permea-
bility and mechanical strength in wet or dry
conditions, our NEXARTM polymer has
tremendous potential for a variety
of applications.
Sales Volume in Kilotons
2010
2011
2012
2013
Advancing Opportunity 5
Opportunity through Innovation
As a global leader in specialty polymers, Kraton is a company built on innovation.
Our scientists created the first SBCs more than 50 years ago, and since then, we
have developed nearly every application that currently exists for SBCs. With a focus on
customized solutions that impart unique attributes to end use products, we create value for
customers by providing the enabling ingredients that set their products apart. Our engineered
polymers enhance the performance and value of products that touch virtually every aspect
of our lives, and we continue to deliver better solutions for a changing world.
CariflexTM products are the ideal alternative
to natural rubber for applications that
demand purity, protection and consistent
high quality. With numerous medical,
consumer and industrial applications,
Cariflex provides the perfect balance of
comfort, purity and strength.
Medical Applications
With the development of CariflexTM isoprene rubber, Kraton branched out from its SBC roots
to meet an increasing need for a pure, high-performance alternative to natural rubber that is
free of the impurities that cause discoloration, odor and allergic reactions. Offering a blend of
purity, performance and comfort that is unmatched by natural rubber or available alternatives,
Cariflex gained favor in the medical industry for solid rubber items such as tube connectors
and medical stoppers and, in its latex form, dipped goods like surgical gloves. It rapidly
became our fastest-growing product family with sales volume that has increased at a
compound annual rate of seven percent from 2008 through 2013. Medical applications
currently represent more than 90 percent of Cariflex sales, but we are also making inroads
in other applications, from electronics to cold-seal adhesives for food products, where purity
is paramount.
PVC Alternatives
As environmental and health concerns have driven demand for alternatives to PVC, Kraton
innovations have provided more sustainable solutions for a variety of industries including
medical and electronics applications. Our Enhanced Rubber Segment (ERS) polymers offer
a high-performance, non-allergenic alternative to PVCs in medical supplies such as IV bags
and medical tubing. Our solutions are also gaining momentum in the wire and cable market
space in which Kraton participates both as a solutions provider and as a supplier to the
compounding community.
Oil Gels
Kraton’s HSBC-based polymers are used in the production of oil gels for a wide variety
of applications ranging from health and beauty products to insulation in telecommunication
cables. Economic growth in China and throughout Asia is expected to translate into continued
investment in infrastructure, which in turn should drive growth in demand for cable gels.
Changing Industry Needs in Personal Care Applications
In 2013, we continued to work with customers on new solutions to address ever-changing
market needs in personal care applications. During the year, we saw growth in sales of
innovative polymers based upon USBC chemistry that enable our customers to offer
products that are designed to meet specific market demands.
6 2013 Annua l Re p or t
We create value for customers
by providing the enabling
ingredients that set their
products apart.
Geographic Breakdown
of Revenue
Americas
39%
Europe, MIddle East &
Africa 39%
Asia Pacific 22%
Advancing Opportunity 7
Advancing Opportunity
As infrastructure demands
increase globally, Kraton’s
HiMA technology addresses
the need for long-lasting and
cost-effective paving solutions
in applications that include
roads, bridges and airports.
8 2013 Annua l Re p or t
Dedicated to creating value for our stockholders, direct customers and end use
consumers, Kraton focuses its innovations on identified customer needs and broad-
based market trends that promote the commercial success of our new products.
During 2013, we made good progress in commercializing and growing several of our
innovation platforms for applications ranging from consumer to industrial products.
NEXAR’s™ Second Commercial Application
A revolutionary technology that has a number of highly attractive properties including unique
cooling qualities, selective permeability and mechanical strength in wet or dry conditions, our
NEXAR polymer has potential for a variety of applications. NEXAR is ideal for outdoor athletic
apparel and sports gear such as base layer shirts for running, exercising and biking; athletic
gloves for golf and other sports; footwear for running, hiking and skating as well as protective
gear for military and first-responder applications. Already used in performance apparel
applications, NEXAR achieved its second commercial application during 2013; it is now
being used to improve the performance of energy recovery ventilation systems to reduce
HVAC load in industrial, commercial and residential structures. In 2014, we will continue
our focus on translation opportunities to move NEXAR into new applications in apparel
and performance fabrics.
Highly Modified Asphalt (HiMA)
With superior strength and fatigue resistance that enables a reduction of up to 40 percent
in the raw material needed for road construction, our innovation grades for modification of
asphalt are gaining favor in several countries with significant infrastructure needs. In addition
to major projects in Brazil and Qatar, HiMA has been used on small, yet high-profile projects
in the U.S.
In Brazil, Kraton has completed multiple trials and projects solving a variety of pavement
performance issues. Most recently, the Viracopos Airport in Campinas, Brazil, chose HiMA
technology to reduce cost and improve performance through thinner pavement designs. The
growth in concessionaire business is a key driver of Kraton’s success as Brazil continues to
expand and improve pavement through private road concessions. We also have expanded our
HiMA applications to countries outside of Brazil, including Peru.
As Qatar prepares for the 2022 World Cup, it has chosen Kraton’s HiMA technology to
meet significant challenges presented by the climate and traffic demands in this region. In
the coming years, we foresee additional opportunities to help address these challenges
while also providing savings through thinner and more durable pavement designs.
In the U.S., the New York City Department of Transportation has incorporated HiMA into
a resurfacing project designed to solve persistent pavement problems along a 53 block
stretch of First Avenue. Following the notable performance of a test section laid in 2012,
a contractor for the city laid a thin layer of asphalt modified with Kraton’s HiMA technology
over a 30 year old concrete surface that was in poor condition. We believe HiMA was chosen
for its extreme durability, greatly improved resistance to rutting and cracking, and its ability
to withstand the effects of inclement weather. Through the use of HiMA, the city was able
to meet performance objectives and enhance road life without disrupting the city’s vital
underground utility infrastructure.
Kraton focuses its innovation efforts on
identified customer needs and broad-based
market trends that promote the commercial
success of our new products. Our innovation
programs are supported by regional innova-
tion centers located in Houston, Amsterdam
and Shanghai.
2013 Revenues by End Use
CariflexTM
9%
Adhesives, Sealants &
Coatings 37%
Paving and Roofing
27%
Advanced Materials
27%
Advancing Opportunity 9
Advancing Opportunity
Global Headquarters
Regional Headquarters
Innovation Center
Manufacturing Facility
Technical Service Center
Customer Service Center
Manufacturing Under Construction
Our polymers are used to address spe-
cific performance requirements in oilfield
applications such as viscosity modification
of drilling fluids. We are also working to
commercialize a drilling fluid and com-
pletion technology that offers several
performance benefits compared to
existing industry offerings.
10 2013 Annua l Re p or t
Oilfield Applications
The oilfield is one of the most promising growth markets for Kraton. We have already
commercialized polymers that impart superior performance characteristics when used for
viscosity modification and as an additive in self-healing cement, and we are moving forward
with new product innovations. Among the positive trends we saw in 2013 was a shift in
customer preferences from USBC to HSBC chemistry, and we are expanding our portfolio
in this higher-margin segment.
During 2014, we expect to launch a new application technology for viscosity modification in
oilfield drilling fluids that has been developed to address specific performance requirements.
We are also working to commercialize a drilling fluid and completion technology that we
believe offers a number of performance benefits relative to existing industry offerings. Our
product solution is ductile with a very high compression set, addressing the oilfield industry’s
needs for high-performing cement solutions for challenging well conditions. In addition, our
compound activates to conform to the temperature profile of the well and, as such, can be
customized to meet the unique conditions for each application. Working with key players in
the industry, we have demonstrated the performance of this product in the laboratory and
are working to apply our solution in a well application in 2014.
The Right Chemistry Everywhere
As a market leader in specialty polymers, Kraton offers an unmatched selection of material
grades and innovations that enhance the lives of millions of people across the world. Being
the only SBC industry participant with SBC manufacturing facilities on four continents – North
America, South America, Europe and Asia – we provide a broad platform for global service
and supply. We continue to expand our footprint and capabilities through investments and
strategic partnerships in key markets.
With a significant share in each of our end use markets, a presence in all regions of the
world, a rich intellectual property portfolio and a legacy of successful innovation, Kraton
is well positioned to grow by creating value for our shareholders, our customers and for
consumers of the products that are enhanced by our polymers.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2013
or
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Commission file number
001-34581
KRATON PERFORMANCE POLYMERS, INC.
(Exact Name of Registrant as Specified in its Charter)
Delaware
(State or other jurisdiction of
incorporation or organization)
15710 John F. Kennedy Blvd,
Suite 300
Houston, TX 77032
(Address of principal executive offices,
including zip code)
20-0411521
(I.R.S. Employer
Identification No.)
281-504-4700
(Registrant’s telephone number,
including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class
Kraton Performance Polymers, Inc. Common Stock,
par value $0.01
Name of Each Exchange on Which Registered
New York Stock Exchange
Securities registered pursuant to Section 12(g) of the Act:
None
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. YES NO
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. YES NO
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject
to such filing requirements for the past 90 days. YES NO
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data
File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for
such shorter period that the registrant was required to submit and post such files). YES NO
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be
contained, to the best of the registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form
10-K or any amendment to this Form 10-K.
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting
company. See definitions of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Securities Exchange
Act. (Check one):
Large accelerated filer:
Non-accelerated filer:
Accelerated filer:
Smaller reporting company:
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). YES NO
Estimated aggregate market value of the common equity held by nonaffiliates of Kraton Performance Polymers, Inc. at June 30, 2013:
$683,229,593. Number of shares of Kraton Performance Polymers, Inc. Common Stock, $0.01 par value, outstanding at February 21, 2014:
32,556,399.
Portions of Kraton Performance Polymers, Inc.’s proxy statement for the 2014 Annual Meeting of Shareholders are incorporated by reference
DOCUMENTS INCORPORATED BY REFERENCE
in Part III.
Index to Annual Report
on Form 10-K for
Year Ended December 31, 2013
PAGE
PART I
Item 1.
Business ............................................................................................................................................................................
Item 1A. Risk Factors ......................................................................................................................................................................
Item 1B. Unresolved Staff Comments.............................................................................................................................................
Properties ..........................................................................................................................................................................
Item 2.
Legal Proceedings ............................................................................................................................................................
Item 3.
Mine Safety Disclosures ...................................................................................................................................................
Item 4.
PART II
Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities .......
Item 5.
Selected Financial Data ....................................................................................................................................................
Item 6.
Item 7.
Management’s Discussion and Analysis of Financial Condition and Results of Operations ...........................................
Item 7A. Quantitative and Qualitative Disclosures About Market Risk ..........................................................................................
Financial Statements and Supplementary Data ................................................................................................................
Item 8.
Item 9.
Changes in and Disagreements with Accountants on Accounting and Financial Disclosure ...........................................
Item 9A. Controls and Procedures ...................................................................................................................................................
Item 9B. Other Information .............................................................................................................................................................
PART III
Item 10. Directors, Executive Officers and Corporate Governance ...............................................................................................
Item 11. Executive Compensation ..................................................................................................................................................
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters .........................
Item 13. Certain Relationships and Related Transactions, and Director Independence .................................................................
Item 14. Principal Accountant Fees and Services ...........................................................................................................................
PART IV
Item 15. Exhibits and Financial Statement Schedules ....................................................................................................................
4
14
27
28
29
29
30
32
36
51
52
52
52
53
54
54
54
54
54
55
2
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION
Some of the statements in this Annual Report on Form 10-K under the headings “Business,” “Risk Factors,” “Selected Financial
Data,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” “Financial Statements and
Supplementary Data” and elsewhere contain forward-looking statements within the meaning of the Private Securities Litigation
Reform Act of 1995. We may also make written or oral forward-looking statements in our periodic reports on Forms 10-Q and 8-K, in
press releases and other written materials and in oral statements made by our officers, directors or employees to third parties.
Statements that are not historical facts, including statements about our beliefs and expectations, are forward-looking statements.
Forward-looking statements are often characterized by the use of words such as “believes,” “estimates,” “expects,” “projects,” “may,”
“intends,” “plans” or “anticipates,” or by discussions of strategy, plans or intentions; anticipated benefits of or performance of our
products; beliefs regarding opportunities for new, high-margin applications and other innovations; adequacy of cash flows to fund our
working capital requirements; our investment in the joint venture with Formosa Petrochemical Corporation (“FPCC”); our
expectations regarding indebtedness to be incurred by our joint venture with FPCC; our proposed combination with the Styrenic Block
Copolymer (“SBC”) business of LCY Chemical Corp. (“LCY”), the expectation that such combination will close in the fourth quarter
of 2014 and expected synergies and other benefits therefrom and costs associated therewith; debt payments, interest payments, capital
expenditures, benefit plan contributions, and income tax obligations; our anticipated 2014 capital expenditures, compliance with the
MACT rule, health, safety and environmental and infrastructure and maintenance projects, projects to optimize the production
capabilities of our manufacturing assets and to support our innovation platform; our ability to meet conditions required to ensure full
access to our senior secured credit facilities; expectations regarding our counterparties’ ability to perform, including with respect to
trade receivables; estimates regarding the tax expense of repatriating certain cash and short-term investments related to foreign
operations; expectations regarding high-margin applications; our ability to realize certain deferred tax assets and our beliefs with
respect to tax positions; expectations regarding our full year effective tax rate; our plans and expectations regarding our planned Asia
expansion project; our expectations regarding the startup of our semi-works facility in Belpre, Ohio during the first quarter of 2014;
estimates related to the useful lives of certain assets for tax purposes; expectations regarding our pension contributions for fiscal year
2014; estimates or expectations related to monomer costs, ending inventory levels and related estimated charges; the outcome and
financial impact of legal proceedings; expectations regarding the spread between FIFO and ECRC in future periods; the estimates and
matters described under the caption “Item 7. Management’s Discussion and Analysis—Results of Operations—Outlook;” and
projections regarding environmental costs and capital expenditures and related operational savings. Such forward-looking statements
involve known and unknown risks, uncertainties, assumptions and other important factors that could cause the actual results,
performance or our achievements, or industry results, to differ materially from historical results, any future results, or performance or
achievements expressed or implied by such forward-looking statements. There are a number of risks and uncertainties that could cause
our actual results to differ materially from the forward-looking statements contained in this report. Important factors that could cause
our actual results to differ materially from those expressed as forward-looking statements are set forth in this report, including but not
limited to those under the heading “Risk Factors.” There may be other factors of which we are currently unaware or deem immaterial
that may cause our actual results to differ materially from the forward-looking statements.
Forward-looking statements are based on current plans, estimates and projections, and, therefore, you should not place undue
reliance on them. Forward-looking statements speak only as of the date they are made, and we undertake no obligation to update them
publicly in light of new information or future events.
Presentation of Financial Statements.
The terms “Kraton,” “our company,” “we,” “our,” “ours” and “us” as used in this report refer collectively to Kraton
Performance Polymers, Inc. and its consolidated subsidiaries.
This Form 10-K includes financial statements and related notes that present the consolidated financial position, results of
operations, comprehensive income and cash flows of Kraton, and its subsidiaries. Kraton is a holding company whose only material
asset is its investment in its wholly owned subsidiary, Kraton Polymers LLC. Kraton Polymers LLC and its subsidiaries own all of our
consolidated operating assets.
3
Item 1.
Business.
Our Company
PART I
General
We are a leading global producer of styrenic block copolymers (“SBCs”) and other engineered polymers. We market our
products under the Kraton®, CariflexTM, and NEXARTM brands. SBCs are highly-engineered synthetic elastomers, which we invented
and commercialized almost 50 years ago, that enhance the performance of numerous end use products by imparting greater flexibility,
resilience, strength, durability and processability.
Our polymers are typically formulated or compounded with other products to achieve improved, customer-specific performance
characteristics in a variety of applications. We seek to maximize the value of our product portfolio by emphasizing complex or
specialized polymers and innovations that yield higher margins than more commoditized products. We sometimes refer to these
complex or specialized polymers or innovations as being more “differentiated.”
Our products are found in many everyday applications, including personal care products such as disposable diapers and the
rubberized grips of toothbrushes, razor blades and power tools. Our products are also used to impart tack and shear properties in a
wide variety of adhesive products and to impart characteristics such as flexibility and durability in sealants and corrosion resistance in
coatings. Our paving and roofing applications provide durability, extending road and roof life.
We also produce Cariflex isoprene rubber and isoprene rubber latex. Our Cariflex products are highly-engineered, non-SBC
synthetic substitutes for natural rubber and natural rubber latex. Our Cariflex products, which have not been found to contain the
proteins present in natural rubber latex and are, therefore, not known to cause allergies, are used in applications such as surgical gloves
and condoms. We believe the versatility of Cariflex provides opportunities for new, high margin applications.
We have a portfolio of innovations at various stages of development and commercialization, including
•
•
•
polyvinyl chloride alternatives for wire and cable, and medical applications;
polymers and compounds for soft skin and coated fabric applications for transportation and consumer markets;
our NEXAR family of membrane polymers for water filtration, heating, ventilation, air conditioning and breathable fabrics;
and
•
synthetic cement formulations and other oilfield applications.
Our total SBC production capacity as of December 31, 2013 was approximately 420 kilotons. Production capacity at our
facilities can vary greatly depending upon feedstock, product mix and operating conditions. We generated approximately $1,292.1
million of sales revenue and 313.5 kilotons of sales volume for the year ended December 31, 2013. In 2013, we generated 14.7% and
38.5% of our sales revenue from innovation-driven and differentiated products, respectively. Our customers are diversified by industry
and geography with more than 800 customers in over 60 countries. We manufacture our polymers at five manufacturing facilities
globally, including our flagship facility in Belpre, Ohio, as well as facilities in Germany, France, Brazil, and Japan. The facility in
Japan is operated by an unconsolidated manufacturing joint venture.
We have had a long-standing relationship with many of our customers and work closely with our customers to design products
that meet application-specific performance and quality requirements. We have a diverse customer base, with no single customer
accounting for more than 10.0% of our sales revenue in 2013 and our top 10 customers together representing approximately 28.3% of
our sales revenue in 2013. Because of the technical expertise and investment required to develop many of our product formulations
and the lead times required to replace them, we believe our customers would likely incur additional costs by changing to an alternative
vendor.
4
Over the past several years, we have implemented a range of strategic initiatives designed to enhance our profitability and end
use market position, with a focus on increasing our scale and global footprint, particularly in Asia. These include fixed asset
investments to expand our capacity in specialized products and enhance productivity at our existing facilities, our 50% investment in
our joint venture, Kraton Formosa Polymers Corporation (“KFPC”), located in Mailiao, Taiwan, and fixed costs management through
headcount reductions, production line closures at our facility in Pernis, Netherlands, and system upgrades. During this period, we
shifted our focus from lower margin business, and we implemented pricing strategies designed to enhance our overall margins and
return on invested capital. With the commercialization of newer innovations such as NEXAR and HiMA and increasing sales of
Cariflex and products for oilfield service applications, our strategy is focused on continuing to advance our portfolio of higher-value,
higher margin products, while, at the same time, expanding sales of our core product grades.
Corporate History
Prior to our initial public offering and related reorganization transactions in December 2009, we were an indirect wholly-owned
subsidiary of TJ Chemical Holdings LLC and were indirectly owned by certain affiliates of TPG Capital, L.P., which we refer to
collectively as “TPG,” and certain affiliates of J.P. Morgan Partners, LLC, which we refer to collectively as “JPMP,” and certain
members of our management. We conduct our business through Kraton Polymers LLC and its consolidated subsidiaries. Prior to our
initial public offering, Kraton Polymers LLC’s parent company was Polymer Holdings LLC, a Delaware limited liability company. On
December 16, 2009, Polymer Holdings LLC was converted from a Delaware limited liability company to a Delaware corporation and
renamed Kraton Performance Polymers, Inc., which remains Kraton Polymers LLC’s parent company. In addition, prior to the closing
of the initial public offering, TJ Chemical was merged into (and did not survive the merger with) Kraton Polymers LLC. Our initial
public offering was completed, and trading in our common stock on the New York Stock Exchange commenced, in December 2009.
TPG and JPMP collectively owned a majority of our common stock following the initial public offering, and through two secondary
public offerings conducted in September 2010 and April 2011, sold all of their holdings in our common stock.
Recent Developments
Entry into Definitive Agreement to Combine with the SBC Business of LCY. As previously announced, on January 28, 2014, we
and two wholly-owned subsidiaries entered into a definitive agreement with LCY Chemical Corp. (“LCY”) and a wholly-owned
subsidiary of LCY (together with LCY, the “LCY Parties”) to combine with the SBC business of LCY. LCY’s SBC business operates
through facilities located in Taiwan, Huizhou, China and Baytown, Texas. LCY will remain as a separate company following the
combination and continue to operate its other lines of business following the closing.
Prior to the execution of the combination agreement, we formed a new holding company organized under the laws of England
(“UK Holdco”). Pursuant to a merger contemplated in the combination agreement, each outstanding share of common stock of our
company will be converted into the right to receive one ordinary share of UK Holdco, and we will become a wholly-owned subsidiary
of UK Holdco. In addition, UK Holdco will issue ordinary shares to the LCY Parties in exchange for LCY’s SBC business, which will
be contributed to UK Holdco through the contribution of the equity interests in a group of LCY’s subsidiaries (the “LCY
Combination”).
The shares to be issued to LCY at closing will constitute 50% of the shares of UK Holdco that will be outstanding immediately
after the closing of the transactions contemplated by the combination agreement. The other 50% of the shares of UK Holdco will be
owned by the stockholders of our company immediately prior to such closing. UK Holdco and LCY have also agreed to enter into a
shareholder agreement (the “Shareholder Agreement”) at the closing of the transactions. The Shareholder Agreement will set forth
certain rights and limitations relating to LCY’s ownership of the UK Holdco shares, including provisions relating to, among other
things, representation on UK Holdco’s board of directors (“UK Holdco Board”), standstill restrictions on certain actions (including the
acquisition by LCY of additional UK Holdco shares), UK Holdco Board approval requirements on certain significant actions by UK
Holdco, preemptive rights for LCY to purchase additional UK Holdco shares, restrictions on the direct or indirect transfer of the UK
Holdco shares to be owned by LCY, arrangements regarding the voting of the UK Holdco shares held by LCY, restrictions on
competition with UK Holdco on the part of LCY and registration rights for the UK Holdco shares to be held by LCY.
The closing of the transactions is subject to approval by the stockholders of both our company and LCY, receipt of certain
regulatory approvals and other conditions. Closing of the transactions is expected to occur in the fourth quarter of 2014. Upon and
after closing, the name of UK Holdco will be Kraton Performance Polymers plc, and the shares will be listed on the NYSE.
5
After the closing of the transactions, the UK Holdco Board will consist of fourteen directors, consisting of seven LCY-
designated directors and seven directors that currently serve on our board of directors. Our chairman of the board of directors, Dan
Smith, will be the initial chairman of the UK Holdco Board upon the closing, and it is anticipated he will serve in that position for two
years following the closing. The chairman for the next two years will be selected by the LCY designees on the UK Holdco Board, and
thereafter the chairman will be selected by the full UK Holdco Board. Kevin M. Fogarty, our current chief executive officer, will serve
as chief executive officer of UK Holdco upon the closing. See “Part I, Item 1A. Risk Factors” below for a discussion of certain risks
and uncertainties relating to the LCY Combination.
Products
Our Kraton polymer products are high performance elastomers that are engineered for a wide range of end use applications. Our
products possess a combination of high strength and low viscosity, which facilitates ease of processing at elevated temperatures and
high processing speeds. Our products can be processed in a variety of manufacturing applications, including injection molding, blow
molding, compression molding, extrusion and hot melt, and solution applied coatings.
Our products are manufactured along the following primary product lines based upon polymer chemistry and process
technologies:
•
•
un-hydrogenated SBCs (“USBCs”);
hydrogenated SBCs (“HSBCs”);
• CariflexTM isoprene rubber (“IR”) and isoprene rubber latex (“IRL”); and
•
compounds.
The majority of worldwide SBC production is dedicated to USBCs, which are primarily used in paving and roofing, adhesives,
sealants and coatings, and footwear applications. HSBCs, which are significantly more complex and capital-intensive to manufacture
than USBCs, are used in applications such as soft touch and flexible materials, personal hygiene products, medical products,
automotive components and certain adhesives and sealant applications. Below is an overview of our four primary product lines.
USBCs. We developed the first USBC polymers in 1964 and built the first dedicated block copolymer facility in Belpre, Ohio,
in 1971. As of December 31, 2013, our USBC product portfolio included 101 core commercial grades of products. Sales of USBC
products comprised approximately 58.3%, 59.1% and 59.3% of our sales revenue in 2013, 2012 and 2011, respectively.
USBCs are used in three of our core end use markets (Advanced Materials; Adhesives, Sealants and Coatings; and Paving and
Roofing) in a range of products to impart performance characteristics such as:
•
•
•
•
resistance to temperature and weather extremes in roads and roofing;
resistance to cracking, reduced sound transmission and better drainage in porous road surfaces;
impact resistance for consumer plastics; and
increased processing flexibility in adhesive applications, such as packaging tapes and labels, and materials used in
disposable diapers.
HSBCs. We developed the first HSBC polymers in the late 1960s for use in production of soft, strong compounds for handles
and grips and elastic components in diapers. As of December 31, 2013, our HSBC product portfolio included 77 core commercial
grades of products. HSBC products are significantly more complex to produce than USBC products and, as a result generate higher
margins than USBCs. Sales of HSBC products comprised 30.3%, 31.2% and 31.6% of our sales revenue in 2013, 2012 and 2011,
respectively.
HSBCs are primarily used in our Advanced Materials and Adhesives, Sealants and Coatings end use markets to impart
performance characteristics such as:
•
•
•
•
•
stretch properties in disposable diapers and adult incontinence products;
soft feel in numerous consumer products such as razor blades, power tools, and automobile internals;
impact resistance for demanding engineering plastic applications;
flexibility for wire and cable plastic outer layers;
improved flow characteristics for many industrial and consumer sealant and lubricating fluids;
6
•
•
•
resistance to ultraviolet light;
processing stability and viscosity; and
elevated temperature resistance.
Cariflex. We market our IR and IRL products under the Cariflex brand name. These products combine the key qualities of
natural rubber, such as good mechanical properties and hysteresis, with purity and clarity enhancements, good flow, low gel content,
and absence of nitrosamines and natural rubber proteins. As of December 31, 2013, our Cariflex product portfolio included 9 core
commercial grades of products. Cariflex comprised 9.0%, 7.4% and 6.9% of our sales revenue in 2013, 2012 and 2011, respectively.
Isoprene rubber (formed from polymerizing isoprene) is a high purity, non-SBC product. Our IR polymers are available as bales
of rubber or as latex. We focus our IR polymers, which are produced using nanotechnology, in demanding applications such as
medical products, adhesives and tackifiers, paints, coatings and photo-resistors. Isoprene rubber latex (emulsion of IR in water) is a
substitute for natural rubber latex, particularly in applications with high purity requirements, such as medical, healthcare, personal care
and food contact operations. Our IRL is specialized polyisoprene latex with a controlled structure and low chemical impurity levels
obtained through an anionic polymerization process followed by a proprietary latex processing step, both of which were first
developed by us. IRL is durable, tear resistant, soft, transparent and odorless. In addition, the synthetic material is non-allergenic and
has superior consistency and other advantages to natural rubber latex. IRL is predominately used in the synthetic surgical gloves and
condoms.
We have undertaken several projects to support anticipated continued growth in demand for our Cariflex products. In 2011, we
commissioned a line conversion project at our Belpre, Ohio, facility, which now provides for production of IR and replaces production
capacity at our former manufacturing facility in Netherlands, which was closed in 2009. During 2011, we also successfully completed
the expansion of our IRL capacity at our Paulinia, Brazil, facility. Further, we executed a contract with a supplier in Japan to expand
manufacturing capacity for IRL. This expansion was completed in January 2013 and effectively doubled our existing capacity in
Japan.
Compounds. Our Compounds are a mixture of Kraton polymers and other polymers, resins, oils or fillers and cover a wide range
of polymers used in consumer and industrial applications. Compounds can be formulated so that they meet the specific requirements
of our customers. These products are primarily used in soft-touch grips, sporting equipment, automotive components and personal care
products. As of December 31, 2013, our Compounds product portfolio included 19 core commercial grades of products. Compounds
comprised 2.3%, 2.1% and 1.9% of our sales revenue in 2013, 2012 and 2011, respectively.
7
Our End Use Markets
Our commercial activities are aligned to serve our four core end use markets: (1) Advanced Materials; (2) Adhesives, Sealants
and Coatings; (3) Paving and Roofing; and (4) Cariflex.
2013
Revenue Mix
($ in millions)
2012
2011
Selected Applications/Products
End Use Markets
Advanced Materials
26.8 %
$ 346.3
26.9 %
$ 382.8
28.0 %
$ 402.6
Consumer disposable and consumer
durable soft touch
Engineering thermoplastics
compatibilization and impact
modification
Personal care
PVC alternatives for medical, wire and
cable
Disposable food packaging and closures
Highly engineered polymer modification
Skin care products and lotions
Automotive interior and exterior
Stoppers for medical/pharmaceutical
Adhesives, Sealants
and Coatings
37.0 %
$ 477.6 35.9 % $ 510.8 34.8 % $ 499.7 Tapes and labels
Non-woven and industrial adhesives
Clear sealants
Lubricant additives
Paving and Roofing
27.1 %
$ 350.9
29.6 %
$ 421.4
29.9 %
$ 429.3
Asphalt modification for performance
roadways, bridges and airports
Asphalt modification for roofing felts
and shingles
Cariflex
9.0 %
$ 116.0
7.4 % $ 105.9 6.9 % $ 99.3 Surgical gloves
Condoms
Other
0.1 %
$ 1.2
0.2 % $
2.2 0.4 % $
6.6 High styrenics packaging
Footwear
Other
Advanced Materials. We sell HSBC, USBC, and customized SBC based compounds, across multiple markets as part of the
Advanced Materials end use market.
Our products primarily compete against a variety of chemical and non-chemical alternatives including, but not limited to,
thermoplastic vulcanizate, thermoplastic polyurethane, PVC, thermoplastic polyolefin, polyethylene terephthalate, polycarbonate,
polyamide, and ethylene-propylene-diene-monomer (“EPDM”) based products. We believe the ability to balance performance
characteristics such as ease of use, desired aesthetics, haptics, and managing total end product costs are principal factors influencing
final product decisions of our customers in this end use market.
Many of our products in this core end use market are customized formulations that are highly engineered to address specific
customer needs, such as improved stretch and resilience characteristics in elastic film applications. As such, they require specialized
product testing and validation, production and process evaluation. This results in long lead time to achieve customer and industry
established approvals.
We believe demand for products in this end use market is principally driven by customer-specific needs and cost. Our
innovation led growth strategy focuses on translating the inherent strengths of our product technologies such as flexibility, resilience,
impact and moisture resistance, and aesthetics (clarity and haptics), and target opportunities where we can expand and/or have the
potential to create new market spaces for our solutions.
Adhesives, Sealants and Coatings. We sell HSBC and USBC products in the Adhesives, Sealants and Coatings end use market.
Our products primarily compete with acrylics, silicones, solvent-based rubber systems and thermoplastic polyolefin elastomers.
The choice between these materials is influenced by bond strength, specific adhesion, consistent performance to specification,
processing speed, hot-melt application, resistance to water and total end-product cost.
8
Our SBCs are used in applications such as adhesives for diapers and hygiene products, sealants and coatings for construction
and automotive applications, viscosity modification in lubricants as well as in health and beauty and cable gels and adhesives for tapes
and labels. Our SBCs in this end use market are compatible with many other formulating ingredients. We have expanded our
offering of formulated compounds for adhesives for protective films that provide improved adhesive performance with no residue or
haze after removal. Furthermore our highly specialized grades are used in various combinations for the manufacturing of printing
plates. One of our newest applications for functionalized SBC’s can be found in sprayable coatings and sealing products.
We believe demand for products in this end use market is driven largely by the consumption of disposable hygiene products that
contain adhesives, particularly in elastic attachment. Further, we believe that cost reduction and consumer market appeal are principal
factors driving increasing use of SBC based adhesives relative to paper labels in the pressure sensitive label market. The trend towards
utilization of SBC based adhesives is primarily driven by cost reduction and higher performance.
Paving and Roofing. We sell USBC products in the Paving and Roofing end use markets.
Our products primarily compete with chemicals such as styrene-butadiene rubber latex, acetates, polyphosphoric acids, and
thermoplastic materials like EPDM, polyethylene, atactic polypropylene and unmodified asphalts. We believe that customer choice in
this end use market is driven principally by total end-product cost, temperature performance, bitumen source, and application.
Styrene-butadiene-styrene (“SBS”)-modified asphalt pavements enhance the strength and elasticity of asphalt-based paving
compositions over an extended temperature range, thus increasing resistance to wear, rutting and cracking and therefore extending
service life. In roofing applications, SBS-modified asphalt produces stronger and more durable felts and shingles, thus reducing the
possibility of damage from weather, ice and water build-up and again extending service life.
We believe the ability to maintain roads in an environment where traffic demands are rising and repair budgets are decreasing is
the primary issue facing governments and other road owners in every region and a principal driver of demand in this end use market.
Our Highly Modified Asphalt Technology (“HiMA”) polymers provide better rut and cracking resistance than other elastic binders,
while achieving 25-40% reduction in road thickness without any major sacrifice of viscosity or temperature performance. We believe
this innovation will extend road life by allowing pavements to withstand heavy traffic loads and varying climate conditions.
Cariflex. We sell IR and IRL in this end use market. We primarily supply the surgical glove, condom and specialty medical
device markets.
Our products primarily compete with natural rubber, conventional Ziegler Natta sourced solid IR, halo butyl rubber and several
synthetic latex alternatives, notably neoprene, nitrile and polychloroprene latex rubber, as well as polyurethane.
In the medical device markets, we believe that demand for products is driven by purity of the product (including lower metal
residuals content, the absence of natural rubber proteins and lower use of plasticisers) and mechanical properties applicable to surgical
gloves, stoppers, closure and other packaging applications. In coatings applications, we believe that demand is driven by the level of
impurity, as low levels facilitate more durable coatings that compete with epoxy coating systems. In electronic applications, we
believe that demand is driven primarily by low metal content, which we believe reduces the likelihood of quality issues.
The surgical glove and condom markets are largely sourced by natural rubber latex products. However, we have seen a trend in
surgeons using gloves made from synthetic latex alternatives, such as our IRL products. We believe this trend is driven by efforts to
avoid allergies to natural rubber proteins, as well as comfort, consistent stretch and wearability factors imparted by synthetic latex
such as our IRL. We have seen a similar trend in the market for condoms, which we believe is driven by these same factors.
Research, Development and Technology
Our research and development program is designed to develop new products and applications, provide technical service to
customers, develop and optimize process technology, and assist in marketing new products. We spent $32.0 million, $31.0 million and
$28.0 million for research and development for the years ended December 31, 2013, 2012 and 2011, respectively. From time to time,
we also engage in customer-sponsored research projects; with average spending of approximately $1.0 million a year for the three-
year period ended December 31, 2013.
Our research and development activities are primarily conducted in laboratories in Houston, Texas, and Amsterdam,
Netherlands. We also own a laboratory in Paulinia, Brazil, that provides technical services to our South American customers. Our
application and technical service laboratories in Shanghai, China, and Tsukuba, Japan, provide support to our Asian customers. In
addition, we have technical service staff located in Mont St. Guibert, Belgium.
9
Our professionals perform research using scientific application equipment located primarily at our Houston, Amsterdam, and
Shanghai research and development facilities. At all of our major research and development facilities, we produce new Kraton product
samples for our customers and provide guidance to our manufacturing organization. Application equipment is used to evaluate
polymers and compounds to determine optimal formulations. Our semi-works project at our Belpre, Ohio, location is mechanically
complete, and the new facility is in the commissioning phase, with startup anticipated during the first quarter 2014. This facility will
replace a pilot line that was previously maintained in Houston, and will provide scale up support to our manufacturing facilities as we
commercialize new products in our innovation pipeline and will generate polymer samples for in-house researchers and external
customers as we explore new products for the marketplace.
Sales and Marketing
Our business is predominantly based on a short sales cycle. We sell our products through a number of channels including a
direct sales force, marketing representatives and distributors, with the majority of our products sold through our direct sales force. In
countries where we generate substantial revenue, our sales force is organized by end use market in order to meet the specific needs of
our customers. In geographic areas where it is not efficient for us to organize our sales force by end use market, we may use one sales
team to service all end use markets.
In smaller markets, we often utilize marketing representatives who act as independent contractors to sell our products. In
addition, we utilize distributors to service our smaller customers in all regions. Distributors sell a wide variety of products, which
allows smaller customers to obtain multiple products from one source. In addition to our long-term relationships with distributors in
North America and Europe, we have established relationships with a wide network of distributors in Latin America and the Asia
Pacific region.
Our direct sales force, marketing representatives and distributors interact with our customers to provide both product advice and
technical assistance. In general, they arrange and coordinate contact between our customers and our research and development
personnel to provide quality control and new product solutions. Our close interaction with our customers has allowed us to develop
and maintain what we consider to be strong customer relationships.
Sales revenue from our customers outside the United States was approximately 69.1%, 67.2% and 65.9% of our total sales
revenue for the years ended December 31, 2013, 2012 and 2011, respectively. Direct sales we make outside of the United States are
generally priced in local currencies and can be subject to currency exchange fluctuations when reported in our consolidated financial
statements, which are maintained in U.S. dollars in accordance with U.S. generally accepted accounting principles (“GAAP”). For
geographic reporting, revenue is attributed to the geographic location in which the customers’ facilities are located. See Note 13
Industry Segment and Foreign Operations to the consolidated financial statements for geographic reporting of sales revenue and long-
lived assets as of and for the years ended December 31, 2013, 2012 and 2011.
We generated our sales revenue from customers located in the following regions:
Revenue by Geography:
Americas .........................................................................................................................
Europe, Middle East and Africa ......................................................................................
Asia Pacific .....................................................................................................................
2013
2012
2011
39.3 %
38.7 %
22.0 %
40.0 %
39.1 %
20.9 %
41.0 %
40.0 %
19.0 %
Sources and Availability of Raw Materials
We use butadiene, styrene and isoprene (also referred to as monomers) as our primary raw materials in manufacturing our
products.
For our U.S. facilities, we procure a substantial majority of our monomers from U.S. suppliers. In Europe, we generally procure
our monomers from regional suppliers and in Brazil we generally purchase all our raw materials from local third-party suppliers. In
Japan, butadiene and isoprene are supplied under our joint venture agreement with JSR Corporation (“JSR”) and styrene is sourced
from local third-party suppliers. We believe our contractual and other arrangements with our suppliers of butadiene, styrene, and
isoprene will generally provide an adequate supply of raw materials at competitive, market-based prices to support our current sales
levels and that alternative sources of raw material supply are generally available to us, including on a spot market basis. However, we
can provide no assurance that suppliers will perform under their contracts, that we will be able to adequately replace expiring or
terminated contracts, that we would be able to obtain substitute arrangements on feasible terms or that we will generally be able to
source raw materials on economic terms in the future.
10
Butadiene. Butadiene is available on the global petrochemical market with approximately eight producers in the Americas, 30 in
Europe, 59 in Asia and six in the Middle East. We currently source our butadiene in the United States pursuant to contractual
arrangements generally having terms ranging from one to two years, subject to renewal conditions, and butadiene in Europe pursuant
to contracts and arrangements with LyondellBasell. The contract covering Germany will expire on December 31, 2040, and is subject
to renewal conditions at the conclusion of the current term unless terminated with prior written notice by either party. We acquire
butadiene in France from LyondellBasell under a contract that became effective on January 1, 2012 and expires on December 31,
2015, subject to renewal conditions. In Brazil, butadiene has been obtained from a local third-party source under contractual
arrangements with terms typically of two years. We are in the process of negotiating a renewed contractual arrangement with this
supplier, who has continued to supply butadiene since the expiration of the prior contract on a spot basis. In Japan, a majority of our
butadiene needs are sourced from JSR on a commercial supply basis.
Styrene. Styrene is available on the global petrochemical market with approximately 11 producers located in the Americas, 20 in
Europe, 52 in Asia and five in the Middle East. We currently source styrene in the United States, Europe and Brazil pursuant to
contractual arrangements generally having terms ranging from one to two years, subject to renewal conditions.
Isoprene. Isoprene is primarily produced and consumed captively by manufacturers for the production of IR, which is primarily
used in the manufacture of rubber tires. As a result, there is limited non-captive isoprene available in the market place. We currently
source our global isoprene requirements through a variety of contractual arrangements generally having terms ranging from one to two
years, subject to renewal conditions. We also purchase additional supplies of isoprene from various suppliers at prevailing market
prices. In Japan, the majority of our isoprene needs are sourced from JSR on a commercial supply basis and from alternative suppliers
as needed. We believe our contractual arrangements with several suppliers as well as spot arrangements and longstanding relationships
with other third-party suppliers of isoprene will generally provide adequate future supplies of isoprene at competitive prices to support
our current sales levels.
Competition
We compete with other SBC producers and non-SBC product producers primarily on the basis of price, breadth of product
availability, product quality and speed of service from order to delivery. We believe our customers also base their supply decisions on
the supplier’s ability to design and produce custom products and the availability of technical support. See “Part I, Item 1. Business”
for further discussion of competition in our end use markets.
SBC Industry. Our most significant competitors in the SBC industry are: Asahi Chemical, Chi Mei, Dynasol Elastomers,
Kuraray Company, Korea Kumho P.C., LCY, LG Chemical, Sinopec, Taiwan Synthetic Rubber Corporation, Versalis and Zeon
Corporation. Generally, however, we believe individual competitors do not compete across all of our end use markets.
Product Substitution. We also compete against a broad range of alternative, non-SBC products within each of our end use
markets. See “Part I, Item 1. Business” for further discussion of product substitution in our end use markets.
Operating and Other Agreements
Operating Agreements. LyondellBasell operates our manufacturing facility located in Berre, France. This facility is situated on a
major LyondellBasell refinery and petrochemical site at which other third party tenants also own facilities. LyondellBasell charges us
fees based on specified costs incurred in connection with operating and maintaining this facility, including the direct and indirect costs
of employees and subcontractors, reasonable insurance costs, certain taxes imposed on LyondellBasell (other than income taxes) and
depreciation and capital charges on certain assets. Pursuant to the agreement, LyondellBasell employs and provides all staff, other
than certain managers, assistant managers and technical personnel, whom we may appoint. In March 2012, we executed a new
operating agreement with LyondellBasell effective as of January 1, 2012. The agreement has an unlimited term, and is terminable as
of any date after December 31, 2014 upon 18 months’ prior notice by either party. The new agreement also provides for site services,
utilities, materials and facilities, which had previously been under a separate agreement.
Pursuant to an agreement dated March 31, 2000, as subsequently amended, LyondellBasell operates and provides certain
services, materials and utilities required to operate our manufacturing facility in Wesseling, Germany. We pay LyondellBasell a
monthly fee, as well as costs incurred by LyondellBasell in providing the various services, even if the facility fails to produce any
output (whether or not due to events within LyondellBasell’s control), and even if we reject some or all output. This agreement is
terminable after an initial term of 40 years upon five years’ prior written notice.
Under certain of these agreements, we are required to indemnify LyondellBasell, including in certain circumstances for loss and
damages resulting from LyondellBassell’s negligence in performing their obligations.
11
Information Systems
We utilize ERP software systems to support each of our facilities worldwide. Our ERP software systems utilize a single global
system, which provides reliability of our systems. The ERP software systems are supported by internal resources. Technical upgrades
to the ERP systems are performed every 12 to 18 months to ensure the recent functionality is available. New technology continues to
be approved and implemented to improve efficiencies, network resiliency and critical information protection. An annual disaster
recovery exercise is performed on critical systems, both internally and those utilizing third-party data centers.
Patents, Trademarks, Copyrights and Other Intellectual Property Rights
We rely on a variety of intellectual property rights to conduct our business, including patents, trademarks and trade secrets. In
2013, we were awarded 51 patents for new products or applications and at December 31, 2013, we had 1,176 granted patents and 249
pending patent applications. Since patents are generally in effect for a period of 20 years as of the filing date, this means that a
significant portion of our portfolio will remain in effect for a long period (assuming most of these applications will be granted). The
granted patents and the applications cover both the United States and foreign countries. We do not expect that the expiration of any
single patent or specific group of patents would have a material impact on our business. Our material trademarks will remain in effect
unless we decide to abandon any of them, subject to possible third-party claims challenging our rights. Similarly, our trade secrets will
preserve their status as such for as long as they are the subject of reasonable efforts, on our part, to maintain their secrecy. A
significant number of patents in our patent portfolio were acquired from Shell Chemicals. Shell Chemicals retained for itself fully-
transferable and exclusive licenses for their use outside of the elastomers field, as well as fully-transferable, non-exclusive licenses
within the field of elastomers for certain limited uses in non-competing activities. Shell Chemicals is permitted to sublicense these
rights. Shell Chemicals also retains the right to enforce these patents outside the elastomers field and recover any damages resulting
from these actions. Shell Chemicals may engage in or be the owner of a business that manufactures and/or sells elastomers in the
elastomers field, so long as they do not use patent rights or technical knowledge exclusively licensed to us.
As a general matter, our trade names are protected by trademark laws. Our products are marketed under the registered
trademarks “Kraton”, “Elexar”, “Giving Innovators Their Edge”, “NEXAR” and “Cariflex.”
In our almost 50 years in the SBC business, we have accumulated a substantial amount of technical and business expertise. Our
expertise includes: product development, design and formulation, information relating to the applications in which our products are
used, process and manufacturing technology, including the process and design information used in the operation, maintenance and
debottlenecking of our manufacturing facilities, and the technical service that we provide to our customers. We hold extensive
discussions with customers and potential customers to define their market needs and product application opportunities. Where we
believe necessary, we have implemented trade secret protection for our technical knowledge through non-analysis, secrecy and related
agreements.
Employees
We had 936 full-time employees at December 31, 2013. In addition, 172 LyondellBasell manufacturing employees operate our
manufacturing facilities and provide maintenance services in Europe under various operating and services arrangements. See “—
Operating and Other Agreements.” None of our employees in the United States are subject to collective bargaining agreements. In
Europe, Brazil and Japan, a significant number of our employees are in arrangements similar to collective bargaining arrangements.
We believe our relationships with our employees continue to be good.
Environmental Regulation
Our operations in the United States and abroad are subject to a wide range of environmental laws and regulations at the
international, national, state and local levels. These laws and regulations govern, among other things, air emissions, wastewater
discharges, solid and hazardous waste management, site remediation programs and chemical registration, use and management.
Pursuant to these laws and regulations, our facilities are required to obtain and comply with a wide variety of environmental
permits for different aspects of their operations. Generally, many of these environmental laws and regulations are becoming
increasingly stringent and the cost of compliance with these various requirements can be expected to increase over time.
12
For example, the U.S. Environmental Protection Agency (“EPA”) issued new “maximum achievable control technology”
(“MACT”) standards for controlling hazardous air emissions from industrial boilers. The MACT rule applies to the coal-burning
boilers at our Belpre, Ohio, facility. On December 20, 2012, the EPA announced that it had finalized the clean air standards for
industrial boilers, and certain incinerators, and non-hazardous secondary materials. On January 31, 2013, the final rule was published
in the Federal Register with an effective date of April 1, 2013 and a compliance date of January 31, 2016, three years from the date of
publication in the Federal Register. We plan to be in compliance with the MACT standards prior to the expiration of the compliance
period. Capital expenditures necessary to comply with the MACT rule are currently estimated to be $59.0 million of which
approximately $6.0 million will be in the form of a capital lease. Through 2013, we have incurred an aggregate $18.0 million, of
which $1.4 million was financed with a capital lease, and we currently expect 2014 capital expenditures for this project to be
approximately $28.1 million, of which $4.1 million will be financed with a capital lease with the balance expected to be incurred in
2015. While this is a compliance driven project, we also expect to lower operating costs by approximately $10.0 million per year by
2016.
Environmental laws and regulations in various jurisdictions also establish programs and, in some instances, obligations to clean
up contamination from current or historic operations. Under some circumstances, the current owner or operator of a site can be held
responsible for remediation of past contamination regardless of fault and regardless of whether the activity was legal at the time that it
occurred. Evaluating and estimating the potential liability related to site remediation projects is a difficult undertaking, and several of
our facilities have been affected by contamination from historic operations.
Our Belpre, Ohio, facility is the subject of a site investigation and remediation program administered by the EPA pursuant to the
Resource Conservation and Recovery Act (“RCRA”). In March 1997, Shell Chemicals entered into a consent order to investigate and
remediate areas of contamination on and adjacent to the site. In March 2003, we joined Shell Chemicals in signing a new consent
order that required additional remediation and assessment of various areas of contamination and continues to require groundwater-
monitoring and reporting. Shell Chemicals continues to take the lead in this program, has posted financial assurance of $5.2 million
for the work required under the consent order and has also indemnified us for the work required under this program, subject to the
condition that we provide notice of any claims on or prior to February 28, 2021. In turn, we have agreed with Shell Chemicals that we
will, for a fee, provide certain services related to the remediation program. We have agreed with Shell Chemicals that we will pay up
to $100,000 per year for the groundwater monitoring associated with the 2003 consent order.
Our Brazilian facility has also been affected by prior Shell Chemicals operations. A Shell Chemicals pesticide manufacturing
operation was previously located on a tract of land adjacent to our Brazilian facility. In addition, areas of our facility were used by
Shell Chemicals as part of its crop protection business. Shell Chemicals has retained responsibility for remediating a former
manufacturing facility located on our site and has also indemnified us for identified waste management areas used in prior operations.
The indemnity for remediation relating directly to the facility for the previous pesticide manufacturing operations and for disposal
activity related to that facility and for third-party claims regarding hazardous substance disposal expires in 2021. Shell Chemicals has
installed a hydraulic barrier to prevent migration of ground water contamination and has completed other cleanup actions on the site.
Shell Chemicals agreed to indemnify us for specific categories of environmental claims brought with respect to matters
occurring before our separation from Shell Chemicals in February 2001. Coverage under the indemnity varies depending upon the
nature of the environmental claim, the location giving rise to the claim and the manner in which the claim is triggered. The indemnity
for specific site clean-up matters and for third-party claims regarding hazardous substance disposal expires in 2021. Claims that may
arise in the future related to past operations may not be covered by the Shell Chemicals’ indemnities, and amounts that are recoverable
under those indemnities may not be sufficient to satisfy claims against us.
In addition, we may in the future be subject to claims that arise solely from events or circumstances occurring after February
2001 that would not, in any event, be covered by the Shell Chemicals’ indemnity. While we recognize that we may, in the future, be
held liable with respect to remediation activities beyond those identified to date, at present we are not aware of any circumstances that
are reasonably expected to give rise to remediation claims that would have a material adverse effect on our results of operations or
cause us to exceed our projected level of anticipated capital expenditures.
In January 2014, our Belpre, Ohio facility experienced a mechanical equipment failure due to inclement weather that resulted in
a release of process solvents into nearby waterways. Applicable authorities were notified, and cleanup activities are underway. Kraton
may be required to pay governmental fines or sanctions in excess of $100,000 in connection with this event.
Insurance
We have levels of insurance that we believe to be customary for a company of our size in our industry. Our insurance policies
are subject to customary deductibles and limits.
13
Seasonality
Seasonal changes and weather conditions typically affect the Paving and Roofing end use market and generally result in higher
sales volumes into this end use market in the second and third quarters of the calendar year compared to the first and fourth quarters of
the calendar year. Our other end use markets tend to show relatively little seasonality.
Available Information
We electronically file reports with the Securities and Exchange Commission (SEC), including annual reports on Form 10-K,
quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to such reports. The public may read and copy any
materials that we file with the SEC at the SEC’s Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549. The public
may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC also
maintains an internet site that contains reports and information statements, and other information regarding issuers that file
electronically with the SEC at http://www.sec.gov. Additionally, information about us, including our reports filed with the SEC, is
available through our web site at http://www.kraton.com. Such reports are accessible at no charge through our web site and are made
available as soon as reasonably practicable after such material is filed with or furnished to the SEC. Our website and the information
contained on that site, or connected to that site, are not incorporated by reference into this report.
14
Item 1A. Risk Factors.
Risk Factors Relating to the Proposed Combination with the SBC Business of LCY
Closing of the combination with LCY is subject to a number of material regulatory conditions.
The LCY Combination is subject to review by the Antitrust Division of the Department of Justice (the “Antitrust Division”) and
the Federal Trade Commission (the “FTC”) under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR
Act”), and by the antitrust and competition authorities in Taiwan, the People’s Republic of China and the Republic of Turkey, and
potentially other jurisdictions. Conditions to closing the LCY Combination include the clearance and approval under the rules of the
antitrust and competition authorities and that there is no judgment or regulatory action of a governmental body in effect that prohibits
the LCY Combination contemplated by the combination agreement. We can provide no assurance that all required regulatory
clearances will be obtained or that the conditions associated with such clearances will be acceptable to either party. In addition, in
some circumstances, a third party could initiate a private action under antitrust laws challenging or seeking to enjoin the LCY
Combination, before or after it is completed. We may not prevail and may incur significant costs in defending or settling any action
under the antitrust and competition laws.
In addition to antitrust and competition law clearances, the transactions are subject to completion of a series of transactions in
which LCY’s SBC operations in Taiwan will be conveyed to a subsidiary of LCY prior to the contribution of the equity interests of
such subsidiary to UK Holdco. Such transactions are subject to the approval of Taiwan regulatory authorities, and we and LCY can
provide no assurance that such approvals will be obtained.
We and LCY are subject to business uncertainties and contractual restrictions while the proposed LCY Combination is pending,
which could adversely affect each party’s business and operations.
In connection with the pending LCY Combination, it is possible that some customers, suppliers and other persons with whom
we or LCY have business relationships may delay or defer certain business decisions or, might decide to seek to terminate, change or
renegotiate their relationship with us or LCY as a result of the LCY Combination, which could negatively affect our and LCY’s
respective revenues and earnings, as well as the market price of our common stock, regardless of whether the LCY Combination is
completed. Under the terms of the combination agreement, we and LCY are subject to certain restrictions on the conduct of our
respective businesses prior to completing the LCY Combination, including, but not limited to, limitations on incurring debt outside of
borrowings under each party’s revolving credit facility in the ordinary course and entering into acquisitions and dispositions, which
may adversely affect our ability to execute certain of our respective business strategies. Furthermore, the process of planning to
integrate two businesses and organizations for the post-LCY Combination period can divert management attention and resources and
could ultimately have an adverse effect on each party.
Failure to successfully combine the businesses in the expected time frame may adversely affect the future results of the
combined organization, and, consequently, the value of our common stock.
The success of the proposed LCY Combination will depend substantially on our ability to realize the anticipated benefits and
synergies from combining our business with LCY’s SBC business. To realize these anticipated benefits, the businesses must be
successfully integrated and combined, and we will incur substantial costs to do so. We currently estimate the cost to achieve expected
annual synergies of $65.0 million (expected to be fully realized by 2017) to be approximately $70.0 million over the three year period
following closing and in addition, expect to incur transaction-related costs associated with completing the combination and integrating
the businesses. The combined organization may not be able to achieve its objectives or expected synergies, in which case the
anticipated benefits of the LCY Combination may not be realized fully or at all. In addition, costs to achieve anticipated synergies and
benefits may exceed our estimates, and the actual integration may result in additional and unforeseen expenses, which could reduce
the anticipated benefits of the LCY Combination. These unrealized benefits and difficulties could result in declines in the market value
of our common stock.
15
Failure to complete the LCY Combination, or significant delays in completing the LCY Combination, could negatively affect the
trading price of our common stock and our future business and financial results.
If the LCY Combination is not completed, or if there are significant delays in completing the LCY Combination, the trading
price of our common stock and our future business and financial results could be negatively affected, and we will be subject to several
risks, including the following:
•
•
•
•
the parties may be liable for damages to one another under the terms and conditions of the combination agreement;
negative reactions from the financial markets, including declines in the price of our common stock due to the fact that
current prices may reflect a market assumption that the LCY Combination will be completed;
having to pay certain significant costs relating to the LCY Combination; and
the attention of our management will have been diverted to the LCY Combination rather than to our current operations and
pursuit of other opportunities that could have been beneficial to the company.
We may not realize the benefits we anticipate from the proposed redomestication of our company from Delaware to the United
Kingdom.
We may not realize the benefits that we expect to realize from the redomestication of our company from Delaware to the United
Kingdom. The redomestication may also expose us to certain risks that could have an adverse effect on us or our results of operations.
For example, tax laws could change in the future, and such changes could cause a material change in our worldwide effective
corporate tax rate and cash flows. As a result, our actual effective tax rate may be materially different from our expectation. Further,
if the redomestication is completed, the rights of our stockholders as stockholders of an English company will differ from the rights
they have currently as shareholders of a U.S. company.
Risk Factors Relating to the Business
LyondellBasell Industries provides significant operating and other services under agreements that are important to our
business. The failure of LyondellBasell to perform its obligations, or the termination of these agreements, could adversely affect
our operations.
We have operating and service agreements with LyondellBasell Industries, or LyondellBasell, that are important to our business.
We are a party to:
•
•
operating agreements under which LyondellBasell (in Berre, France, and Wesseling, Germany) operates and maintains our
European manufacturing facilities and employs and provides substantially all of the staff for those facilities; these operating
agreements also provide for site services, utilities, materials and facilities, which had previously been under a separate
agreements; and
lease agreements under which we lease our European manufacturing sites (a 96 kiloton capacity facility in Wesseling,
Germany and a 87 kiloton capacity facility in Berre, France) from LyondellBasell.
Under the terms of the above agreements, either party is permitted to terminate the applicable agreement in a variety of
situations. The operating agreement relating to the Berre facility is terminable by either party upon 18 months’ written notice. As of
the date of this filing, no such notice has been given by either party. Should LyondellBasell fail to provide these services or should any
operating agreement be terminated, we would be forced to obtain these services from third parties or provide them ourselves.
Similarly, if in connection with or independent from the termination of an operating agreement, LyondellBasell terminates a facility
lease, we would be forced to relocate our manufacturing facility. The failure of LyondellBasell to perform its obligations under, or the
termination of, any of these agreements could materially adversely affect our operations and, depending on market conditions at the
time of any such termination, we may not be able to enter into substitute arrangements in a timely manner, if at all, and if we are able
to enter into a substitute arrangement, it may not be on terms as favorable to us.
Conditions in the global economy and capital markets may adversely affect the company’s results of operations, financial
condition and cash flows.
Our products are sold in markets that are sensitive to changes in general economic conditions, such as automotive, construction
and consumer products. Downturns in general economic conditions can cause fluctuations in demand for our products, product prices,
volumes and margins. A decline in the demand for our products or a shift to lower-margin products due to deteriorating economic
conditions could adversely affect sales of our products and our profitability and could also result in impairments of certain of our
assets.
16
Our business and operating results have been affected by the global recession, fluctuating commodity prices, volatile exchange
rates and other challenges currently affecting the global economy and our customers. Uncertainty regarding global economic
conditions poses a continuing risk to our business, as consumers and businesses may postpone spending in response to tighter credit,
negative financial news or declines in income or asset values, which may reduce demand for our products. If global economic and
market conditions, or economic conditions in key markets, remain uncertain or deteriorate further, our results of operations, financial
condition and cash flows could be materially adversely affected.
The failure of our raw materials suppliers to perform their obligations under long-term supply agreements, or our inability to
replace or renew these agreements when they expire, could increase our cost for these materials, interrupt production or
otherwise adversely affect our results of operations.
Our manufacturing processes use three primary raw materials: butadiene, styrene and isoprene. We have entered into long-term
supply agreements with Shell Chemicals, LyondellBasell and others to supply our raw material needs in the United States and Europe.
As these contracts expire, we may be unable to renew these contracts or obtain new long-term supply agreements on terms favorable
to us, if at all, which may significantly impact our operations.
In addition, most of our long-term contracts contain provisions that allow our suppliers to limit, or allocate, the amount of raw
materials shipped to us below the contracted amount in certain circumstances. If we are required to obtain alternate sources for raw
materials because a supplier is unwilling or unable to perform under raw material supply agreements or if a supplier terminates its
agreements with us, we may not be able to obtain these raw materials from alternative suppliers in sufficient quantities or in a timely
manner, and we may not be able to enter into long-term supply agreements on terms as favorable to us, if at all. A lack of availability
of raw materials could have a material adverse effect on our results of operations.
If the availability of isoprene is limited, we may be unable to produce some of our products in quantities or on economic terms
sought by our customers, which could have an adverse effect on our sales of products requiring isoprene.
Isoprene is not widely available, and the few isoprene producers tend to use their production for captive manufacturing purposes
or to sell only limited quantities into the world chemicals market. As a result, there is limited non-captive isoprene available for
purchase in the markets in which we operate.
Currently, we source our isoprene requirements for the United States and Europe from a portfolio of suppliers. In Japan, we
obtain the majority of our isoprene requirements from our joint venture partner, and from alternative suppliers as needed. In Brazil,
isoprene is primarily obtained from a local third party supplier. These suppliers may not be able to meet our isoprene requirements,
and we may not be able to obtain isoprene in quantities required for our operations on terms favorable to us, or at all. A lack of
availability of isoprene in the quantities we require to produce products containing isoprene could have a material adverse effect on
our results of operations.
Because there is limited non-captive isoprene availability, the market for isoprene is thin and prices are particularly volatile.
Prices for isoprene are impacted by the supply and prices of natural and synthetic rubber, prevailing energy prices and the existing
supply and demand of isoprene in the market. In the past, tight supply in the isoprene market has been exacerbated by operational
problems of some key producers and reduced availability of crude C5 inputs for the extraction units. More recently, the trend toward
lighter ethylene cracker feedslates has reduced the supply of crude C5 in the United States. This decrease has been replaced by imports
of crude C5 and/or isoprene. Significant increases in the cost of isoprene could have a material adverse impact on our business,
financial condition or results of operations.
If the availability of butadiene is limited, we may be unable to produce some of our products in quantities or on economic terms
sought by our customers, which could have an adverse effect on our sales of products requiring butadiene.
The North American market is structurally short of butadiene and has relied on imports of crude C4 and/or butadiene to balance
demand. With the trend toward lighter ethylene cracker feedslates in the United States, there has been a reduction in the supply of
crude C4. The North American market has been supplemented by imports of crude C4 and butadiene. Historically, the European
market has been better balanced and provided exports to North America. Currently, our butadiene requirements in the United States
are satisfied by several suppliers, and LyondellBasell is our major butadiene supplier in Europe. In general, the quantity of butadiene
available in any one region is dependent on the cracking inputs of olefins plants, ethylene demand, inter-regional demand for
butadiene and demand for other oil derivatives. Suppliers may not be able to meet our butadiene requirements, and we may not be able
to obtain substitute supplies of butadiene from alternative suppliers in a timely manner or on favorable terms. A lack of availability of
butadiene in the quantities we require to produce products containing butadiene could have a material adverse effect on our results of
operations.
17
If the availability of styrene is limited, we may be unable to produce some of our products in quantities or on economic terms
sought by our customers, which could have an adverse effect on facility utilization and our sales of products requiring styrene.
We satisfy our styrene requirements in the United States and Europe pursuant to purchase agreements with terms of one to two
years, subject to renewal conditions. We have more than one supplier in each of these regions and also generally have alternatives for
either modifying the contract, supply portfolio or obtaining spot supply. As contracts expire, we cannot give assurances that we will
obtain new long-term supply agreements or that the terms of any such agreements will be on terms favorable to us, and consequently
our future acquisition costs for styrene may therefore increase.
Increases in the costs of our raw materials could have an adverse effect on our financial condition and results of operations if
those costs cannot be passed onto our customers.
Our results of operations are directly affected by the cost of raw materials. We use butadiene, styrene, and isoprene as our
primary raw materials in manufacturing our products. On a first-in, first-out (FIFO) basis, these monomers together represented
approximately $609.5 million, $732.9 million and $658.9 million or 57.2%, 61.5% and 58.8% of our total cost of goods sold for the
years ended December 31, 2013, 2012 and 2011, respectively. Since the cost of our three primary raw materials comprise a significant
amount of our total cost of goods sold, our selling prices for our products and therefore our total sales revenue is impacted by
movements in our raw material costs, as well as the cost of other inputs. In the past we have experienced erratic and significant
changes in the costs of these monomers, the cost of which has generally correlated with changes in energy prices, supply and demand
factors, and prices for natural and synthetic rubber. The pricing for butadiene has historically been particularly volatile. Political unrest
in the Middle East and market dislocation resulting from U.S. sanctions relating thereto could lead to increases in the price of crude
oil, and, as a result, in the price of our primary raw materials. In addition, product mix can have an impact on our overall unit selling
prices, since we provide an extensive product offering and therefore experience a wide range of unit selling prices. Because of the
significant portion of our cost of goods sold represented by these three monomers, our gross profit margins could be adversely
affected by changes in the cost of these raw materials if we are unable to pass the increases on to our customers.
In response to volatile raw material price increases, we have aggressively pursued price increases for our products to offset
increased costs. Although we have been successful in recovering a substantial amount of the raw material cost increases while
retaining customers, there can be no assurance that we can continue to recover raw material costs or retain customers in the future. As
a result of our pricing actions, customers may become more likely to consider competitors’ products, some of which may be available
at a lower cost. Significant loss of customers could result in a material adverse effect on our results of operations.
Significant fluctuations in raw material costs may result in volatility in our quarterly operating results and impact the market
price of our common stock.
We use the FIFO basis of accounting for inventory and cost of goods sold, and therefore gross profit. In periods of raw material
price volatility, reported results under FIFO will differ from what the results would have been if cost of goods sold were based on
estimated current replacement cost (ECRC). Specifically, in periods of declining raw material costs, reported gross profit will be lower
under FIFO than under ECRC, and in periods of rising raw material costs, gross profit will be higher under FIFO than under ECRC.
However, because monomer costs are difficult to predict, we cannot accurately anticipate fluctuations in monomer costs with
precision, or effectively or economically hedge against the effects of any such change. If monomer costs fluctuate in a quarter, our
earnings will be affected, the magnitude of which could be significant, which could cause our earnings to depart from the periodic
expectations of financial analysts or investors and, therefore, the market price of our common stock may be volatile as a result.
Our end use markets are highly competitive, and we may lose market share to other producers of styrenic block copolymers or to
producers of other products that can be substituted for our products.
Our industry is highly competitive, and we face significant competition from both large international producers and from
smaller regional competitors. Our competitors may improve their competitive position in our core end use markets by successfully
introducing new products, improving their manufacturing processes or expanding their capacity or manufacturing facilities. Further,
some of our competitors benefit from advantageous cost positions that could make it increasingly difficult for us to compete in
markets for less-differentiated applications. If we are unable to keep pace with our competitors’ product and manufacturing process
innovations or cost position, our financial condition and results of operations could be materially adversely affected.
In addition, competition between styrenic block copolymers and other products within the end use markets in which we compete
is intense. Increased competition from existing or newly developed SBC or non-SBC products may reduce demand for our products in
the future and our customers may decide on alternate sources to meet their requirements. If we are unable to successfully compete
with other producers of styrenic block copolymers or if other products can be successfully substituted for our products, our sales may
decline.
18
If we are not able to continue the technological innovation and successful commercial introduction of new products, our
customers may turn to other producers to meet their requirements.
Our industry and the end use markets into which we sell our products experience periodic technological change and ongoing
product improvements. In addition, our customers may introduce new generations of their own products or require new technological
and increased performance specifications that would require us to develop customized products. Innovation or other changes in our
customers’ product performance requirements may also adversely affect the demand for our products. Our future growth and
profitability will depend on our ability to gauge the direction of the commercial and technological progress in all key end use markets,
and upon our ability to successfully develop, manufacture and market products in such changing end use markets. In order to maintain
our profit margins and our competitive position, we must continue to identify, develop and market innovative products on a timely
basis to replace existing products. We may not be successful in developing new products and technology that successfully compete
with newly introduced products and materials, and our customers may not accept, or may have lower demand for, any of our new
products. Further, an important part of our strategy is the creation of demand for innovations that we develop and introduce to the
markets. If we fail to keep pace with evolving technological innovations, fail to modify our products in response to our customers’
needs or fail to develop innovations that generate additional demand, then our business, financial condition and results of operations
could be adversely affected as a result of reduced sales of our products or diminished return on investment in innovations..
Our business relies on intellectual property and other proprietary information, and our failure to protect our rights could harm
our competitive advantages with respect to the manufacturing of some of our products.
Our success depends to a significant degree upon our ability to protect and preserve our intellectual property and other
proprietary information relating to our business. However, we may be unable to prevent third parties from using our intellectual
property and other proprietary information without our authorization or from independently developing intellectual property and other
proprietary information that is similar to ours, particularly in those countries where the laws do not protect our proprietary rights to the
same degree as in the United States. The use of our intellectual property and other proprietary information by others could reduce or
eliminate any competitive advantage we have developed, potentially causing us to lose sales or otherwise harm our business. If it
becomes necessary for us to litigate to protect these rights, any proceedings could be burdensome and costly, and we may not prevail.
In addition, we acquired a significant number of patents from Shell Chemicals. According to the agreements with Shell
Chemicals relating to their contribution of these patents to us and our ownership of these patents, Shell Chemicals retained for itself
fully-transferable and exclusive licenses to their use outside of the elastomers business, as well as fully-transferable non-exclusive
licenses within the field of elastomers for certain limited uses in non-competing activities. Shell Chemicals is permitted to sublicense
these rights. Shell Chemicals also retains the right to enforce these patents outside the elastomers field and recover any damages
resulting from these actions.
Our patent applications and issued patents may not provide us with any competitive advantage and may be challenged by third
parties. Our competitors may also attempt to design around our patents or copy or otherwise obtain and use our intellectual property
and other proprietary information. Moreover, our competitors may already hold or have applied for patents in the United States or
abroad that, if enforced or issued, could possibly prevail over our patent rights or otherwise limit our ability to manufacture or sell one
or more of our products in the United States or abroad. With respect to our pending patent applications, we may not be successful in
securing patents for these claims. Our failure to secure these patents may limit our ability to protect inventions that these applications
were intended to cover. In addition, the expiration of a patent can result in increased competition with consequent erosion of profit
margins.
It is our policy to enter into confidentiality agreements with our employees and third parties to protect our unpatented
proprietary manufacturing expertise, continuing technological innovation and other trade secrets, but our confidentiality agreements
could be breached or may not provide meaningful protection for our trade secrets or proprietary manufacturing expertise. Adequate
remedies may not be available in the event of an unauthorized use or disclosure of our trade secrets and manufacturing expertise.
Violations by others of our confidentiality agreements and the loss of employees who have specialized knowledge and expertise could
harm our competitive position and cause our sales and operating results to decline as a result of increased competition. In addition,
others may obtain knowledge of our trade secrets through independent development or other access by legal means.
The applicable governmental authorities may not approve our pending service mark and trademark applications. A failure to
obtain trademark registrations in the United States and in other countries could limit our ability to obtain and retain our trademarks
and impede our marketing efforts in those jurisdictions. Moreover, third parties may seek to oppose our applications or otherwise
challenge the resulting registrations. In the event that our trademarks are successfully challenged, we could be forced to rebrand our
products, which could result in loss of brand recognition and could require us to devote resources to advertising and marketing new
brands.
19
The failure of our patents, trademarks or confidentiality agreements to protect our intellectual property and other proprietary
information, including our processes, apparatuses, technology, trade secrets, trade names and proprietary manufacturing expertise,
methods and compounds, could have a material adverse effect on our competitive advantages over other producers.
Our products may infringe the intellectual property rights of others, which may cause us to incur unexpected costs or prevent us
from selling our products.
Many of our competitors have a substantial amount of intellectual property. We cannot guarantee that our processes and
products do not and will not infringe issued patents (whether present or future) or other intellectual property rights belonging to others,
including, without limitation, situations in which our products, processes or technologies may be covered by patent applications filed
by other parties in the United States or abroad.
From time to time, we oppose patent applications that we consider overbroad or otherwise invalid in order to maintain the
necessary freedom to operate fully in our various business lines without the risk of being sued for patent infringement. If, however,
patents are subsequently issued on any such applications by other parties, or if patents belonging to others already exist that cover our
products, processes or technologies, we could be liable for infringement or have to take other remedial or curative actions to continue
our manufacturing and sales activities with respect to one or more products.
We may also be subject to legal proceedings and claims in the ordinary course of our business, including claims of alleged
infringement of the patents, trademarks and other intellectual property rights of third parties by us or our licensees in connection with
their use of our products. Intellectual property litigation is expensive and time-consuming, regardless of the merits of any claim, and
could divert our management’s attention from operating our business.
If we were to discover that our processes, technologies or products infringe the valid intellectual property rights of others, we
might need to obtain licenses from these parties or substantially re-engineer our products in order to avoid infringement. We may not
be able to obtain the necessary licenses on acceptable terms, or at all, or be able to re-engineer our products successfully. Moreover, if
we are sued for infringement and lose, we could be required to pay substantial damages and/or be enjoined from using or selling the
infringing products or technology. If we incur significant costs to litigate our intellectual property rights or to obtain licenses, or if our
inability to obtain required licenses for our processes, technologies or products prevents us from selling our products , our business
and results of operations could be materially adversely affected.
A major failure of our information systems could harm our business.
We depend on integrated information systems to conduct our business. We may experience operating problems with our
information systems as a result of system failures, viruses, computer “hackers” or other causes. If our systems for protecting against
these risks prove not to be sufficient, we could be adversely affected by, among other things, loss or damage of intellectual property,
proprietary information, or customer data, having our business operations interrupted, and increased costs to prevent, respond to, or
mitigate attacks on our systems. Any significant disruption or slowdown of our systems could cause customers to cancel orders or
cause standard business processes to become inefficient or ineffective, which could adversely affect our financial position, results of
operations or cash flows.
Our business is subject to seasonality that may affect our quarterly operating results and impact the market price of our
common stock.
Seasonal changes and weather conditions typically affect our Paving and Roofing end use market. In particular, sales volumes
for paving products generally rise in the warmer months and generally decline during the colder months of fall and winter. Roofing
product sales volumes tend to be more consistent throughout the year. In addition, abnormally cold or wet seasons may cause reduced
purchases from our Paving and Roofing customers. However, because seasonal weather patterns are difficult to predict, we cannot
accurately estimate fluctuations in our quarterly Paving and Roofing sales in any given year. If Paving and Roofing results cause our
operating results to fall below the periodic expectations of financial analysts or investors, the market price of our common stock may
decline.
Substantial indebtedness could adversely affect our financial condition and prevent us from fulfilling our obligations under the
senior secured credit facilities and the senior notes.
As of December 31, 2013, we had $350.0 million principal amount of indebtedness outstanding in the form of senior unsecured
notes. Additionally, we have entered into an asset-based revolving credit facility consisting of a $150.0 million U.S. senior secured
revolving credit facility and a $100.0 million Dutch senior secured revolving credit facility. As of December 31, 2013, the facilities
were undrawn, and available borrowing capacity was $186.9 million.
20
We may request up to an aggregate of $100.0 million of additional revolving facility commitments of which up to an aggregate
of $40.0 million may be additional Dutch revolving facility commitments, provided that we satisfy additional conditions described in
the senior secured credit facilities, and provided further that the U.S. revolver commitment is at least 60% of the commitments after
giving effect to such increase.
Although the terms of our senior secured credit facilities and the indenture governing the senior notes contain restrictions on the
incurrence of additional indebtedness, these restrictions are subject to a number of important exceptions, and additional indebtedness
that we may incur from time to time to finance projects or for other reasons in compliance with these restrictions could be substantial.
For example, we expect a significant portion of the construction of the 30 kiloton plant in Mailiao, Taiwan by our KFPC joint venture
will be financed with indebtedness, half of which we or one of our subsidiaries would guarantee. If we and our restricted subsidiaries
incur significant additional indebtedness, the related risks that we face could increase.
Our indebtedness could:
• make it more difficult for us to satisfy our financial obligations;
•
•
•
•
•
•
•
increase our vulnerability to adverse economic and industry conditions;
increase the risk that we breach financial covenants and other restrictions in our debt agreements, which can be exacerbated
by volatility in the cost of our monomers and the resulting impact on our earnings;
require us to dedicate a substantial portion of our cash flow from operations to make payments on our indebtedness, thereby
reducing the availability of our cash flow to fund working capital, capital expenditures and other general corporate
purposes;
limit our flexibility in planning for, or reacting to, changes in the business and industry in which we operate;
restrict us from exploiting business opportunities;
place us at a disadvantage compared to our competitors that have less debt and lease obligations; and
limit our ability to borrow additional funds for working capital, capital expenditures, acquisitions, debt service
requirements, execution of our business strategy and other general corporate purposes or to refinance our existing debt.
Our ability to pay principal of and interest on indebtedness, fund working capital and make anticipated capital expenditures
depends on our future performance, which is subject to general economic conditions and other factors, some of which are beyond our
control. There can be no assurance that our business will generate sufficient cash flow from operations or that future borrowings will
be available under the senior secured credit facilities to fund liquidity needs, including debt service. Furthermore, if we decide to
undertake additional investments in existing or new facilities, this will likely require additional capital, and there can be no assurance
that this capital will be available.
Our debt instruments, including our senior secured credit facilities and the indenture governing our senior notes, impose
significant operating and financial restrictions on us and affect our ability to access liquidity.
Our senior secured credit facilities and the indenture governing our senior notes contain, and any future indebtedness may
contain, a number of restrictive covenants that impose significant operating and financial restrictions on us. Under the terms of our
senior secured credit facilities, we are subject to a financial covenant requiring us to maintain a fixed charge coverage ratio of 1.0 to
1.0 if availability under the facilities is below specified amounts. In addition, our senior secured credit facilities and indenture include
restrictions on our ability to, in certain circumstances, among other things:
•
place liens on our or our subsidiaries’ assets;
• make investments other than permitted investments;
•
incur additional indebtedness;
• merge, consolidate or dissolve;
•
•
•
•
sell assets;
engage in transactions with affiliates;
change the nature of our business;
change our or our subsidiaries’ fiscal year or organizational documents; and
• make restricted payments (including certain equity issuances).
21
A failure by us or our subsidiaries to comply with the covenants and restrictions contained in the agreements governing our
indebtedness could result in an event of default under such indebtedness, which could adversely affect our ability to respond to
changes in our business and manage our operations. Upon the occurrence of an event of default under any of the agreements
governing our indebtedness, the lenders could elect to declare all amounts outstanding to be due and payable and exercise other
remedies as set forth in the agreements. Further, an event of default or acceleration of indebtedness under one instrument may
constitute an event of default under another instrument. If any of our indebtedness were to be accelerated, there can be no assurance
that our assets would be sufficient to repay this indebtedness in full, which could have a material adverse effect on our ability to
continue to operate as a going concern.
Chemical manufacturing is inherently hazardous, which could result in accidents that disrupt our operations or expose us to
significant losses or liabilities.
Hazards associated with chemical manufacturing and the related storage and transportation of raw materials, products and
wastes exist in our operations and the operations of other occupants with whom we share manufacturing sites. These hazards could
lead to an interruption or suspension of operations and have an adverse effect on the productivity and profitability of a particular
manufacturing facility or on us as a whole. These potential risks include, but are not necessarily limited to:
•
•
•
•
pipeline and storage tank leaks and ruptures;
explosions and fires;
inclement weather and natural disasters;
terrorist attacks;
• mechanical failure; and
•
chemical spills and other discharges or releases of toxic or hazardous substances or gases.
These hazards may result in personal injury and loss of life, damage to property and contamination of the environment, which
may result in a suspension of operations and the imposition of civil or criminal penalties, including governmental fines, expenses for
remediation and claims brought by governmental entities or third parties. The loss or shutdown of operations over an extended period
at our Belpre facility, which is our largest manufacturing facility, or any of our other major operating facilities could have a material
adverse effect on our financial condition and results of operations. Our property, business interruption and casualty insurance may not
fully insure us against all potential hazards incidental to our business.
We may be liable for damages based on product liability claims brought against our customers in our end use markets.
Many of our products provide critical performance attributes to our customers’ products that are sold to consumers who could
potentially bring product liability suits in which we could be named as a defendant. The sale of these products entails the risk of
product liability claims. If a person were to bring a product liability suit against one of our customers, the customer may attempt to
seek contribution from us. A person may also bring a product liability claim directly against us. A successful product liability claim or
series of claims against us in excess of our insurance coverage, for which we are not otherwise indemnified, could have a material
adverse effect on our financial condition or results of operations. There can be no assurance that our efforts to protect ourselves from
product liability claims in this regard will ultimately protect us from any such claims.
As a global business, we are exposed to local business risks in different countries, which could have a material adverse effect on
our financial condition or results of operations.
We have significant operations in foreign countries, including manufacturing facilities, research and development facilities,
sales personnel and customer support operations. Currently, we operate, or others operate on our behalf, facilities in Brazil, Germany,
France and Japan, in addition to our operations in the United States. In February 2013, we executed definitive agreements governing
the formation of a 50/50 joint venture with FPCC in Mailiao, Taiwan.
Our foreign operations are subject to risks inherent in doing business in foreign countries, including, but not necessarily limited
to:
•
•
•
•
new and different legal and regulatory requirements in local jurisdictions;
export duties or import quotas;
domestic and foreign customs and tariffs or other trade barriers;
potential staffing difficulties and labor disputes;
22
•
risk of non-compliance with the United States Foreign Corrupt Practices Act or similar anti-bribery legislation in other
countries by agents or other third-party representatives;
• managing and obtaining support and distribution for local operations;
•
•
•
•
•
•
•
•
increased costs of transportation or shipping;
credit risk and financial conditions of local customers and distributors;
potential difficulties in protecting intellectual property;
risk of nationalization of private enterprises by foreign governments;
potential imposition of restrictions on investments;
potentially adverse tax consequences, including imposition or increase of withholding and other taxes on remittances and
other payments by subsidiaries;
foreign currency exchange restrictions and fluctuations;
local political and social conditions, including the possibility of hyperinflationary conditions and political instability in
certain countries; and
•
civil unrest, including labor unrest, in response to local political conditions.
We may not be successful in developing and implementing policies and strategies to address the foregoing risks in a timely and
effective manner at each location where we do business. Consequently, the occurrence of one or more of the foregoing risks could
have a material adverse effect on our international operations or upon our financial condition and results of operations.
Compliance with extensive environmental, health and safety laws could require material expenditures, changes in our
operations or site remediation.
Materials such as butadiene, styrene and isoprene, which are used in the manufacture of our products, can represent potentially
significant health and safety concerns. Our products are also used in a variety of end uses that have specific regulatory requirements
such as those relating to products that have contact with food or medical end uses.
We use large quantities of hazardous substances and generate hazardous wastes in our manufacturing operations. Consequently,
our operations are subject to extensive environmental, health and safety laws and regulations at the international, national, state and
local level in multiple jurisdictions. These laws and regulations govern, among other things, air emissions, wastewater discharges,
solid and hazardous waste management, site remediation programs and chemical use and management. Many of these laws and
regulations have become more stringent over time and the costs of compliance with these requirements may increase, including costs
associated with any necessary capital investments. In addition, our production facilities require operating permits that are subject to
renewal and, in some circumstances, revocation. The necessary permits may not be issued or continue in effect, and renewals of any
issued permits may contain significant new requirements or restrictions. The nature of the chemical industry exposes us to risks of
liability due to the use, production, management, storage, transportation and sale of materials that are heavily regulated or hazardous
and can cause contamination or personal injury or damage if released into the environment.
Because of the nature of our operations, we could be subject to legislation and regulation affecting the emission of greenhouse
gases. In the last five years, the EPA promulgated regulations applicable to projects involving greenhouse gas emissions above a
certain threshold, and the U.S. and certain states within the U.S. have enacted, or are considering, limitations on greenhouse gas
emissions. Jurisdictions outside the U.S. are also addressing greenhouse gases by legislation or regulation. In addition, efforts have
been made and continue to be made at the international level toward the adoption of international treaties or protocols that would
address global greenhouse gas emissions. These requirements to limit greenhouse gas emissions may require us to incur capital
investments to upgrade our operations to comply with any future greenhouse gas emissions controls. While the impact of any such
legislation, regulation, treaties or protocols is currently speculative, any such legislation, regulation, treaties or protocols, if enacted,
may have an adverse effect on our operations or financial condition. Further, some scientific studies on the effect of the emission of
greenhouse gases on climate suggest that adverse weather events may become stronger or more frequent in the future in certain of the
areas in which we operate, although the scientific studies are not unanimous. Due to their location, some of our operations may be
vulnerable to operational and structural damages resulting from hurricanes and other severe weather systems. Our insurance may not
cover all associated losses. We are taking steps to mitigate physical risks from storms, but no assurance can be given that future storms
will not have a material adverse effect on our business.
23
Compliance with environmental laws and regulations generally increases the costs of transportation and storage of raw materials
and finished products, as well as the costs of storage and disposal of wastes. We may incur substantial costs, including fines, damages,
criminal or civil sanctions and remediation costs, or experience interruptions in our operations for violations arising under
environmental laws, regulations or permit requirements.
Regulation of our employees’ exposure to butadiene could require material expenditures or changes in our operations.
Butadiene is a known carcinogen in laboratory animals at high doses and is being studied for its potential adverse health effects.
The Occupational Safety and Health Administration limits the permissible employee exposure to butadiene. Future studies on the
health effects of butadiene may result in additional regulations or new regulations in Europe that further restrict or prohibit the use of,
and exposure to, butadiene. Additional regulation of butadiene could require us to change our operations, and these changes could
affect the quality of our products and materially increase our costs.
We may be subject to losses due to lawsuits arising out of environmental damage or personal injuries associated with chemical
manufacturing.
We face the risk that individuals could, in the future, seek damages for personal injury due to exposure to chemicals at our
facilities or to chemicals otherwise owned or controlled by us. We may be subject to future claims with respect to workplace exposure,
workers’ compensation and other matters that are filed after the date of our acquisition of Shell Chemicals’ elastomers business. While
Shell Chemicals has agreed to indemnify us for certain claims brought with respect to matters occurring before our separation from
Shell Chemicals in February 2001, those indemnity obligations are subject to limitations, and we cannot be certain that those
indemnities will be sufficient to satisfy claims against us. In addition, we face the risk that future claims would fall outside of the
scope of the indemnity due either to the limitations on the indemnity or to their arising from events and circumstances occurring after
February 2001. Finally, under certain of the lease and operating agreements under which LyondellBasell leases and provides services
to our sites in Wesseling, Germany, and Berre, France, we are required to indemnify LyondellBasell in certain circumstances,
including in certain circumstances for loss and damages resulting from LyondellBasell’s negligence in performing their obligations.
Some environmental laws could impose on us the entire cost of clean-up of contamination present at a facility even though we
did not cause the contamination. These laws often identify the site owner as one of the parties that can be jointly and severally liable
for on-site remediation, regardless of fault or whether the original activity was legal at the time it occurred. For example, our Belpre,
Ohio, facility is the subject of a required remediation program to clean up past contamination at the site and at an adjacent creek and
we are a party to that site clean-up order. While Shell Chemicals has posted financial assurance of $5.2 million for this program and
has taken the lead in implementing the program, we may incur costs and be required to take action under this program. Similarly, the
Shell Chemicals indemnity for remediation at the Belpre facility may not cover all claims that might be brought against us.
Our Paulinia, Brazil, facility also has on-site contamination resulting from past operations of Shell Chemicals. Although an
indemnity from Shell Chemicals covers claims related to specified areas within the facility, we may be required to undertake and pay
for remediation of these and other areas. The indemnity coverage from Shell Chemicals is limited in time and amount and we cannot
rely upon it to cover possible future claims for on-site contamination separate from the areas specified in the indemnity. The Paulinia
facility is also adjacent to a former Shell Chemicals site where we believe past manufacturing of hydrocarbons resulted in significant
contamination of soil and groundwater and required relocation of nearby residents. It is our understanding that the Shell Chemicals
portion of the site has changed ownership several times, which may impact financial responsibility for contamination on the site.
While we are not aware of any significant contamination at our Paulinia facility, we could potentially be the subject of claims related
to pesticide contamination and effects at some point in the future.
In general, there is always the possibility that a third-party plaintiff or claimant, or governmental or regulatory authority, could
seek to include us in an action or claim for damages, clean-up, or remediation pertaining to events or circumstances occurring or
existing at one or more of our sites prior to the time of our ownership or occupation of the applicable site. In the event that any of
these actions or claims were asserted against us, our results of operations could be adversely affected.
Regulatory and statutory changes applicable to us or our customers could adversely affect our financial condition and results of
operations.
We and many of the applications for the products in the end use markets in which we sell our products are regulated by various
national and local rules, laws and regulations. Changes in any of these areas could result in additional compliance costs, seizures,
confiscations, recall or monetary fines, any of which could prevent or inhibit the development, distribution and sale of our products.
For example, changes in environmental regulations restricting the use of disposable diapers could cause a decline in sales to producers
of that product. In addition, we benefit from certain trade protections, including anti-dumping protection. If we were to lose these
protections, our results of operations could be adversely affected.
24
We are subject to customs, international trade, export control, antitrust, zoning and occupancy and labor and employment laws
that could require us to modify our current business practices and incur increased costs.
We are subject to numerous regulations, including customs and international trade laws, export control, antitrust laws and
zoning and occupancy laws that regulate manufacturers generally and/or govern the importation, promotion and sale of our products,
the operation of factories and warehouse facilities and our relationship with our customers, suppliers and competitors. If these
regulations were to change or were violated by our management, employees, suppliers, buying agents or trading companies, the costs
of certain goods could increase, or we could experience delays in shipments of our goods, be subject to fines or penalties, or suffer
reputational harm, which could reduce demand for our products and hurt our business and negatively impact our results of operations.
In addition, changes in federal and state minimum wage laws and other laws relating to employee benefits could cause us to incur
additional wage and benefits costs, which could negatively impact our profitability.
Legal requirements are frequently changed and subject to interpretation, and we are unable to predict the ultimate cost of
compliance with these requirements or their effects on our operations. We may be required to make significant expenditures or modify
our business practices to comply with existing or future laws and regulations, which may increase our costs and materially limit our
ability to operate our business.
Fluctuations in currency exchange rates may significantly impact our results of operations and may significantly affect the
comparability of our results between financial periods.
Our operations are conducted by subsidiaries in many countries. The results of the operations and the financial position of these
subsidiaries are reported in the relevant foreign currencies and then translated into U.S. dollars at the applicable exchange rates for
inclusion in our consolidated financial statements. The main currencies to which we are exposed, besides the U.S. dollar, are the Euro,
Japanese Yen and Brazilian Real. The exchange rates between these currencies and the U.S. dollar in recent years have fluctuated
significantly and may continue to do so in the future. A depreciation of these currencies against the U.S. dollar will decrease the U.S.
dollar equivalent of the amounts derived from these operations reported in our consolidated financial statements and an appreciation of
these currencies will result in a corresponding increase in such amounts. Because many of our raw material costs are determined with
respect to the U.S. dollar rather than these currencies, depreciation of these currencies may have an adverse effect on our profit
margins or our reported results of operations. Conversely, to the extent that we are required to pay for goods or services in foreign
currencies, the appreciation of such currencies against the U.S. dollar will tend to negatively impact our results of operations. In
addition, currency fluctuations may affect the comparability of our results of operations between financial periods.
We incur currency transaction risk whenever we enter into either a purchase or sale transaction using a currency other than the
local currency of the transacting entity. From time to time, we use hedging strategies to reduce our exposure to currency fluctuations.
Given the volatility of exchange rates, there can be no assurance that we will be able to effectively manage our currency transaction
risks, that our hedging activities will be effective or that any volatility in currency exchange rates will not have a material adverse
effect on our financial condition or results of operations.
We may have additional tax liabilities.
We are subject to income taxes and state taxes in the U.S., as well as numerous foreign jurisdictions. Significant judgment is
required in determining our worldwide provision for income taxes. In the ordinary course of our business, there are many transactions
and calculations where the ultimate tax determination is uncertain. Although we believe our tax estimates are reasonable, the final
determination of tax audits and any related litigation could be materially different to that which is reflected in our consolidated
financial statements. Should any tax authority take issue with our estimates, our results of operations, financial position and cash flows
could be adversely affected.
Our formation of a joint venture to expand HSBC capacity in Asia is subject to risks and uncertainties.
We are a 50/50 joint venture partner with FPCC to build, own and operate a 30 kiloton HSBC plant at FPCC’s petrochemical
site in Mailiao, Taiwan. Construction of the HSBC plant commenced recently; however, the plant may not be successfully constructed
and operated within our expected timeframe or budget or yield expected results. In addition, the project remains subject to numerous
known and unknown contingencies, including material governmental approvals and permitting; cost and availability of raw materials,
labor and financing; weather and operational delays; and economic, political and other disruptions. If any of these risks materialize,
our prospects in Asia and as a result, our ability to meet demand for HSBC products could be materially adversely affected.
25
In January 2014, a group of local residents in Mailiao, Taiwan, sued the Taiwanese Executive Yuan (the executive branch of the
Taiwanese government) to overturn an appeal decision rendered by the Executive Yuan in which it had overturned a prior ruling of the
Taiwan Environmental Protection Administration. The Taiwan EPA ruling in question required the inclusion of restrictive conditions
relating to FPCC’s entire petrochemical site in Mailiao, Taiwan, which is the site of our joint venture with FPCC, in the environmental
permit for the construction of the HSBC plant by our joint venture company. Neither we nor our joint venture is a party to the
proceedings, nor do we or our joint venture have any right under Taiwan law to join the proceedings. We have been informed that the
court in the proceeding has issued a ruling that could reinstate the restrictive conditions in FPCC’s environmental permit, although as
of the date of this filing, we do not have clear guidance on the reasoning for or the extent of the judge’s ruling. The ruling could
conflict with the prior appeal decision of the Executive Yuan, and if the ruling is not overturned, it could adversely impact the ability
of the joint venture to obtain material operating permits in the future.
Our relationship with our employees could deteriorate, which could adversely affect our operations.
As a manufacturing company, we rely on our employees and good relations with our employees to produce our products and
maintain our production processes and productivity. We had 936 full-time employees as of December 31, 2013. A significant number
of our non-U.S. employees are subject to arrangements similar to collective bargaining arrangements. With respect to these
employees, we may not be able to negotiate labor agreements on satisfactory terms, and actions by our employees may disrupt our
business. If these workers were to engage in a strike, work stoppage or other slowdown, our operations could be disrupted or we could
experience higher labor costs. In addition, if our other employees were to become unionized, in particular our employees at our
Belpre, Ohio facility, we could experience significant operating disruptions and higher ongoing labor costs, which could adversely
affect our business and financial condition and results of operations. Because many of the personnel who operate our European
facilities are employees of LyondellBasell, relations between LyondellBasell and its employees may also adversely affect our business
and financial condition and results of operations.
Loss of key personnel or our inability to attract and retain new qualified personnel could hurt our business and inhibit our
ability to operate and grow successfully.
Our success in the highly competitive markets in which we operate will continue to depend to a significant extent on our key
employees. We are dependent on the expertise of our executive officers. Loss of the services of any of our executive officers could
have an adverse effect on our prospects. We may not be able to retain our key employees or to recruit qualified individuals to join our
company. The loss of key employees could result in high transition costs and could disrupt our operations.
We generally do not have long-term contracts with our customers and the loss of customers could adversely affect our sales and
profitability.
With some exceptions, our business is based primarily upon individual sales orders with our customers. As such, our customers
could cease buying our products from us at any time, for any reason, with little or no recourse. If multiple customers elected not to
purchase products from us, our business prospects, financial condition and results of operations could be adversely affected.
A decrease in the fair value of pension assets could materially increase future funding requirements of the pension plan.
We sponsor a defined benefit pension plan. The total projected benefit obligation of our defined benefit pension plan exceeded
the fair value of the plan assets by approximately $29.5 million at December 31, 2013. We contributed $6.2 million to the pension
plan in 2013. Among the key assumptions inherent in the actuarially calculated pension plan obligation and pension plan expense are
the discount rate and the expected rate of return on plan assets. If discount rates or actual rates of return on invested plan assets were to
decrease, the pension plan obligation could increase materially. The size of future required pension contributions could result in our
dedicating a substantial portion of our cash flow from operations to making the contributions, which could materially adversely affect
our business, financial condition and results of operations.
Domestic or international natural disasters or terrorist attacks may disrupt our operations, decrease the demand for our
products or otherwise have an adverse impact on our business.
Chemical related assets, and U.S. corporations such as ours, may be at greater risk of future terrorist attacks than other possible
targets in the U.S. and throughout the world. Moreover, extraordinary events such as natural disasters may negatively affect local
economies, including those of our customers or suppliers. The occurrence of such events cannot be predicted, although they can be
expected to continue to adversely impact the economy in general and our specific markets. The resulting damage from such an event
could include loss of life, property damage or site closure. Any, or a combination, of these factors could adversely impact our results
of operations, financial position and cash flows.
26
Delaware law and some provisions of our organizational documents make a takeover of our company more difficult.
Provisions of our charter and bylaws may have the effect of delaying, deferring or preventing a change in control of our
company. A change of control could be proposed in the form of a tender offer or takeover proposal that might result in a premium
over the market price for our common stock. In addition, these provisions could make it more difficult to bring about a change in the
composition of our board of directors, which could result in entrenchment of current management. For example, our charter and
bylaws:
•
•
•
•
•
•
•
establish a classified board of directors so that not all members of our board of directors are elected at one time;
require that the number of directors be determined, and provide that any vacancy or new board seat may be filled, only by
the board;
do not permit stockholders to act by written consent;
do not permit stockholders to call a special meeting;
permit the bylaws to be amended by a majority of the board without shareholder approval, and require that a bylaw
amendment proposed by stockholders be approved by two-thirds of all outstanding shares;
establish advance notice requirements for nominations for elections to our board of directors or for proposing matters that
can be acted upon by stockholders at stockholder meetings; and
authorize the issuance of undesignated preferred stock, or “blank check” preferred stock, by our board of directors without
shareholder approval.
Our Kraton Performance Polymers, Inc. Executive Severance Program and the equity arrangements with our executive officers
also contain change in control provisions. Under the terms of these arrangements, the executive officers are entitled to receive
significant cash payments, immediate vesting of options, restricted shares and notional shares, and continued medical benefits in the
event their employment is terminated under certain circumstances within one year following a change in control, and with respect to
certain equity awards, within two years following a change in control.
Any Supplemental Pension Benefits a participant may have accrued under the Kraton Polymers U.S. LLC Pension Benefit
Restoration Plan also vests immediately on a change of control and any amounts accrued under the Kraton Polymers LLC Executive
Deferred Compensation Plan are immediately payable upon a change of control. We disclose in proxy statements filed with the SEC
potential payments to our named executive officers in connection with a change of control. Further, certain change of control
transactions, including our proposed transaction with LCY, constitute an event of default under our credit facility and require us to
repurchase our outstanding senior notes at a price equal to 101% of their principal amount, plus any accrued and unpaid interest. The
combination agreement with LCY provides as a condition to closing that we obtain a waiver or an amendment under our credit facility
and, in the case of our notes, a consent or alternatively obtain backstop financing to fund the change of control repurchase. We intend
to obtain the applicable waivers or obtain alternative financing to satisfy the closing condition, but there can be no assurance that we
will be successful in doing so. See “Item 7. Management’s Discussion and Analysis—Liquidity and Capital Resources—Known
Trends and Uncertainties.”
These arrangements and provisions of our organizational documents and Delaware law may have the effect of delaying,
deferring or preventing changes of control or changes in management of our company, even if such transactions or changes would
have significant benefits for our stockholders. As a result, these provisions could limit the price some investors might be willing to pay
in the future for shares of our common stock.
We do not currently pay dividends and may not pay any dividends for the foreseeable future.
We do not currently pay dividends, and we may not pay dividends to our stockholders for the foreseeable future. The senior
secured credit facilities and our senior notes indenture limit our ability to pay cash dividends and may preclude us from paying cash
dividends, and we may be subject to other restrictions on our ability to pay dividends from time to time. In addition, because we are a
holding company, our ability to pay dividends depends on our receipt of cash dividends and distributions from our subsidiaries.
Accordingly, investors must be prepared to rely on sales of their common stock after price appreciation to earn an investment return,
which may never occur. Investors seeking cash dividends should not purchase our common stock. Any determination to pay dividends
in the future will be made at the discretion of our board of directors and will depend upon our results of operations, financial
conditions, contractual restrictions, restrictions imposed by applicable law or the SEC and other factors our board deems relevant.
27
We are a holding company with nominal net worth and will depend on dividends and distributions from our subsidiaries to pay
any dividends.
Kraton Performance Polymers, Inc. is a holding company with nominal net worth. We do not have any assets or conduct any
business operations other than our investments in our subsidiaries, including Kraton Polymers LLC. As a result, our ability to pay
dividends, if any, will be dependent upon cash dividends and distributions or other transfers from our subsidiaries. Payments to us by
our subsidiaries will be contingent upon their respective earnings and subject to any limitations on the ability of such entities to make
payments or other distributions to us. In addition, our subsidiaries are separate and distinct legal entities and have no obligation to
make any funds available to us.
Item 1B. Unresolved Staff Comments.
None.
Item 2.
Properties.
Our principal executive offices are located at 15710 John F. Kennedy Boulevard, Suite 300, Houston, Texas 77032.
We believe that our properties and equipment are generally in good operating condition and are adequate for our present needs.
Production capacity at our sites can vary greatly depending upon feedstock, product mix and operating conditions.
Our properties consist primarily of manufacturing and research and development facilities for the production of specialty
chemicals. The following table sets forth our principal facilities:
Acres
Location
Belpre, Ohio .................................................................................................... 350
Wesseling, Germany ....................................................................................... 8.1
Berre, France ................................................................................................... 9.0
Paulinia, Brazil ................................................................................................ 179
Kashima, Japan ............................................................................................... 11.6
Houston, Texas ............................................................................................... N/A
Shanghai, China .............................................................................................. N/A
Amsterdam, Netherlands ................................................................................. N/A
Tsukuba, Japan ................................................................................................ 4.5
Use
Owned/Leased
3,600,000 Manufacturing
354,000 Manufacturing
392,000 Manufacturing
2,220,000 Manufacturing
395,000 Manufacturing
105,500
33,000
32,015
23,327
R&D
R&D
R&D
R&D
Owned (1)
Owned (2)
Owned (2)
Owned
Owned (3)
Leased (4)
Leased (4)
Leased (4)
Leased (4)
Approximate
Square Footage
(1) A portion of the HSBC capacity at the Belpre facility is owned by Infineum USA, a joint venture between Shell Chemicals and
ExxonMobil.
(2) We lease the land, but own the manufacturing facility and production equipment.
(3) The Kashima, Japan, facility is owned by our 50%-50% joint venture with JSR.
(4) We lease the facility, but own the equipment.
Belpre, Ohio. Our Belpre site is our largest manufacturing facility, with connections to barge, rail and truck shipping and
receiving facilities. The Belpre facility has approximately 192 kilotons of production capacity to which we are entitled. The Belpre
facility currently produces USBC, HSBC, and Cariflex products. A portion of the HSBC capacity at Belpre is owned by Infineum
USA. Infineum is a joint venture between Shell Chemicals and ExxonMobil that makes products for the lubricant additives business.
Under a facility sharing agreement that terminates in 2030, we operate Infineum’s share of the HSBC assets to manufacture a line of
products for Infineum, and Infineum is entitled to a portion of the HSBC capacity at Belpre. Other than those assets owned by
Infineum, we own the Belpre facility and the land on which it is located.
Wesseling, Germany. Our Wesseling manufacturing facility is located on the premises of LyondellBasell. The facility has direct
access to major highways and extensive railway connections. Production capacity is approximately 96 kilotons. LyondellBasell owns
the land on the premises and leases it to us. The lease is for a term of 30 years, beginning from March 31, 2000 and is extended
automatically for a successive period of 10 years unless terminated upon one-year’s written notice by either party. We own the SBC
manufacturing facility and production equipment in the facility. The Wesseling facility currently produces USBC products.
LyondellBasell provides us operating and site services, utilities, materials and facilities under a long-term production agreement.
LyondellBasell has the right to approve any expansion of our facility at Wesseling although its consent may only be withheld if an
expansion would be detrimental to the site.
28
Berre, France. Our Berre manufacturing facility is located in southeastern France. The facility has direct access to sea, rail and
road transport and has a production capacity of approximately 87 kilotons. The Berre site is leased to us by LyondellBasell, which
operates the facility and with which our lease exists under a long-term lease due to expire in 2030, however the lease is terminable by
either party upon 18 months’ written notice. As of the date of this filing, no such notice has been given by either party. We own the
SBC manufacturing facility and production equipment at Berre. We currently produce USBC and HSBC products there. We have an
operating agreement with LyondellBasell for various site services, utilities and facilities under a long-term agreement.
Paulinia, Brazil. Our Paulinia manufacturing facility is located with access to major highways. The facility currently has a
production capacity of approximately 29 kilotons of USBC in addition to capacity dedicated to producing Cariflex products. We own
the facility and the land at Paulinia. BASF owns the adjacent site and shares title to the facilities that are common to the two
companies such as the administration building, cafeteria and maintenance facilities.
Kashima, Japan. Our Kashima manufacturing facility is owned and operated by a joint venture named Kraton JSR Elastomers
K.K., (“KJE”), between us and JSR. The Kashima facility is located northeast of Tokyo on the main island of Honshu at a JSR site
that includes several synthetic rubber facilities and butadiene and isoprene extraction units. This facility is serviced by rail, barge and
truck connections. Production capacity is approximately 31 kilotons of USBC products, and we are generally entitled to 50% of this
production pursuant to our joint venture agreement.
JSR markets its portion of the production under its own trademarks, and we market our portion of the production under the
Kraton® brand name although this amount may vary from time to time based on the economic interest of the joint venture. We and
JSR each have a right of first refusal on the transfer of the joint venture interests of the other.
Research, Development and Technical Service Facilities. Our research and development activities are primarily conducted in
laboratories in Houston, Texas, and Amsterdam, Netherlands. We support our customers via a technical service network of
laboratories around the globe. Our technical service laboratories are located in Shanghai, China, Tsukuba, Japan, and Paulina, Brazil.
In addition we have a technical service office in Mont St. Guibert, Belgium.
We perform application development and technical service support in all locations. In addition, our research and development
centers in Houston and Amsterdam carry out polymer and process development to support our manufacturing sites as well as our
customers.
29
Item 3.
Legal Proceedings.
We received notice in July, 2012 from the tax authorities in Brazil assessing R$ 5.9 million in connection with tax credits that
were generated from the purchase of certain goods. The credits were subsequently applied against taxes owed. The tax authorities
assert that the goods purchased were not eligible to earn a credit. We have appealed this assessment and contend that the tax credits
were earned. While the outcome of this proceeding cannot be predicted with certainty, we do not expect this matter to have a material
adverse effect upon our financial position, results of operations or cash flows.
In January 2014, our Belpre, Ohio facility experienced a mechanical equipment failure due to inclement weather that resulted in
a release of process solvents into nearby waterways. Applicable authorities were notified, and cleanup activities are underway. Kraton
may be required to pay governmental fines or sanctions in excess of $100,000 in connection with this event.
We and certain of our subsidiaries, from time to time, are parties to various other legal proceedings, claims and disputes that
have arisen in the ordinary course of business. These claims may involve significant amounts, some of which would not be covered by
insurance. While the outcome of these proceedings cannot be predicted with certainty, our management does not expect any of these
other existing matters, individually or in the aggregate, to have a material adverse effect upon our financial position, results of
operations or cash flows. Furthermore, Shell Chemicals has agreed, subject to certain limitations, to indemnify us for certain claims
brought with respect to matters occurring before February 28, 2001. As of the date of this Form 10-K, we have not been named as
parties in any of these claims. Our right to indemnification from Shell Chemicals is subject to certain time limitations. A substantial
settlement payment or judgment in excess of our accruals could have a material adverse effect on our financial position, results of
operations or cash flows.
For information regarding legal proceedings, including environmental matters, see “Part I, Item 1. Business—Environmental
Regulation” and Note 11 Commitments and Contingencies (subsections (b) and (d) of which are incorporated herein by reference) to
the consolidated financial statements for further discussion.
Item 4. Mine Safety Disclosures.
Not applicable.
30
PART II
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.
Our common stock has been listed on the New York Stock Exchange (NYSE) under the symbol “KRA” since December 17,
2009. Prior to that date, our equity securities were not listed on any exchange in each period indicated or traded on any public trading
market. The following table sets forth the high and low intraday sales prices of our common stock per share, as reported by the NYSE.
2013
Fourth Quarter ............................................................................................................................................ $
Third Quarter ............................................................................................................................................. $
Second Quarter ........................................................................................................................................... $
First Quarter ............................................................................................................................................... $
2012
Fourth Quarter ............................................................................................................................................ $
Third Quarter ............................................................................................................................................. $
Second Quarter ........................................................................................................................................... $
First Quarter ............................................................................................................................................... $
Stock Price Range
High
Low
23.98 $
22.16 $
23.73 $
28.26 $
26.69 $
27.30 $
27.75 $
31.17 $
18.38
18.33
18.82
23.25
19.54
18.76
17.61
20.73
We have not previously declared or paid any dividends or distributions on our common stock. As of February 24, 2014, we had
approximately 108 shareholders of record of our common stock and approximately 4,998 beneficial owners.
Stock Performance Graph
The following graph reflects the comparative changes in the value from December 17, 2009, the first trading day of our common
stock on the NYSE, through December 31, 2013, assuming an initial investment of $100 and the reinvestment of dividends, if any, in
(1) our common stock, (2) the S&P SmallCap 600 Index, and (3) the Dow Jones U.S. Specialty Chemicals Index. The information
under this caption is not deemed to be “soliciting material” or to be “filed” with the SEC or subject to Regulation 14A or 14C under
the Securities Exchange Act of 1934 or to the liabilities of Section 18 of the Securities Exchange Act of 1934, and will not be deemed
to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except to the
extent we specifically incorporate it by reference into such a filing. Historical performance should not be considered indicative of
future stockholder returns.
31
Total Return to Shareholders’
(Includes reinvestment of dividends)
Company Name / Index
Kraton Performance Polymers, Inc. ..............................
S&P SmallCap 600 Index .............................................
Dow Jones U.S. Specialty Chemicals ...........................
12/31/09
12/31/10
Annual Return Percentage,
Years Ending
12/31/11
12/31/12
12/31/13
0.37 %
3.68 %
1.04 %
128.24 %
26.31 %
37.19 %
(34.41 )%
1.02 %
(2.82 )%
18.37 %
16.33 %
32.23 %
(4.08 )%
41.31 %
22.88 %
Company Name / Index
Kraton Performance Polymers, Inc. ............... $
S&P SmallCap 600 Index .............................. $
Dow Jones U.S. Specialty Chemicals ............ $
Base Period
12/17/09
Cumulative Value of $100 Investment, through
December 31, 2013
12/31/09
12/31/10
12/31/11
12/31/12
12/31/13
100.00 $
100.00 $
100.00 $
100.37 $
103.68 $
101.04 $
229.09 $
130.95 $
138.62 $
150.26 $
132.28 $
134.70 $
177.87 $
153.88 $
178.11 $
170.61
217.45
218.87
Dividends
We have not previously declared or paid any dividends or distributions on our common stock and have instead deployed
earnings to fund the development of our business. Any future determination to pay dividends will be at the discretion of our board of
directors and will depend on our financial condition, results of operations, capital expenditure requirements, restrictions contained in
current and future financing instruments and other factors that our board of directors deems relevant. Because we are a holding
company, our ability to pay dividends depends on our receipt of cash dividends and distributions from our subsidiaries. The terms of
our senior notes and senior secured credit facilities restrict our ability and the ability of our subsidiaries to pay dividends, as may the
terms of any of our future debt or preferred securities. For more information about these restrictions, see Note 6 Long-Term Debt to
the consolidated financial statements.
Kraton Polymers LLC—Debt Refinancing
In March 2013, we entered into an asset-based revolving credit facility consisting of a $150.0 million U.S. senior secured
revolving credit facility and a $100.0 million Dutch senior secured revolving credit facility (the “Senior Secured Credit Facilities”).
The Senior Secured Credit Facilities replaced the then existing senior secured credit facility and we repaid in full all outstanding
amounts payable under the previously existing indebtedness. Borrowings under the Senior Secured Credit Facilities are subject to
certain limitations. See Note 6 Long-Term Debt to the consolidated financial statements for further discussion.
32
Item 6.
Selected Financial Data.
The selected financial data below should be read in conjunction with “Management’s Discussion and Analysis of Financial
Condition and Results of Operations” included under Item 7 of this Form 10-K as well as the consolidated financial statements and the
related notes.
Consolidated statements of operations data:
Operating revenue:
2013
2012
Years ended December 31,
2011
(in thousands, except per share data)
2010
Sales revenue ........................................................... $ 1,292,121 $ 1,423,122 $ 1,437,479 $ 1,228,425 $
0
Other revenue(1) .....................................................
1,228,425
Total operating revenue .................................
927,932
Cost of goods sold .............................................................
Gross profit........................................................................
300,493
Operating expenses:
0
1,292,121
1,066,289
225,832
0
1,423,122
1,191,680
231,442
0
1,437,479
1,121,293
316,186
Research and development ......................................
Selling, general and administrative .........................
Depreciation and amortization ................................
Impairment of long-lived assets ..............................
Total operating expenses ...............................
Gain (loss) on extinguishment of debt ...............................
Earnings of unconsolidated joint venture (2).....................
Interest expense, net ..........................................................
Income (loss) before income taxes ....................................
Income tax expense (benefit) ............................................
Consolidated net income (loss) .........................................
Net loss attributable to noncontrolling interest ........
Net income (loss) attributable to Kraton ........................... $
32,014
105,558
63,182
0
200,754
0
530
30,470
(4,862 )
(3,887 )
(975 ) $
(357 )
(618 ) $
31,011
98,555
64,554
5,434
199,554
0
530
29,303
3,115
19,306
(16,191 ) $
0
(16,191 ) $
27,996
101,606
62,735
0
192,337
(2,985 )
529
29,884
91,509
584
90,925 $
0
90,925 $
23,628
92,305
49,220
0
165,153
0
487
23,969
111,858
15,133
96,725 $
0
96,725 $
2009
920,362
47,642
968,004
792,472
175,532
21,212
79,504
66,751
0
167,467
23,831
403
33,956
(1,657 )
(1,367 )
(290 )
0
(290 )
Earnings (loss) per common share:
Basic ........................................................................ $
Diluted ..................................................................... $
(0.02 ) $
(0.02 ) $
(0.50 ) $
(0.50 ) $
2.85 $
2.81 $
3.13 $
3.07 $
(0.01 )
(0.01 )
Weighted average common shares outstanding:
Basic ........................................................................
Diluted .....................................................................
32,096
32,096
31,939
31,939
31,786
32,209
30,825
31,379
19,808
19,808
(1) Other revenue includes the sale of by-products generated in the production of IR and SIS at Pernis, where we ceased production
on December 31, 2009.
(2) Represents our 50% joint venture interest in Kraton JSR Elastomers K.K., which is accounted for using the equity method of
accounting.
2013
2012
As of December 31,
2011
(in thousands)
2010
2009
Consolidated balance sheets data:
Cash and cash equivalents ............................................ $
92,750 $
Total assets .................................................................... $ 1,194,797 $ 1,229,189 $ 1,153,756 $ 1,080,723 $
382,675 $
Total debt ...................................................................... $
392,500 $
448,017 $
175,872 $
223,166 $
350,989 $
88,579 $
69,291
974,499
384,979
Other data:
Ratio of earnings to fixed charges .................................
0.80:1.00
1.02:1.00
3.54:1.00
5.07:1.00 0.95:1.00
2013
2012
2011
2010
2009
Our earnings were insufficient to cover our fixed charges by approximately $8.7 million and $1.6 million for the years ended
December 31, 2013 and 2009, respectively.
33
EBITDA, Adjusted EBITDA, Adjusted EBITDA at ECRC and Gross Profit at ECRC
We consider EBITDA, Adjusted EBITDA, Adjusted EBITDA at estimated current replacement cost (ECRC) and Gross Profit at
ECRC to be important supplemental measures of our performance and believe they are frequently used by investors, securities
analysts and other interested parties in the evaluation of our performance and/or that of other companies in our industry, including
period-to-period comparisons. In addition, management uses these measures to evaluate operating performance, and our incentive
compensation plan bases incentive compensation payments on our Adjusted EBITDA and Adjusted EBITDA at ECRC performance,
along with other factors. EBITDA, Adjusted EBITDA, Adjusted EBITDA at ECRC and Gross Profit at ECRC have limitations as
analytical tools and in some cases can vary substantially from other measures of our performance. You should not consider any of
them in isolation, or as substitutes for analysis of our results under U.S. generally accepted accounting principles (“GAAP”).
2013
Years ended December 31,
2012
(in thousands)
2011
EBITDA(1) ....................................................................................................................... $
Adjusted EBITDA(2) ........................................................................................................
Adjusted EBITDA at ECRC(3).........................................................................................
Gross Profit at ECRC(3) ...................................................................................................
88,790 $
110,169
140,906
256,569
96,972 $
113,309
143,842
261,975
184,128
194,327
127,995
249,854
(1) EBITDA represents net income before interest, taxes, depreciation and amortization.
Limitations for EBITDA as an analytical tool include the following:
• EBITDA does not reflect our cash expenditures, or future requirements for capital expenditures or contractual
commitments;
• EBITDA does not reflect changes in, or cash requirements for, our working capital needs;
• EBITDA does not reflect the significant interest expense, or the cash requirements necessary to service interest payments,
on our debt;
•
although depreciation and amortization are non-cash charges, the assets being depreciated and amortized will often have to
be replaced in the future and EBITDA does not reflect any cash requirements for such replacements;
• EBITDA calculation under the terms of our debt agreements may vary from EBITDA presented herein, and our
presentation of EBITDA herein is not for purposes of assessing compliance or non-compliance with financial covenants
under our debt agreements;
•
other companies in our industry may calculate EBITDA differently than we do, limiting its usefulness as a comparative
measure; and
• EBITDA is not a measure of discretionary cash available to us to invest in the growth of our business.
(2) We prepare Adjusted EBITDA by adjusting EBITDA to eliminate the impact of a number of items we do not consider indicative
of our ongoing operating performance. We explain how each adjustment is derived and why we believe it is helpful and
appropriate in the reconciliation below. You are encouraged to evaluate each adjustment and the reasons we consider it
appropriate for supplemental analysis. As an analytical tool, Adjusted EBITDA is subject to the limitations applicable to
EBITDA described above. In addition, in evaluating Adjusted EBITDA, you should be aware that in the future we may incur
expenses similar to the adjustments in this presentation. Our presentation of Adjusted EBITDA should not be construed as an
inference that our future results will be unaffected by unusual or non-recurring items.
34
(3) Adjusted EBITDA at ECRC is Adjusted EBITDA net of the impact of the spread between the FIFO basis of accounting and
ECRC and Gross Profit at ECRC is gross profit net of the impact of the spread between the FIFO basis of accounting and
ECRC. Although we report our financial results using the FIFO basis of accounting, as part of our pricing strategy, we measure
our business performance using the estimated current replacement cost of our inventory and cost of goods sold. We maintain our
perpetual inventory in our global enterprise resource planning system. The carrying value of our inventory is determined using
FIFO. At the beginning of each month, we determine the estimated current cost of our raw materials for that particular month,
and using the same perpetual inventory system that we use to manage inventory and therefore costs of goods sold under FIFO,
we revalue our ending inventory to reflect the total cost of such inventory as if it was valued using the estimated current
replacement cost. The result of this revaluation from FIFO creates the spread between FIFO and ECRC. With inventory valued
under FIFO and ECRC, we then have the ability to report cost of goods sold and therefore EBITDA, Adjusted EBITDA,
Adjusted EBITDA at ECRC, Gross Profit, and Gross Profit at ECRC under both our FIFO convention and under estimated
current replacement cost. As an analytical tool, Adjusted EBITDA at ECRC is subject to the limitations applicable to EBITDA
described above, as well as the following limitations:
•
•
due to volatility in raw material prices, Adjusted EBITDA at ECRC may, and often does, vary substantially from
EBITDA, net income and other performance measures, including net income calculated in accordance with US GAAP;
and
Adjusted EBITDA at ECRC may, and often will, vary significantly from EBITDA calculations under the terms of our
debt agreements and should not be used for assessing compliance or non-compliance with financial covenants under our
debt agreements.
Because of these and other limitations, EBITDA, Adjusted EBITDA and Adjusted EBITDA at ECRC should not be considered
as a measure of discretionary cash available to us to invest in the growth of our business.
Our presentation of non-GAAP financial measures and the adjustments made therein should not be construed as an inference
that our future results will be unaffected by unusual or non-recurring items, and in the future we may incur expenses or charges
similar to the adjustments made in the presentation of our non-GAAP financial measures.
As a measure of our performance, Gross Profit at ECRC is limited because it often varies substantially from gross profit
calculated in accordance with US GAAP due to volatility in raw material prices.
We compensate for these limitations by relying primarily on our GAAP results and using EBITDA, Adjusted EBITDA,
Adjusted EBITDA at ECRC and Gross Profit at ECRC only as supplemental measures. See our financial statements included
elsewhere in this Form 10-K.
We reconcile Gross Profit to Gross Profit at ECRC as follows:
Gross profit ....................................................................................................................... $
Add (deduct):
2013
Years ended December 31,
2012
(in thousands)
2011
225,832 $
231,442 $
316,186
Spread between FIFO and ECRC ............................................................................
Gross profit at ECRC ........................................................................................................
30,737
256,569
30,533
261,975
(66,332 )
249,854
35
We reconcile consolidated net income (loss) to EBITDA, Adjusted EBITDA and Adjusted EBITDA at ECRC as follows:
Net income (loss) attributable to Kraton ........................................................................... $
Net loss attributable to noncontrolling interest .................................................................
Consolidated net income (loss) .........................................................................................
Add (deduct):
Interest expense, net ................................................................................................
Income tax expense (benefit)...................................................................................
Depreciation and amortization expenses .................................................................
EBITDA ............................................................................................................................ $
Add (deduct):
Settlement gain(a)....................................................................................................
Property tax dispute(b) ............................................................................................
Storm related charges(c) ..........................................................................................
Retirement plan settlement(d) .................................................................................
Restructuring charges(e) ..........................................................................................
Fees related to a proposed business combination(f) ................................................
Non-cash compensation expense(g) ........................................................................
Impairment of long-lived assets(h) ..........................................................................
Production downtime related to MACT legislation(i) .............................................
Loss on extinguishment of debt(j) ...........................................................................
Adjusted EBITDA ............................................................................................................ $
Add (deduct):
2013
Years ended December 31,
2012
(in thousands)
2011
(618 ) $
(357 )
(975 )
(16,191 ) $
0
(16,191 )
90,925
0
90,925
30,470
(3,887)
63,182
88,790 $
29,303
19,306
64,554
96,972 $
29,884
584
62,735
184,128
0
0
0
0
815
9,164
7,894
0
3,506
0
110,169 $
(6,819 )
6,211
2,481
1,100
1,359
0
6,571
5,434
0
0
113,309 $
0
0
0
0
1,755
0
5,459
0
0
2,985
194,327
Spread between FIFO and ECRC ............................................................................
Adjusted EBITDA at ECRC .............................................................................................
30,737
140,906
30,533
143,842
(66,332 )
127,995
(a) Receipt from LyondellBasell in settlement of disputed charges, which is recorded in cost of goods sold.
(b) Charge associated with resolution of a property tax dispute in France, of which $5.6 million is recorded in cost of goods sold
and $0.6 million is recorded in selling, general and administrative expenses.
(c) Storm related charge at our Belpre, Ohio facility, which is recorded in cost of goods sold.
(d) Retirement plan settlement charge associated with a disbursement from a benefit plan upon the retirement of an employee,
which is recorded in selling, general and administrative expenses.
(e) Severance expenses, fees associated with the public offering of our senior notes and secondary public offering of our common
stock and charges associated with the restructuring of our European organization, which are primarily recorded in selling,
general and administrative expenses in 2013 and 2011, and primarily in cost of goods sold in 2012.
Primarily professional fees, related to our proposed combination with the styrenic block copolymer operations of LCY Chemical
Corp., which are recorded in selling, general and administrative expenses.
(f)
(g) We have historically recorded these costs in selling, general and administrative expenses; however, beginning in the second
quarter of 2013, a portion of these costs were recorded in cost of goods sold and research and development expenses.
Impairment of long-lived assets, of which $3.4 million and $2.0 million were associated with the HSBC facility and other long-
term assets, respectively.
(h)
(i) Costs of production downtime at our Belpre, Ohio facility, in preparation for the installation of natural gas boilers to replace the
coal-burning boilers required by the MACT legislation, which is recorded in cost of goods sold.
Loss on extinguishment of debt arising from the 2011 refinancing.
(j)
36
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations
INTRODUCTION
Management’s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with
the Item 8. Financial Statements and Supplementary Data. This discussion contains forward-looking statements and involves
numerous risks and uncertainties, including, but not limited to those described in the Item 1A. Risk Factors and below under the
caption “Factors Affecting Our Results of Operations.” Actual results may differ materially from those contained in any forward-
looking statements.
OVERVIEW
We are a leading global producer of styrenic block copolymers (“SBCs”) and other engineered polymers. We market our
products under the Kraton®, CariflexTM, and NEXARTM brands. SBCs are highly-engineered synthetic elastomers, which we invented
and commercialized almost 50 years ago, that enhance the performance of numerous end use products by imparting greater flexibility,
resilience, strength, durability, and processability.
Our polymers are typically formulated or compounded with other products to achieve improved, customer-specific performance
characteristics in a variety of applications. We seek to maximize the value of our product portfolio by emphasizing complex or
specialized polymers and innovations that yield higher margins than more commoditized products. We refer to these complex or
specialized polymers or innovations as being more “differentiated.”
Our products are found in many everyday applications, including personal care products such as disposable diapers and the
rubberized grips of toothbrushes, razor blades, and power tools. Our products are also used to impart tack and shear properties in a
wide variety of adhesive products and to impart characteristics such as, flexibility and durability in sealants and corrosion resistance in
coatings. Our paving and roofing applications provide durability, extending road and roof life.
We also produce Cariflex isoprene rubber and isoprene rubber latex. Our Cariflex products are highly-engineered, non-SBC
synthetic substitutes for natural rubber and natural rubber latex. Our Cariflex products, which have not been found to contain the
proteins present in natural rubber latex and are, therefore, not known to cause allergies, are used in applications such as surgical gloves
and condoms. We believe the versatility of Cariflex provides opportunities for new, high margin applications.
We have a portfolio of innovations at various stages of development and commercialization, including
•
•
•
polyvinyl chloride alternatives for wire and cable, and medical applications;
polymers and compounds for soft skin and coated fabric applications for transportation and consumer markets;
our NEXAR family of membrane polymers for water filtration, heating, ventilation, air conditioning and breathable fabrics;
and
•
synthetic cement formulations and other oilfield applications.
Our products are manufactured along the following primary product lines based upon polymer chemistry and process
technologies:
•
•
un-hydrogenated SBCs (“USBCs”);
hydrogenated SBCs (“HSBCs”);
• Cariflex isoprene rubber (“IR”) and isoprene rubber latex (“IRL”); and
•
compounds.
37
The majority of worldwide SBC production is dedicated to USBCs, which are primarily used in paving and roofing, in
adhesives, sealants and coatings, and in footwear applications. HSBCs, which are significantly more complex and capital-intensive to
manufacture than USBCs, are primarily used in more differentiated applications, such as soft touch and flexible materials, personal
hygiene products, medical products, automotive components, and certain adhesives and sealant applications.
Product Line Sales Revenue:
USBCs .............................................................................................................................
HSBCs .............................................................................................................................
Cariflex ............................................................................................................................
Compounds ......................................................................................................................
Other ................................................................................................................................
2013
2012
2011
58.3 %
30.3 %
9.0 %
2.3 %
0.1 %
59.1 %
31.2 %
7.4 %
2.1 %
0.2 %
59.3 %
31.6 %
6.9 %
1.9 %
0.3 %
End Use Markets Sales Revenue:
Advanced Materials .........................................................................................................
Adhesives, Sealants and Coatings ....................................................................................
Paving and Roofing .........................................................................................................
Cariflex ............................................................................................................................
Other ................................................................................................................................
2013
2012
2011
26.8 %
37.0 %
27.1 %
9.0 %
0.1 %
26.9 %
35.9 %
29.6 %
7.4 %
0.2 %
28.0 %
34.8 %
29.9 %
6.9 %
0.4 %
2013 Financial Overview
• Sales volume was 313.5 kilotons in 2013 compared to 313.4 kilotons in 2012.
• Sales revenue was $1,292.1 million in 2013 compared to $1,423.1 in 2012.
• Gross profit was $225.8 million in 2013 compared to $231.4 million in 2012. Gross profit at ECRC was $256.6 million in
2013 compared to $262.0 million in 2012.
• Adjusted EBITDA was $110.2 million in 2013 compared to $113.3 million in 2012. Adjusted EBITDA at ECRC was
$140.9 million in 2013 compared to $143.8 million in 2012.
• Net loss attributable to Kraton was $(0.6) million or $(0.02) per diluted share in 2013 compared to net loss of $(16.2)
million or $(0.50) per diluted share in 2012. Diluted loss per share was impacted by items that are discussed further in Net
loss attributable to Kraton.
• Cash provided by operating activities was $105.5 million in 2013 compared to $146.3 million in 2012.
RESULTS OF OPERATIONS
Factors Affecting Our Results of Operations
Raw Materials and Product Mix. Our results of operations are directly affected by the cost of raw materials. We use butadiene,
styrene, and isoprene as our primary raw materials in manufacturing our products. On a FIFO basis, these monomers together
represented approximately $609.5 million, $732.9 million and $658.9 million or 57.2%, 61.5% and 58.8% of our total cost of goods
sold for the years ended December 31, 2013, 2012 and 2011, respectively. Since the cost of our three primary raw materials comprise
a significant amount of our total cost of goods sold, our selling prices for our products and therefore our total sales revenue is
impacted by movements in our raw material costs, as well as the cost of other inputs. In addition, product mix can have an impact on
our overall unit selling prices, since we provide an extensive product offering and therefore experience a wide range of unit selling
prices.
The cost of butadiene and isoprene is impacted by worldwide supply and demand for the monomers, prevailing energy prices
and prices for natural and synthetic rubber. The cost of styrene is impacted by worldwide supply and demand for styrene, benzene and
ethylene and prevailing energy prices. In aggregate, average purchase prices decreased for butadiene and isoprene during 2013
compared to 2012, with an increase in average purchase prices for styrene. Average butadiene purchase prices were lower during 2012
compared to 2011. Average isoprene and styrene purchase prices were higher in 2012 compared to 2011, with a more significant
increase in isoprene prices.
38
We use the FIFO basis of accounting for inventory and cost of goods sold, and therefore gross profit. In periods of raw material
price volatility, reported results under FIFO will differ from what the results would have been if cost of goods sold were based on
ECRC. Specifically, in periods of rising raw material costs, reported gross profit will be higher under FIFO than under ECRC.
Conversely, in periods of declining raw material costs, reported gross profit will be lower under FIFO than under ECRC. In
recognition of the fact that the cost of raw materials affects our results of operations and the comparability of our results of operations
we provide the difference, or spread, between FIFO and ECRC.
•
•
•
In 2013, reported results under FIFO were lower than results would have been on an ECRC basis by $30.7 million;
In 2012, reported results under FIFO were lower than results would have been on an ECRC basis by $30.5 million;
In 2011, reported results under FIFO were higher than results would have been on an ECRC basis by $66.3 million.
International Operations and Currency Fluctuations. We operate a geographically diverse business, serving customers in over
60 countries from five manufacturing facilities on four continents. Our sales and production costs are mainly denominated in U.S.
dollars, Euro, Japanese Yen and Brazilian Real. From time to time, we use hedging strategies to reduce our exposure to currency
fluctuations.
We generated our sales revenue from customers located in the following regions:
Revenue by Geography:
Americas ..........................................................................................................................
Europe, Middle East and Africa .......................................................................................
Asia Pacific ......................................................................................................................
2013
2012
2011
39.3 %
38.7 %
22.0 %
40.0 %
39.1 %
20.9 %
41.0 %
40.0 %
19.0 %
Our financial results are subject to gains and losses on currency translations, which occur when the financial statements of
foreign operations are translated into U.S. dollars. The financial statements of operations outside the United States where the local
currency is considered to be the functional currency are translated into U.S. dollars using the exchange rate at each balance sheet date
for assets and liabilities and the average exchange rate for each period for revenue, expenses, gains and losses and cash flows. The
effect of translating the balance sheet into U.S. dollars is included as a component of accumulated other comprehensive income (loss).
Any appreciation of the functional currencies against the U.S. dollar will increase the U.S. dollar equivalent of amounts of revenue,
expenses, gains and losses and cash flows, and any depreciation of the functional currencies will decrease the U.S. dollar amounts
reported. Our results of operations are also subject to currency transaction risk. We incur currency transaction risk when we enter into
either a purchase or sale transaction using a currency other than the local currency of the transacting entity. The estimated impact from
currency fluctuations amounted to a pre-tax loss of $4.8 million, a pre-tax loss of $6.4 million and a pre-tax income of $1.1 million for
the years ended December 31, 2013, 2012 and 2011, respectively. The primary driver for our pre-tax losses in 2013 and 2012 was the
change in foreign currency exchange rates between the Japanese Yen and U.S. dollar and the Euro and U.S. dollar, respectively. The
primary driver for our pre-tax income in 2011 was the change in foreign currency exchange rates between the Euro and U.S. dollar.
Seasonality. Seasonal changes and weather conditions typically affect the Paving and Roofing end use market generally
resulting in higher sales volumes into this end use market in the second and third quarters of the calendar year versus the first and
fourth quarters of the calendar year. However, sales volumes into this end use market were lower in the second and third quarter of
2012 than in the first quarter of 2012, during which demand was higher than normal, particularly in Europe and North America
paving. Our other end use markets tend to show relatively little seasonality.
Outlook
In the first quarter of 2014 we experienced weather-related downtime at our Belpre, Ohio facility. In addition, our facility in
Berre, France experienced an operating disruption resulting from a small fire which impacted one of the production lines at this
facility. We currently estimate that these outages will result in lost production of approximately five kilotons, primarily in our HSBC
product family. The aggregate negative impact of these events on estimated first quarter 2014 EBITDA and diluted earnings per share
is currently estimated to be approximately $12.0 million and $0.37 per share, respectively, comprised of incremental expenses
incurred to resume normal operations and the impact of under-absorbed fixed production costs. We currently do not expect these
events will have a material impact on 2014 results beyond what we currently estimate will be recognized in the first quarter of 2014.
We currently estimate that in 2014 we will incur transaction costs and expenses, primarily related to professional fees, of
between $15.0 million ($0.46 per diluted share) and $28.0 million ($0.86 per diluted share) associated with our proposed combination
with the SBC business of LCY Chemical Corp.
39
The negative impact of the operating disruptions at Belpre, Ohio and Berre, France and the transaction costs associated with our
proposed combination with the SBC business of LCY will be reflected in our GAAP net income (loss) and earnings (loss) per diluted
share in our 2014 results, but will be excluded for purposes of determining Adjusted EBITDA and Adjusted EBITDA at ECRC.
We currently estimate that our results in the first quarter of 2014 will reflect a positive spread between FIFO and ECRC of
approximately $3.0 million.
Year Ended December 31, 2013 Compared to Year Ended December 31, 2012
Sales Revenue
Sales revenue amounted to $1,292.1 million on sales volumes of 313.5 kilotons for the year ended December 31, 2013
compared to $1,423.1 million on sales volumes of 313.4 kilotons for the year ended December 31, 2012. The $131.0 million or 9.2%
revenue decline (a decline of $121.7 million or 8.6% excluding a $9.3 million negative effect from currency fluctuations) was largely
due to a reduction in global product sales prices associated with lower average raw material costs of $110.4 million and a $10.3
million negative effect associated with sales revenue mix.
The following factors influenced sales revenue in our end use markets:
• Advanced Materials. Sales revenue was $346.3 million for the year ended December 31, 2013 compared to $382.8 million
for the year ended December 31, 2012. The $36.5 million or 9.5% revenue decline (a decline of $34.7 million or 9.1%
excluding a $1.8 million negative effect from currency fluctuations) was primarily due to lower average selling prices,
reflective of lower average raw materials costs, primarily butadiene, as sales volumes were essentially flat. With respect to
innovation sales volumes, we experienced growth in personal care applications, partially offset by lower sales volumes in
wire and cable applications.
• Adhesives, Sealants and Coatings. Sales revenue was $477.6 million for the year ended December 31, 2013 compared to
$510.8 million for the year ended December 31, 2012. The $33.2 million or 6.5% revenue decline, which includes a slight
decline in innovation revenue (a decline of $28.1 million or 5.5% excluding a $5.1 million negative effect from currency
fluctuations) was primarily due to lower average selling prices indicative of lower average raw material costs, primarily
butadiene and isoprene, as sales volumes were essentially flat.
• Paving and Roofing. Sales revenue was $350.9 million for the year ended December 31, 2013 compared to $421.4 million
for the year ended December 31, 2012. The $70.5 million or 16.7% revenue decline (a decline of $72.8 million or 17.3%
excluding a $2.3 million positive effect from currency fluctuations) was primarily due to lower average selling prices
indicative of lower average raw material costs, primarily butadiene. In addition, although first half 2013 sales volumes
were down 15.1% compared to the first half of 2012, primarily due to the effect of poor weather conditions in North
America and Europe, second half 2013 sales volumes were up 14.7% due to improved demand compared to the second
half of 2012. As a result, overall sales volumes decreased 1.0% year on year. Innovation sales volumes grew on improved
demand for roofing applications and growth in our HiMA paving applications.
• CariflexTM. Sales revenue was $116.0 million for the year ended December 31, 2013 compared to $105.9 million for the
year ended December 31, 2012. The $10.1 million or 9.5% revenue increase (an increase of $14.8 million or 14.0%
excluding a $4.7 million negative effect from currency fluctuations) reflects a 13.5% increase in sales volumes, mainly in
the surgical glove market and other medical and innovation applications.
• Other sales revenue decreased $1.0 million to $1.2 million for the year ended December 31, 2013.
Cost of Goods Sold
Cost of goods sold was $1,066.3 million for the year ended December 31, 2013 compared to $1,191.7 million for the year ended
December 31, 2012. The $125.4 million or 10.5% decrease was driven largely by an $119.6 million reduction in raw material costs, a
$5.4 million reduction due to changes in foreign currency exchange rates, a $4.6 million reduction due to sales mix, and the absence of
net charges amounting to $2.3 million recorded in 2012, which related to a property tax dispute in France, storm-related charges,
restructuring and other charges and the LBI settlement. Partially offsetting these decreases in cost of goods sold were increased costs
from the production downtime related to the MACT legislation of $3.5 million, increased turnaround costs of $2.5 million, and other
increases in cost of goods sold.
40
Gross Profit
Gross profit was $225.8 million for the year ended December 31, 2013 compared to $231.4 million for the year ended
December 31, 2012, a decrease of $5.6 million or 2.4%. Gross profit as a percentage of sales revenue was 17.5% and 16.3% for the
years ended December 31, 2013 and 2012, respectively. Gross profit at ECRC was $256.6 million for the year ended December 31,
2013 compared to $262.0 million for the year ended December 31, 2012, a decrease of $5.4 million or 2.1%, largely due to the factors
discussed in “Sales Revenue” and “Cost of Goods Sold.”
Operating Expenses
• Research and Development. Research and development expenses were $32.0 million for the year ended December 31,
2013 compared to $31.0 million for the year ended December 31, 2012, an increase of $1.0 million or 3.2% primarily due
to an increase in employee related costs partially offset by decreased lease expense for our research and development
facilities. Research and development expenses were 2.5% and 2.2% of sales revenue for the years ended December 31,
2013 and 2012, respectively.
• Selling, General and Administrative. Selling, general and administrative expenses were $105.6 million for the year ended
December 31, 2013 compared to $98.6 million for the year ended December 31, 2012, an increase of $7.0 million or
7.1%. The increase was primarily due to $9.2 million of professional fees related to the proposed combination with the
SBC Business of LCY, a $1.1 million increase in costs associated with the joint venture with FPCC and a $1.0 million
increase in other professional fees, partially offset by a $1.0 million decrease in employee related costs, lower legal
expenses of $1.1 million, and the absence of a 2012 retirement plan settlement charge of $1.1 million and a $0.6 million
charge associated with the resolution of a property tax dispute in France during 2012. Selling, general and administrative
expenses were 8.2% and 6.9% of sales revenue for the years ended December 31, 2013 and 2012, respectively.
• Depreciation and Amortization. Depreciation and amortization was $63.2 million for the year ended December 31, 2013
compared to $64.6 million for the year ended December 31, 2012, a decrease of $1.4 million or 2.1%.
•
Impairment of long-lived assets. We did not incur any impairment charges of long-lived assets for the year ended
December 31, 2013 compared to a $5.4 million charge for the year ended December 31, 2012.
Interest expense, net
Interest expense, net was $30.5 million for the year ended December 31, 2013 compared to $29.3 million for the year ended
December 31, 2012, an increase of $1.2 million or 4.0%. The reduction in interest expense associated with lower outstanding
indebtedness was more than offset by charges aggregating $5.8 million incurred in connection with our 2013 refinancing.
Income tax expense (benefit)
Our income tax provision was a $3.9 million benefit and a $19.3 million expense for the years ended December 31, 2013 and
2012, respectively. Our effective tax rate was 79.9% and 619.8% for the years ended December 31, 2013 and 2012, respectively. Our
effective tax rates differed from the U.S. corporate statutory tax rate of 35.0%, primarily due to the mix of pre-tax income or loss
earned in certain jurisdictions and the change in our valuation allowance.
We record a valuation allowance when it is more likely than not that some portion or all of the deferred tax assets will not be
realized. As of December 31, 2013 and December 31, 2012, a valuation allowance of $90.0 million and $90.4 million, respectively,
has been provided for net operating loss carryforwards and other deferred tax assets. For the year ended December 31, 2013, we have
recorded changes in the valuation allowance for deferred tax assets as a result of our assessed ability to realize the tax benefit of our
net operating loss carryforwards in certain jurisdictions, primarily in the United States. We decreased our valuation allowance by $0.4
million in 2013, which includes a $0.5 million decrease due to changes in other comprehensive income, partially offset by a $0.1
million increase to the income tax provision. The $0.1 million is comprised of $10.2 million of current year operating losses, offset by
$10.1 million of income tax benefit related to the tax effect of unrealized pension gains. We increased our valuation allowance by
$36.2 million in 2012, of which $30.7 million was included in the income tax provision and $5.5 million represents changes in equity.
The $30.7 million increase in the valuation allowance is comprised of $13.5 million related to the reversal of the benefit recorded for
prior year’s net operating losses and $17.2 million related to current year operating losses. We consider the reversal of deferred tax
liabilities within the net operating loss carryforward period, projected future taxable income and tax planning strategies in making this
assessment. Excluding the change in our valuation allowance, our effective tax rates would have been an 81.4% and 366.1% benefit
for the years ended December 31, 2013 and 2012, respectively.
41
Net loss attributable to Kraton
Net loss attributable to Kraton was $(0.6) million or $(0.02) per diluted share for the year ended December 31, 2013, an
increase in net income of $15.6 million, compared to a net loss of $(16.2) million or $(0.50) per diluted share for the year ended
December 31, 2012.
Net loss for the year ended December 31, 2013 included the following:
• Restructuring charges of $0.7 million or $0.02 per diluted share
• Fees related to the proposed combination with the SBC Business of LCY of $9.2 million or $0.28 per diluted share
• Charges associated with the credit facility refinancing of $5.8 million or $0.18 per diluted share
• Production downtime related to MACT legislation of $3.5 million or $0.11 per diluted share
•
Income tax benefit related to a portion of the change in our valuation allowance for deferred tax assets of $10.1
million or $0.31 benefit per diluted share
• Negative spread between FIFO and ECRC of $30.7 million or $0.96 per diluted share
Net loss for the year ended December 31, 2012 included the following:
• Receipt from LyondellBasell in settlement of disputed charges of $6.9 million or $0.22 benefit per diluted share
• Property tax dispute settlement charge of $6.2 million or $0.20 per diluted share
• Restructuring and other charges of $1.2 million or $0.03 per diluted share
• Retirement plan settlement charge of $1.1 million or $0.03 per diluted share
• Storm related charges of $2.5 million or $0.08 per diluted share
•
•
Impairment of long-lived assets of $5.4 million or $0.17 per diluted share
Income tax expense related to a portion of the change in our valuation allowance for deferred tax assets of $13.5
million or $0.42 per diluted share
• Negative spread between FIFO and ECRC of $30.5 million or $0.95 per diluted share
Year Ended December 31, 2012 Compared to Year Ended December 31, 2011
Sales Revenue
Sales revenue decreased $14.4 million or 1.0% to $1,423.1 million for the year ended December 31, 2012 from $1,437.5 million
for the year ended December 31, 2011. Excluding the negative effect of changes in foreign currency exchange rates totaling $66.7
million, revenue increased $52.3 million or 3.6%, of which $42.2 million resulted from a 3.4% increase in sales volume and $12.6
million resulted from increased average selling prices. Sales volumes were 313.4 kilotons and 303.0 kilotons for the years ended
December 31, 2012 and 2011, respectively. Sales volumes increased primarily in Europe and Asia Pacific, which more than offset
lower sales volumes into North America.
The following factors influenced our sales revenue in each of our end use markets:
• Advanced Materials. Sales revenue decreased $19.8 million or 4.9% to $382.8 million for the year ended December 31,
2012 from $402.6 million for the year ended December 31, 2011. Excluding the $10.3 million impact of changes in foreign
currency exchange rates, sales revenue declined $9.5 million or 2.4%. Sales volume was down 2.8% due to reduced sales of
less differentiated products in all regions, partially offset by sales volume growth of higher value HSBC products, primarily
in Asia Pacific. With respect to innovation sales volume, we experienced growth in PVC alternatives for medical and wire
and cable applications.
• Adhesives, Sealants and Coatings. Sales revenue increased $11.1 million or 2.2% to $510.8 million for the year ended
December 31, 2012 from $499.7 million for the year ended December 31, 2011. Excluding a negative impact from changes
in foreign currency exchange rates of $23.2 million, sales revenue was up $34.3 million or 6.9%. In addition to an increase
in average selling prices, sales volume increased 3.7% with growth in all regions except North America, which was down
modestly on lower sales volumes of less differentiated products. Sales volume increased for our innovation grades in
lubricant additive, printing plate and oilfield applications.
42
• Paving and Roofing. Sales revenue decreased $7.8 million or 1.8% to $421.4 million for the year ended December 31, 2012
from $429.3 million for the year ended December 31, 2011. Excluding the effect of changes in foreign currency exchange
rates totaling $26.7 million, revenue increased $18.9 million or 4.4% due to higher sales volumes partially offset by a
decline in average selling prices, driven by lower average monomer costs. Sales volumes were up 7.6% primarily in the
European and Middle Eastern, South American and Asia Pacific paving markets, which more than offset a decline in North
America roofing volumes.
• CariflexTM. Sales revenue increased $6.6 million or 6.7% to $105.9 million for the year ended December 31, 2012 from
$99.3 million for the year ended December 31, 2011. Excluding the $6.4 million impact from changes in foreign currency
exchange rates, sales revenue improved $13.0 million or 13.1%. The revenue increase reflects increased sales volume,
mainly in surgical glove applications, and an increase in average selling prices across the Cariflex portfolio.
• Other sales revenue decreased $4.5 million to $2.2 million for the year ended December 31, 2012.
Cost of Goods Sold
Cost of goods sold increased $70.4 million or 6.3% to $1,191.7 million for the year ended December 31, 2012 from $1,121.3
million for the year ended December 31, 2011. The increase was driven largely by increased monomer costs in the amount of $85.2
million, which includes the year-over-year $96.9 million negative impact associated with the spread between the FIFO and ECRC
basis, increased sales volumes in the amount of $30.9 million, a $5.6 million charge associated with the resolution of a property tax
dispute in France, storm related charges of $2.5 million and restructuring and related charges of $1.0 million, partially offset by a
$53.9 million decrease from changes in foreign currency exchange rates, and a $6.8 million benefit associated with a refund received
in settlement of a matter with LyondellBasell (the “LBI settlement”).
Gross Profit
Gross profit decreased $84.7 million or 26.8% to $231.4 million for the year ended December 31, 2012 from $316.2 million for
the year ended December 31, 2011. For the year ended December 31, 2012, our reported gross profit under FIFO was lower than what
it would have been under ECRC by approximately $30.5 million and for the year ended December 31, 2011 was higher by $66.3
million. See “—Factors Affecting Our Results of Operations—Raw Materials and Product Mix” above.
Operating Expenses
• Research and Development. Research and development expense increased $3.0 million or 10.8%, primarily due to an
increase in employee related costs commensurate with additions to staffing levels among our scientists and increased lease
expense for our research and development facilities, partially offset by lower maintenance and operational costs. Research
and development expenses were 2.2% of sales revenue for the year ended December 31, 2012 and 1.9% of sales revenue for
the year ended December 31, 2011.
•
Selling, General and Administrative. Selling, general and administrative expense decreased $3.1 million or 3.0%. The
decrease was primarily due to $2.9 million in lower information technology costs, $1.8 million from changes in foreign
currency exchange rates and $1.2 million in restructuring and related costs, partially offset by $1.1 million of increased non-
cash compensation expense, $1.1 million retirement plan settlement charge and a $0.6 million charge associated with the
resolution of a property tax dispute in France. Selling, general and administrative expenses were 6.9% of sales revenue for
the year ended December 31, 2012 and 7.1% of sales revenue for the year ended December 31, 2011.
• Depreciation and Amortization. Depreciation and amortization increased $1.8 million or 2.9%, primarily due to increased
levels of capital expenditures and depreciation of our asset retirement obligations.
•
Impairment of long-lived assets. We recorded a pre-tax charge of $5.4 million in the aggregate for the impairment of long-
lived assets, of which $3.4 million was related to the HSBC facility in Mailiao, Taiwan and $2.0 million related to other
long-lived assets. Our subsequent entry into definitive documents for the joint venture did not affect these charges.
Loss on Extinguishment of Debt
In connection with the refinancing of our indebtedness in the first quarter of 2011, we incurred a $3.0 million loss on the
extinguishment of debt.
43
Interest expense, net
Interest expense, net decreased $0.6 million or 1.9% to $29.3 million for the year ended December 31, 2012 from $29.9 million
for the year ended December 31, 2011. The decrease was primarily due to charges aggregating $5.2 million associated with the debt
refinancing in the first quarter of 2011, partially offset by increased average debt balances.
Income tax expense
Our income tax expense was $19.3 million and $0.6 million for the years ended December 31, 2012 and 2011, respectively. Our
effective tax rate was 619.8% and 0.6% for the years ended December 31, 2012 and 2011, respectively. Our effective tax rates differed
from the U.S. corporate statutory tax rate of 35.0%, primarily due to the mix of pre-tax income earned in foreign jurisdictions and our
limited ability to utilize net operating loss carryforwards in certain jurisdictions, primarily in the United States.
We record a valuation allowance when it is more likely than not that some portion or all of the deferred tax assets will not be
realized. As of December 31, 2012 and 2011, a valuation allowance of $90.4 million and $54.2 million, respectively, has been
provided for net operating loss carryforwards and other deferred tax assets. We increased our valuation allowance by $36.2 million in
2012, of which $30.7 million represents current period net operating losses and a reversal of the benefit recorded for prior net
operating losses and $5.5 million represents changes in other comprehensive income (loss). We reduced our valuation allowance by
$12.2 million in 2011 of which $17.3 million represents the benefit of utilizing net operating losses and the assessment of our ability
to utilize net operating losses in future periods, partially offset by a $5.1 million increase which represents changes in other
comprehensive income (loss). Excluding the change in our valuation allowance, our effective tax rate would have been a 366.1%
benefit and a 19.5% expense for the years ended December 31, 2012 and 2011, respectively.
Our pre-tax income is generated in a number of jurisdictions and is subject to a number of different effective tax rates that are
significantly lower than the U.S. corporate statutory tax rate of 35.0%. For the year ended December 31, 2012, we earned $63.0
million of pre-tax income in jurisdictions with a full year effective tax rate of 8.7%. For the year ended December 31, 2011, we earned
$83.6 million of pre-tax income in jurisdictions with a full year effective tax rate of 11.6%.
Net income (loss) attributable to Kraton
Net loss was $16.2 million or $0.50 per diluted share for the year ended December 31, 2012, a decrease of $107.1 million
compared to net income of $90.9 million or $2.81 per diluted share for the year ended December 31, 2011. Net loss for the year ended
December 31, 2012 included charges of approximately $16.4 million, net of tax, associated with a property tax dispute in France,
impairment related charges, storm related charges, restructuring and related charges, a retirement plan settlement charge and costs
associated with our March 2012 offering, partially offset by $6.9 million, net of tax, associated with the receipt from LyondellBasell in
settlement of disputed charges. These items, net of tax, increased our diluted loss per share by $0.30 for the year ended December 31,
2012. Net income for the year ended December 31, 2011 included charges of approximately $9.8 million, net of tax, or $0.31 per
diluted share associated with restructuring and related charges, costs associated with debt refinancing, costs associated with a
secondary public offering of our common stock and charges associated with evaluating acquisition transactions. The impact of the
change in our deferred tax asset valuation allowance increased our diluted loss per share by $0.95, of which $0.42 relates to the
reversal of the benefit recorded for prior year’s net operating losses and $0.53 relates to the current year operating losses for the year
ended December 31, 2012, and increased our diluted earnings per share by $0.54 for the year ended December 31, 2011.
44
Critical Accounting Policies
The preparation of financial statements in conformity with accounting principles generally accepted in the United States of
America requires management to make assumptions and estimates that directly affect the amounts reported in the consolidated
financial statements. Certain critical accounting policies requiring significant judgments, estimates, and assumptions are described in
this section. We consider an accounting estimate to be critical if (1) it requires assumptions to be made that are uncertain at the time
the estimate is made, and (2) changes to the estimate or different estimates that could have reasonably been used would have
materially changed our consolidated financial statements.
We believe the current assumptions and other considerations used to estimate amounts reflected in our consolidated financial
statements are appropriate. However, should our actual experience differ from these assumptions and other considerations used in
estimating these amounts, the impact of these differences could have a material impact on our consolidated financial statements.
Allowance for Doubtful Accounts. The allowance for doubtful accounts is our best estimate of the amount of probable credit
losses in our existing receivables and is determined based on our assessment of the credit worthiness of individual customers,
historical write-off experience and global economic data. We review the allowance for doubtful accounts quarterly. Account balances
are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered
remote. We do not have any off-balance sheet credit exposure related to our customers.
Inventories. Our inventory is principally comprised of finished goods inventory. Inventories are stated at the lower of cost or
market as primarily determined on a first-in, first-out basis. We evaluate the carrying cost of our inventory on a quarterly basis for this
purpose. If the cost of the inventories exceeds their market value, provisions are made for the difference between the cost and the
market value.
Property, Plant and Equipment. Property, plant and equipment are recorded at cost. Major renewals and improvements that
extend the useful lives of equipment are capitalized. Repair and maintenance costs are expensed as incurred. Disposals are removed at
carrying cost less accumulated depreciation with any resulting gain or loss reflected in earnings. We capitalize interest costs which are
incurred as part of the cost of constructing major facilities and equipment. Depreciation is recognized using the straight-line method
over the following estimated useful lives:
Machinery and equipment .....................................................................................................................................................
Building and land improvements ..........................................................................................................................................
Manufacturing control equipment .........................................................................................................................................
Office equipment...................................................................................................................................................................
Research equipment and facilities .........................................................................................................................................
Vehicles ................................................................................................................................................................................
Computer hardware/information systems .............................................................................................................................
20 years
20 years
10 years
5 years
5 years
5 years
3 years
Long-Lived Assets. In accordance with Impairment or Disposal of Long-Lived Assets Subsections of FASB ASC Subtopic 360-
10, Property, Plant, and Equipment—Overall, (FASB Statement No. 144, Accounting for the Impairment or Disposal of Long-Lived
Assets), long-lived assets, such as property, plant, and equipment, and purchased intangible assets subject to amortization are reviewed
for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If
circumstances require a long-lived asset or asset group be tested for possible impairment, we first compare undiscounted cash flows
expected to be generated by that asset or asset group to its carrying value. If the carrying value of the long-lived asset or asset group is
not recoverable on an undiscounted cash flow basis, impairment is recognized to the extent that the carrying value exceeds its fair
value. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values
and third-party independent appraisals, as considered necessary.
Asset Retirement Obligations (“ARO”). Our ARO consists of estimated costs of dismantlement, removal, site reclamation and
similar activities associated with our facilities. We recognize the fair value of a liability for an ARO in the period in which we have an
existing legal obligation associated with the retirement of our facilities and the obligation can reasonably be estimated. The associated
asset retirement cost is capitalized as part of the carrying cost of the asset. The recognition of an ARO requires that we make
numerous estimates, assumptions and judgments regarding such factors as the existence of a legal obligation for an ARO; estimated
probabilities, amounts and timing of settlements; the credit-adjusted risk-free rate to be used; discount rate and inflation rates. In
periods subsequent to initial measurement of the ARO, we recognize changes in the liability resulting from the accretion of the
liability to its non-discounted amount and revisions to either the timing or the amount of the original estimate of undiscounted cash
flows. Revisions also result in increases or decreases in the carrying cost of these assets. Increases in the ARO liability due to
accretion is charged to depreciation and amortization expense. The related capitalized cost, including revisions thereto, is charged to
depreciation and amortization expense. See Note 11 Commitments and Contingencies (subsection (c)) to the consolidated financial
statements.
45
Contingencies. We are routinely involved in litigation, claims and disputes incidental to our business. Professional judgment is
required to classify the likelihood of these contingencies occurring. A contingency is categorized as probable, reasonably possible, or
remote. A contingency is classified as probable if the future event or events are likely to occur. For the probable contingencies, a loss
is accrued and disclosed as of the date of the financial statements if it is both probable that an asset has been impaired or a liability has
been incurred at the date of the financial statements and the amount of loss can be reasonably estimated. A reasonably possible
contingency occurs if the chance of the future event or events happening is more than remote but less than likely (reasonably possible
but not probable). We disclose the loss contingencies in the footnotes to the financial statements but do not recognize any liability. A
remote contingency is one where the chance of the future event or events occurring is slight. We neither accrue for nor disclose the
liability in the notes to the financial statements.
Share-Based Compensation. Share-based compensation cost is measured at the grant date based on the fair value of the award.
We recognize these costs using the straight-line method over the requisite service period. The Kraton Performance Polymers, Inc.
2009 Equity Incentive Plan (the “Equity Plan”) allows for the grant to key employees, independent contractors, and eligible non-
employee directors of incentive stock options, non-qualified stock options (which together with the incentive stock options, are
referred to herein as (“Options”)), stock appreciation rights, restricted stock awards and restricted stock unit awards, in addition to
other equity or equity-based awards as our board determines from time to time. We estimate the fair value of stock options using the
Black-Scholes valuation model. Since our equity interests were privately held prior to our initial public offering we have limited
publicly traded stock history, and as a result our estimated volatility is based on a combination of our historical volatility and similar
companies’ stock that are publicly traded. Until such time that we have enough publicly traded stock history to estimate volatility
based solely on our stock, we expect to estimate volatility of options granted based on a combination of our historical volatility and
similar companies’ stock that are publicly traded. The expected term of options represents the period of time that options granted are
expected to be outstanding. For all periods presented, we used the simplified method to calculate the expected term of options. The
risk free interest rate for the periods within the contractual life of the option is based on the U.S. Treasury yield curve in effect at the
time of grant. For all periods presented, the dividend yield is assumed to be zero based on historical and expected dividend activity.
Forfeitures are based substantially on the history of cancellations of similar awards granted in prior years. See Note 3 Share-Based
Compensation to the consolidated financial statements.
Income Taxes. We conduct operations in separate legal entities in different jurisdictions. As a result, income tax amounts are
reflected in our consolidated financial statements for each of those jurisdictions.
Income taxes are recorded utilizing an asset and liability approach. This method gives consideration to the future tax
consequences associated with the differences between the financial accounting and tax basis of the assets and liabilities as well as the
ultimate realization of any deferred tax asset resulting from such differences. Valuation allowances are recorded to reduce deferred tax
assets when it is more likely than not that a tax benefit will not be realized. In determining whether a valuation allowance is required,
the company evaluates primarily (a) the impact of cumulative losses in past years, and (b) current and/or recent losses. A recent trend
in earnings despite cumulative losses is a prerequisite to considering not recording a valuation allowance.
In assessing the realizability of deferred tax assets, we consider whether it is more likely than not that some portion or all of the
deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future
taxable income during the periods in which those temporary differences become deductible. We consider the scheduled reversal of
deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Based upon the level of
historical taxable income and projections for future taxable income over the periods in which the deferred tax assets are deductible, we
believe it is more likely than not that we will realize the benefits of these deductible differences, net of the existing valuation
allowances.
Benefit Plan Valuations. We sponsor a noncontributory defined benefit pension plan (“Pension Plan”), a non-qualified defined
benefit pension plan, and an additional post-retirement benefit plan (“Retiree Medical Plan”). We annually evaluate significant
assumptions related to the benefits and obligations of these plans. Our estimation of the projected benefit obligations and related
benefit expense requires that certain assumptions be made regarding such variables as expected return on plan assets, discount rates,
rates of future compensation increases, estimated future employee turnover rates and retirement dates, distribution election rates,
mortality rates, retiree utilization rates for health care services and health care cost trend rates. The determination of the appropriate
assumptions requires considerable judgment concerning future events and has a significant impact on the amount of the obligations
and expense recorded. We rely in part on actuarial studies when determining the appropriateness of certain of the assumptions used in
determining the benefit obligations and the annual expenses for these plans.
The discount rates are determined annually and are based on rates of return of high-quality long-term fixed income securities
currently available with maturities consistent with the projected benefit payout period. The expected long-term rate of return on assets
is derived from a review of anticipated future long-term performance of individual asset classes and consideration of an appropriate
asset allocation strategy, given the anticipated requirements of the Pension Plan, to determine the average rate of earnings expected on
46
the funds invested to provide for the pension plan benefits. We also consider recent fund performance and historical returns in
establishing the expected rate of return.
Movements in the capital markets impact the market value of the investment assets used to fund our Pension Plan. Future
changes in plan asset returns, assumed discount rates and various other factors related to our pension and post-retirement plans will
impact future pension expenses and liabilities.
The estimated effect of alternate assumptions on the 2014 estimated annual expense for the Pension Plan and Retiree Medical
Plan were performed at varying discount rates, expected return on assets, expected salary increase, and, in the case of our Retiree
Medical Plan, health care cost increases.
The measurement date of the Pension Plan’s assets and obligations was December 31, 2013. We applied a 5.02% discount rate,
assumed an 8.5% long term expected rate of return on plan assets and assumed an expected salary rate increase of 3.0%. The
percentage of equity securities in our Pension Plan as of December 31, 2013 was approximately 57.6%, up from approximately 55.3%
as of December 31, 2012, and the percentage of debt securities as of December 31, 2013 was approximately 33.8%, down from
approximately 36.5% as of December 31, 2012. The plan’s strategic target asset allocation as of December 31, 2013 was 50% equity,
30% debt and 20% other, with the “other” component consisting of a global market fund, a real estate fund, and a commodity fund,
among others. We have assumed that the funds in the “other” category together would behave similarly to debt and therefore included
the 20% “other” as bonds in our assessment.
We estimated a range of returns on the plan assets using a historical stochastic simulation model that determines the compound
average annual return (assuming these asset classes—stocks, bonds and cash) over a 20-year historical period (the approximate
duration of our liabilities under the Pension Plan). The distribution of results from these simulations provides the “best estimate range”
of the expected results (the 25th to 75th percentile).
Based on the plan’s current target asset allocation, the “best estimate range” for asset returns (before non-investment expenses)
was 6.3% to 10.7%. The asset return assumption set for determining the 2014 FASB ASC 715 expense was 8.5%, after non-
investment expenses paid by the Trust. Non-investment expenses have ranged from 0.4% to 0.6% over the last 3 years. Using the
high-end of this range, the 8.5% return after non-investment expenses assumption is equivalent to a gross assumption of 9.1% (8.5% +
0.6%). A 9.1% rate falls within the “best estimate range”, between the 50th and 75th percentile.
For the Pension Plan, a 100 basis point decrease in the assumed discount rate would result in a corresponding increase of $2.1
million in our estimated Pension Plan expense for 2014. A 100 basis point decrease from 8.5% in the rate of return on plan assets
would result in a corresponding increase of $0.9 million and a 100 basis point increase in the expected salary rate would result in a
corresponding increase of $0.9 million in expenses for 2014, in each case holding all other assumptions and factors constant.
For the Retiree Medical Plan, a 100 basis point decrease in the assumed discount rate would result in a corresponding increase
of $0.3 million in our estimated expense and a 100 basis point increase in the assumed health care trend rate would result in a
corresponding increase of $0.1 million in our estimated expense for 2014, in each case holding all other assumptions and factors
constant. For additional information about our benefit plans, See Note 12 Employee Benefits to the consolidated financial statements.
Revenue Recognition. Sales are recognized in accordance with the provisions of ASC 605, Revenue Recognition—Overall, when
the revenue is realized or realizable, and has been earned. Revenue for product sales is recognized when risk and title to the product
transfer to the customer, which usually occurs at the time shipment is made. Our products are generally sold free on board shipping
point or, with respect to countries other than the United States, an equivalent basis. As such, title to the product passes when the
product is delivered to the freight carrier. Our standard terms of delivery are included in our contracts of sale, order confirmation
documents and invoices. Shipping and other transportation costs charged to customers are recorded in both sales and cost of sales.
We have entered into agreements with some of our customers whereby they earn rebates from us when the volume of their
purchases of our product reach certain agreed upon levels. We recognize the rebate obligation ratably, as a reduction of revenue.
47
LIQUIDITY AND CAPITAL RESOURCES
Known Trends and Uncertainties
Kraton Performance Polymers, Inc. is a holding company without any operations or assets other than the operations of its
subsidiaries. Cash flows from operations of our subsidiaries, cash on hand and available borrowings under our credit facility are our
principal sources of liquidity.
In March 2013, we entered into an asset-based revolving credit facility consisting of a U.S. senior secured revolving credit
facility of $150.0 million and a Dutch senior secured revolving credit facility of $100.0 million (the “Senior Secured Credit
Facilities”), to replace our then-existing senior secured credit facility, and repaid in full all outstanding amounts payable under the
previously existing facility. The Senior Secured Credit Facilities are secured by receivables and inventory, and borrowing availability
under the facilities is subject to borrowing base limitations based on the level of receivables and inventory available for security. The
Senior Secured Credit Facilities include a $100.0 million uncommitted accordion feature that, subject to borrowing base availability
and approval of the bank syndicate, could increase aggregate availability to $350.0 million. We cannot guarantee that all of the
lending counterparties contractually committed to fund a revolving credit draw request will actually fund future requests, although we
currently believe that each of the counterparties would meet their funding requirements. The Senior Secured Credit Facilities terminate
on March 27, 2018; however we may, from time to time, request that the lenders extend the maturity of their commitments; provided
that at no time shall there be more than four maturity dates under the Senior Secured Credit Facilities.
The Senior Secured Credit Facilities contain certain customary events of default, including, without limitation, a failure to make
payments under the facilities, cross-default with respect to other indebtedness and cross-judgment default, certain bankruptcy events
and certain change of control events. Consummation of our pending transaction with LCY would constitute a change of control, and
therefore an event of default, under the Senior Secured Credit Facilities. Under the combination agreement with LCY, it is a condition
to the parties’ obligations to close the transaction that we obtain an amendment or waiver to the Senior Secured Credit Facilities
providing that the transactions with LCY will not constitute a change of control thereunder. We intend to seek an amendment or
waiver to satisfy the closing condition.
The Senior Secured Credit Facilities contain a financial covenant requiring us to maintain a fixed charge coverage ratio of 1.0 to
1.0 if availability under the facilities is below specified amounts. Our failure to comply with this financial maintenance covenant
would give rise to a default under the Senior Secured Credit Facilities. If factors arise that negatively impact our profitability, we may
not be able to satisfy this covenant. If we are unable to satisfy this covenant or other provisions of the Senior Secured Credit Facilities
at any future time we would need to seek an amendment or waiver of such covenants or other provisions. The respective lenders under
the Senior Secured Credit Facilities may elect not to consent to any amendment or waiver requests that we may make in the future,
including the request we plan to make in connection with our pending transaction with LCY, and, if they do consent, they may do so
on terms that are not favorable to us. In the event that we are unable to obtain any such waiver or amendment and we are not able to
refinance or repay our Senior Secured Credit Facilities, our inability to meet the covenants or other provisions of the Senior Secured
Credit Facilities would constitute an event of default, which would permit the bank lenders to accelerate the Senior Secured Credit
Facilities. Such acceleration may in turn constitute an event of default under our senior notes or other indebtedness. In the case of our
pending transaction with LCY, failure to obtain the specified consent or waiver from the lenders would result in a failure of a closing
condition under the combination agreement. At December 31, 2013, we were in compliance with the covenants under the Senior
Secured Credit Facilities.
Based upon current and anticipated levels of operations, we believe that cash flows from operations of our subsidiaries, cash on
hand, and borrowings available to us will be sufficient to fund our expected financial obligations, planned capital expenditures and
anticipated liquidity requirements, including working capital requirements, our investment in the joint venture with FPCC, debt
payments, interest payments, benefit plan contributions and income tax obligations. However, these cash flows are subject to a number
of risks and uncertainties, including, but not limited to, earnings, sensitivities to the cost of raw materials, seasonality and fluctuations
in foreign currency exchange rates. Because feedstock costs generally represent a substantial portion of our cost of goods sold, in
periods of rising feedstock costs, we generally consume cash in operating activities due to increases in accounts receivable and
inventory costs, partially offset by increased value of accounts payable. Conversely, during periods in which feedstock costs are
declining, we generate cash flow from decreases in working capital. Additionally, our combination agreement with LCY contains
restrictions on our incurrence of indebtedness, subject to specified exceptions that include borrowings under the Senior Secured Credit
Facilities in the ordinary course. If we needed borrowings in excess of $10.0 million above what is available to us under the Senior
Secured Credit Facilities and LCY did not provide its consent, our ability to fund our financial obligations may be adversely affected.
48
Going forward there can be no assurance that our business will generate sufficient cash flow from operations or that future
borrowings will be available under our senior secured credit facilities to fund liquidity needs and enable us to service our
indebtedness. At December 31, 2013, we had $175.9 million of cash and cash equivalents, which includes $66.8 million of cash-on-
hand at KFPC, the consolidated joint venture in Asia. As of December 31, 2013, our available borrowing capacity was $186.9 million
of which $0 million was drawn and as of the date of this filing, our available borrowing capacity was $192.1 million, of which $0
million was drawn. Excluding the $66.8 million of KFPC cash, our liquidity at December 31, 2013 amounted to $296.0 million. Our
available cash and cash equivalents are held in accounts managed by third-party financial institutions and consist of cash invested in
interest bearing funds and operating accounts. To date, we have not experienced any losses or lack of access to our invested cash or
cash equivalents; however, we cannot provide any assurance that adverse conditions in the financial markets will not impact access to
our invested cash and cash equivalents.
For additional information regarding our Senior Secured Credit Facilities, see “—Senior Secured Credit Facilities” in Note 6
Long-Term Debt to the consolidated financial statements, which is incorporated herein by reference.
We made contributions of $6.2 million to our pension plan for the year ended December 31, 2013 and $8.0 million for the year
ended December 31, 2012. We expect our total pension plan contributions for the year ended December 31, 2014 to be $7.2 million.
Our pension plan obligations are predicated on a number of factors, the primary ones being the return on our pension plan assets and
the discount rate used in deriving our pension obligations. If the investment return on our pension plan assets does not meet or exceed
expectations during 2014, and the discount rate decreases from the prior year, higher levels of contributions could be required in 2015
and beyond.
As of December 31, 2013, we had $163.9 million of cash and short-term investments related to foreign operations that
management asserts are permanently reinvested. As a result of net operating loss carryforwards, management estimates that no
additional cash tax expense would be incurred if this cash were repatriated.
Turbulence in U.S. and international markets and economies may adversely affect our liquidity and financial condition, the
liquidity and financial condition of our customers, and our ability to timely replace maturing liabilities and access the capital markets
to meet liquidity needs, resulting in adverse effects on our financial condition and results of operations. However, to date we have
been able to access borrowings available to us in amounts sufficient to fund liquidity needs. Total receivables, net of allowances, for
customers located in Italy, Spain, Portugal, Greece and Ireland aggregated approximately $5.4 million at December 31, 2013. We have
not incurred to date, nor do we currently expect to incur any material losses associated with these trade receivables.
Our ability to pay principal and interest on our indebtedness, fund working capital, make anticipated capital expenditures and
fund our investment in the joint venture with FPCC depends on our future performance, which is subject to general economic
conditions and other factors, some of which are beyond our control. “See Part I, Item 1A. Risk Factors” for further discussion.
Operating Cash Flows and Liquidity
Net cash provided by operating activities totaled $105.5 million for the year ended December 31, 2013 and $146.3 million for
the year ended December 31, 2012. This represents a net decrease of $40.9 million, which was primarily driven by changes in working
capital. The net change in working capital was a source of cash of $43.8 million in 2013 compared to a source of cash of $72.9 million
in 2012; a period-over-period decline in cash flows of $29.1 million. The period-over-period changes are as follows:
•
•
•
•
$42.4 million decrease in cash flows associated with inventories of products, materials and supplies, largely due to changes
in the quantity of raw material and finished goods inventories and to a lesser extent the costs of raw materials and finished
goods inventories;
$17.8 million decrease in cash flows associated with accounts receivable reflecting changes in timing of cash receipts and
sales volumes, partially offset by decreases in revenue per ton; partially offset by
$6.3 million increase in cash flows associated with trade accounts payable primarily due to the timing of payments partially
offset by a decrease in the cost of raw materials; and
$24.9 million net increase in cash flows due to the timing of payments of other items, including related party transactions,
taxes, and pension costs.
49
Net cash provided by operating activities totaled $146.3 million for the year ended December 31, 2012 and $64.8 million for the
year ended December 31, 2011. This represents a net increase of $81.6 million, which was driven by changes in working capital,
partially offset by a decrease in net income, as follows:
•
•
•
•
$128.6 million decrease in inventories of products, materials and supplies, largely due to lower cost and lower quantities;
$24.4 million decrease in accounts receivable primarily related to lower sales revenue and improved days sales outstanding;
$5.3 million increase in trade accounts payable primarily due to the timing of payments; and
$9.7 million increase in related party payables associated with purchases and timing of payments to our joint venture in
Japan; partially offset by
•
$107.1 million decrease in net income.
Investing Cash Flows
Net cash used in investing activities totaled $88.7 million for the year ended December 31, 2013 and $69.9 million for the year
ended December 31, 2012. Capital projects in 2013 included the following:
•
•
$25.3 million to support our innovation platform, which includes $17.9 million related to the semi-works facility;
$32.1 million related to projects to optimize the production capabilities of our manufacturing assets, which includes $13.6
million to comply with the MACT rule; and
•
$18.9 million related to health, safety and environmental, including infrastructure and maintenance projects.
Net cash used in investing activities totaled $69.9 million for the year ended December 31, 2012 and $64.4 million for the year
ended December 31, 2011. Capital projects in 2012 included the following:
•
•
•
$22.3 million to support our innovation platform, which includes $20.2 million related to the semi-works facility;
$23.8 million related to projects to optimize the production capabilities of our manufacturing assets; and
$18.1 million related to health, safety and environmental, including infrastructure and maintenance projects.
Expected Capital Expenditures. We currently expect 2014 capital expenditures, excluding funding for the joint venture with
FPCC, will be approximately $75.0 million to $80.0 million. Included in this estimate is approximately $28.1 million to comply with
the MACT rule, of which $4.1 million will be financed with a capital lease, and approximately $16.0 million to $22.0 million for
health, safety and environmental and infrastructure and maintenance projects. The remaining anticipated 2014 capital expenditures are
primarily associated with projects to optimize the production capabilities of our manufacturing assets and to support our innovation
platform.
In addition, we anticipate the total FPCC joint venture project construction cost will be at least $200.0 million. We currently
estimate that the joint venture’s 2014 capital expenditures will be approximately $110.0 million to $120.0 million. We and FPCC
intend to pursue opportunities to obtain debt financing for project costs at the joint venture level. Based on our current assumptions
with respect to final project cost, timing and the extent to which the project can be funded through third-party debt financing, we
estimate our share of the funding for the joint venture will be approximately $50.0 million of which $41.6 million has been funded
during the year ended December 31, 2013.
Financing Cash Flows and Liquidity
Our consolidated capital structure as of December 31, 2013 was approximately 56.7% equity, 38.8% debt and 4.5%
noncontrolling interest compared to approximately 52.4% equity and 47.6% debt as of December 31, 2012.
Net cash used in financing activities totaled $62.2 million for the year ended December 31, 2013 compared to net cash provided
by financing activities of $53.4 million for the year ended December 31, 2012, representing a period-over-period decline in cash from
financing activities of $115.6 million. In 2013, we repaid the $96.9 million remaining principal amount of term loans and received
$41.6 million from FPCC, which represents their portion of the equity investment in the joint venture. In 2012, we increased the
amount outstanding under the 6.75% Senior Notes by $100.0 million and made a $40.0 million voluntary prepayment on the term loan
portion of the senior secured credit facility.
50
Net cash provided by financing activities totaled $53.4 million for the year ended December 31, 2012 and net cash used in
financing activities totaled $0.1 million for the year ended December 31, 2011. The $53.5 million increase in cash provided by
financing activities was driven primarily by:
•
•
•
$393.2 million repayment of debt primarily related to the refinancing in February 2011, compared to a $45.6 million
repayment of debt during 2012, which primarily includes a $40.0 million voluntary prepayment on the term loan portion of
the senior secured credit facility in September 2012;
$12.1 million decrease in debt issuance costs paid; partially offset by
$298.8 million decrease in proceeds from debt, primarily related to $150.0 million term debt and $250.0 million senior
notes in February 2011, compared to $101.3 million from the issuance of senior notes in March 2012; and
•
$7.3 million decrease in proceeds from the exercise of employee stock options.
Description of 6.75% Senior Notes due 2019
Kraton Polymers LLC and its wholly-owned financing subsidiary Kraton Polymers Capital Corporation issued $350.0 million
aggregate principal amount of 6.75% senior notes that mature on March 1, 2019. The notes are general unsecured, senior obligations
and are unconditionally guaranteed on a senior unsecured basis. We pay interest on the notes at 6.75% per annum, semi-annually in
arrears on March 1 and September 1 of each year. Prior to March 1, 2015, we may redeem all or a part of the senior notes, at a
redemption price equal to 100.00% of the principal amount of the senior notes redeemed plus the applicable premium as of, plus
accrued and unpaid interest, if any, to the applicable redemption date. After March 1, 2015, we may redeem all or a part of the senior
notes for 103.375%, 101.688%, and 100.000% of the principal amount in 2015, 2016 and 2017 and thereafter, respectively. See Note 6
Long-Term Debt, for further discussion.
Consummation of our pending transaction with LCY would constitute a change of control under the indenture governing our
6.75% senior notes, which would require us to offer to repurchase all outstanding notes at a price in cash equal to 101% of the
aggregate principal amount thereof, plus accrued and unpaid interest. Under the combination agreement with LCY, it is a condition to
the parties’ obligations to close the transaction that we (a) obtain a consent from noteholders under the indenture providing that the
transactions with LCY will not constitute a change of control thereunder or (b) put into place arrangements with debt financing
sources to provide financing for the change of control repurchase offer. We intend to obtain such a consent or put into place such a
financing arrangement to satisfy the closing condition. The terms or cost to obtain such consent or put into place such financing may
be unfavorable, and we may not be successful in obtaining such a consent or putting into place such an arrangement, which would
result in a failure of the closing condition under our combination agreement with LCY. At December 31, 2013, we were in
compliance with the covenants under the indenture governing our 6.75% senior notes.
Other Contingencies
As a chemicals manufacturer, our operations in the United States and abroad are subject to a wide range of environmental laws
and regulations at both the national and local levels. These laws and regulations govern, among other things, air emissions, wastewater
discharges, solid and hazardous waste management, site remediation programs and chemical use and management.
Pursuant to these laws and regulations, our facilities are required to obtain and comply with a wide variety of environmental
permits for different aspects of their operations. Generally, many of these environmental laws and regulations are becoming
increasingly stringent, and the cost of compliance with these various requirements can be expected to increase over time.
In the context of the separation in February 2001, Shell Chemicals agreed to indemnify us for specific categories of
environmental claims brought with respect to matters occurring before the separation. However, the indemnity from Shell Chemicals
is subject to dollar and time limitations. Coverage under the indemnity also varies depending upon the nature of the environmental
claim, the location giving rise to the claim and the manner in which the claim is triggered. Therefore, if claims arise in the future
related to past operations, we cannot give assurances that those claims will be covered by the Shell Chemicals’ indemnity and also
cannot be certain that any amounts recoverable will be sufficient to satisfy claims against us.
In addition, we may in the future be subject to claims that arise solely from events or circumstances occurring after February
2001, which would not, in any event, be covered by the Shell Chemicals’ indemnity. While we recognize that we may in the future be
held liable for remediation activities beyond those identified to date, at present we are not aware of any circumstances that are
reasonably expected to give rise to remediation claims that would have a material adverse effect on our results of operations or cause
us to exceed our projected level of anticipated capital expenditures.
51
The EPA issued new MACT standards for controlling hazardous air emissions from industrial boilers. The MACT rule applies
to the coal-burning boilers at our Belpre, Ohio facility. On December 20, 2012, the EPA announced that it had finalized the clean air
standards for industrial boilers, and certain incinerators, and non-hazardous secondary materials. On January 31, 2013 the final rule
was published in the Federal Register with an effective date of April 1, 2013 and a compliance date of January 31, 2016, three years
from publication in the Federal Register. We plan to be in compliance with the MACT standards prior to the expiration of the
compliance period.
Except for the foregoing, we currently estimate that any expenses incurred in maintaining compliance with environmental laws
and regulations will not materially affect our results of operations or cause us to exceed our level of anticipated capital expenditures.
However, we cannot give assurances that regulatory requirements or permit conditions will not change, and we cannot predict the
aggregate costs of additional measures that may be required to maintain compliance as a result of such changes or expenses.
We had no material operating expenditures for environmental fines, penalties, government imposed remedial or corrective
actions during the years ended December 31, 2013, 2012 or 2011.
Off-Balance Sheet Arrangements
We are not a party to any material off-balance sheet arrangements as of December 31, 2013, other than operating leases.
Contractual Obligations
Our principal outstanding contractual obligations relate to the senior notes and related interest payments, the operating leases of
some of our facilities, the minimum purchase obligations required under our KFPC joint venture agreement and other agreements, and
the feedstock contracts with LyondellBasell and others to provide us with styrene, butadiene and isoprene. The following table
summarizes our contractual cash obligations as of December 31, 2013 for the periods indicated.
Total
Dollars in Millions
350.0
Long-term debt obligations ...................... $
122.1
Estimated interest payments on debt ........
44.1
Operating lease obligations ......................
1.6
Capital lease obligation ............................
Purchase obligations(1) ............................ 4,406.2
Estimated Pension obligations(2) .............
34.3
Total contractual cash obligations ............ $ 4,958.3 $
Payments Due by Period
2014
2015
2016
2017
2018
2019 and
after
0
23.7
9.7
1.6
344.4
4.9
384.3 $
0
23.7
8.5
0
286.7
3.6
322.5 $
0
23.6
5.7
0
170.3
5.4
205.0 $
0
23.6
5.1
0
169.6
3.7
202.0 $
0
23.6
4.7
0
350.0
3.9
10.4
0
211.9 3,223.3
14.1
242.8 $ 3,601.7
2.6
(1)
Included in the above table are our estimated minimum purchases required under our KFPC joint venture agreement. Due to the
indefinite term of this joint venture, we have based our minimum purchases on an assumed 20 year useful life of the facility.
(2) This represents our future pension contributions utilizing the following assumptions:
• The plan was “frozen” at December 31, 2013;
• All assets at December 31, 2013 were moved into a portfolio of high quality bonds whose cash flow matches the expected
cash flow of the “frozen” plan. The yield on the portfolio of bonds as of December 31, 2013 is equal to the estimated PPA
effective rate at January 1, 2014. Assets were assumed to remain in such portfolio until all obligations of the plan were paid
out;
• An estimated PPA effective rate as of January 1, 2014 of 4.51%.;
• All contributions are made at the latest date allowable by law; and
• All other assumptions as used in the 2013 funding actuarial valuation of the plan are met.
Impact of Inflation. Our results of operations and financial condition are presented based on historical cost. While it is difficult
to accurately measure the impact of inflation due to the imprecise nature of the estimates required, we believe the effects of inflation,
if any, on our results of operations and financial condition have been immaterial.
52
Item 7A. Quantitative and Qualitative Disclosures about Market Risk.
We are exposed to certain market risks, including risks from changes in interest rates, foreign currency exchange rates, and
commodity prices that could impact our financial condition, results of operations and cash flows. We selectively manage our exposure
to these and other market risks through regular operating and financing activities as well as through the use of market risk sensitive
instruments. We use such financial instruments as risk management tools and not for speculative investment purposes. The market risk
sensitive instruments that we have entered into as of December 31, 2013 consist of a series of non-deliverable forward contracts,
forward contracts, and foreign currency option contracts.
Interest rate risk. We were exposed to interest rate risk as a result of our previously outstanding variable rate debt under our
senior secured credit agreement which we refinanced in March 2013 and repaid all our outstanding indebtedness. Associated with the
refinancing we terminated and settled the existing interest rate swap agreement that was in place to hedge or otherwise protect against
interest rate fluctuations on a portion of our variable rate debt.
Foreign currency exchange risk. We conduct operations in many countries around the world. Our results of operations are
subject to both currency transaction risk and currency translation risk. We incur currency transaction risk when we enter into either a
purchase or sale transaction using a currency other than the local currency of the transacting entity. We are subject to currency
translation risk because our financial condition and results of operations are measured and recorded in the relevant domestic currency
and then translated into U.S. dollars for inclusion in our historical consolidated financial statements. We attempt to selectively manage
significant exposures to potential foreign currency exchange losses based on current market conditions, future operating activities, and
the associated cost in relation to the perceived risk of loss. The purpose of our foreign currency risk management activities is to
minimize the risk that our cash flows from the sale and/or purchase of services and products in foreign currencies will be adversely
affected by changes in exchange rates.
Periodically, we enter into foreign currency agreements to hedge or otherwise protect against fluctuations in foreign currency
exchange rates. These agreements typically do not qualify for hedge accounting and gains/losses resulting from both the up-front
premiums and/or settlement of the hedges at expiration of the agreements are recognized in the period in which they are incurred. In
2013, we entered into a series of foreign currency option and forward contracts to reduce our exposure to exchange rate volatility.
These contracts were structured such that the underlying foreign currency exchange gains/losses would be offset by the mark-to-
market impact of the hedging instruments and reduce the impact of foreign currency exchange movements throughout the year. The
notional amounts of open foreign currency option and forward contracts were $44.9 million at December 31, 2013 and $48.5 million
at December 31, 2012. The notional amounts of our option and forward contracts do not generally represent amounts exchanged by
the parties, and thus are not a measure of our exposure or of the cash requirements related to these contracts. As such, cash flows
related to these contracts are typically not material. The amounts exchanged are calculated by reference to the notional amounts and
by other terms of the contracts, such as exchange rates.
In addition, we entered into a series of non-deliverable forward and foreign currency option contracts to protect our net
investment in various foreign subsidiaries against adverse changes in exchange rates by fixing the U.S. dollar/Euro exchange rate and
the New Taiwan Dollar/Euro exchange rate. These contracts qualified for hedge accounting in accordance with ASC 815-35 “Net
Investment Hedges” and typically settled weekly or monthly and all were settled at December 31, 2013. See Note 8 Fair Value
Measurements, Financial Instruments and Credit Risk to the consolidated financial statements for further discussion.
We use a sensitivity analysis model to measure the impact of a 10% adverse movement of foreign currency exchange rates
against the U.S. dollar. A hypothetical 10% adverse change in the value of all our foreign currency positions relative to the U.S. dollar
as of December 31, 2013 would result in a $0.8 million pre-tax loss for our net monetary assets denominated in currencies other than
the U.S. dollar.
There are certain limitations inherent in the sensitivity analyses presented, primarily due to the assumption that interest rates and
exchange rates change instantaneously in an equally adverse fashion. In addition, the analyses are unable to reflect the complex
market reactions that normally would arise from the market shifts modeled. While this is our best estimate of the impact of the various
scenarios, these estimates should not be viewed as forecasts.
Commodity price risk. We are exposed to commodity price risk due to our forward contractual purchase commitments for raw
materials. Styrene, butadiene and isoprene are primarily supplied by a portfolio of suppliers under long-term supply contracts and
arrangements with various expiration dates. We are subject to future purchase commitments for commodities under minimum
purchase contracts for raw materials. Based on pricing as of December 31, 2013, a hypothetical 10.0% change in the market price for
these raw materials would change our 2014 cost of goods sold by $39.3 million.
53
Item 8.
Financial Statements and Supplementary Data.
The financial statements are set forth herein commencing on page F-5 of this report.
Item 9.
Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.
None.
Item 9A. Controls and Procedures.
Evaluation of Disclosure Controls and Procedures
An evaluation of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-
15 under the Securities Exchange Act of 1934) was carried out under the supervision and with the participation of our management,
including our Chief Executive Officer and Chief Financial Officer. As of December 31, 2013, based upon that evaluation, the Chief
Executive Officer and Chief Financial Officer concluded that the design and operation of these disclosure controls and procedures
were effective.
Management’s Annual Report on Internal Control over Financial Reporting
See Management’s Annual Report on Internal Control over Financial Reporting on page F-2 of the audited consolidated
financial statements provided under Item 8 of this Form 10-K.
Attestation Report of the Registered Public Accounting Firm
See Report of Independent Registered Public Accounting Firm on page F-3 of the audited consolidated financial statements
provided under Item 8 of this Form 10-K.
Changes in Internal Control over Financial Reporting
There has been no change in our internal control over financial reporting that occurred during the three months ended
December 31, 2013 that has materially affected, or is reasonably likely to materially affect, our internal control over financial
reporting.
Item 9B. Other Information.
None.
54
PART III
Item 10. Directors, Executive Officers and Corporate Governance.
Information in response to this item is incorporated by reference to our Proxy Statement relating to our 2014 annual meeting of
shareholders. The Proxy Statement will be filed with the SEC within 120 days after the end of the fiscal year covered by this Form 10-
K pursuant to Regulation 14A under the Exchange Act.
Item 11. Executive Compensation.
Information in response to this item is incorporated by reference to our Proxy Statement relating to our 2014 annual meeting of
shareholders. The Proxy Statement will be filed with the SEC within 120 days after the end of the fiscal year covered by this Form 10-
K pursuant to Regulation 14A under the Exchange Act.
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.
Information in response to this item is incorporated by reference to our Proxy Statement relating to our 2014 annual meeting of
shareholders. The Proxy Statement will be filed with the SEC within 120 days after the end of the fiscal year covered by this Form 10-
K pursuant to Regulation 14A under the Exchange Act.
Item 13. Certain Relationships and Related Transactions, and Director Independence.
Information in response to this item is incorporated by reference to our Proxy Statement relating to our 2014 annual meeting of
shareholders. The Proxy Statement will be filed with the SEC within 120 days after the end of the fiscal year covered by this Form 10-
K pursuant to Regulation 14A under the Exchange Act.
Item 14. Principal Accountant Fees and Services.
Information in response to this item is incorporated by reference to our Proxy Statement relating to our 2014 annual meeting of
shareholders. The Proxy Statement will be filed with the SEC within 120 days after the end of the fiscal year covered by this Form 10-
K pursuant to Regulation 14A under the Exchange Act.
55
PART IV
Item 15. Exhibits and Financial Statement Schedules.
(a) 1. Financial Statements
The following financial statements are included in Item 8:
Kraton Performance Polymers, Inc.
The reports of KPMG LLP, Independent Registered Public Accounting Firm
(i)
(ii) Consolidated Balance Sheets as of December 31, 2013 and 2012
(iii) Consolidated Statements of Operations—years ended December 31, 2013, 2012 and 2011
(iv) Consolidated Statements of Comprehensive Income (Loss)—years ended December 31, 2013, 2012 and 2011
(v) Consolidated Statements of Changes in Equity—years ended December 31, 2013, 2012 and 2011
(vi) Consolidated Statements of Cash Flows—years ended December 31, 2013, 2012 and 2011
(vii) Notes to consolidated financial statements
2. Exhibits
The exhibits listed on the accompanying Exhibit Index are filed as part of this report and are on file with us.
(b) Exhibits
See Item 15(a) 2 above.
(c) Financial Statement Schedule
See Schedule II.
56
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this
report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: February 27, 2014
Kraton Performance Polymers, Inc.
/S/ KEVIN M. FOGARTY
Kevin M. Fogarty
President and Chief Executive Officer
This report has been signed below by the following persons on behalf of the registrant and in the capacities indicated on
February 27, 2014.
Signature
Title
/S/ KEVIN M. FOGARTY
Kevin M. Fogarty
/S/ STEPHEN E. TREMBLAY
Stephen E. Tremblay
/S/ JASON P. CLARK
Jason P. Clark
/S/ RICHARD C. BROWN*
Richard C. Brown
/S/ ANNA C. CATALANO*
Anna C. Catalano
/S/ STEVEN J. DEMETRIOU*
Steven J. Demetriou
/S/ DOMINIQUE FOURNIER*
Dominique Fournier
/S/ JOHN J. GALLAGHER, III*
John J. Gallagher
/S/ BARRY J. GOLDSTEIN*
Barry J. Goldstein
/S/ FRANCIS S. KALMAN*
Francis S. Kalman
/S/ DAN F. SMITH*
Dan F. Smith
/S/ KAREN A. TWITCHELL*
Karen A. Twitchell
*By:
/S/ STEPHEN E. TREMBLAY
Stephen E. Tremblay
As attorney-in-fact
President, Chief Executive Officer and a Director (Principal
Executive Officer)
Vice President and Chief Financial Officer (Principal Financial
Officer)
Chief Accounting Officer (Principal Accounting Officer)
Director
Director
Director
Director
Director
Director
Director
Director
Director
57
KRATON PERFORMANCE POLYMERS, INC.
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
Audited Consolidated Financial Statements
Management’s Annual Report on Internal Control Over Financial Reporting .........................................................................
The reports of KPMG LLP, Independent Registered Public Accounting Firm ........................................................................
Consolidated Balance Sheets as of December 31, 2013 and 2012 ............................................................................................
Consolidated Statements of Operations for Years Ended December 31, 2013, 2012 and 2011 ................................................
Consolidated Statements of Comprehensive Income (Loss) for Years Ended December 31, 2013, 2012 and 2011 ................
Consolidated Statements of Changes in Equity for Years Ended December 31, 2013, 2012 and 2011 ....................................
Consolidated Statements of Cash Flows for Years Ended December 31, 2013, 2012 and 2011 ..............................................
Notes to Consolidated Financial Statements .............................................................................................................................
Page
F-2
F-3
F-5
F-6
F-7
F-8
F-9
F-10
F-1
Management’s Annual Report on Internal Control over Financial Reporting
Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in
Rules 13a-15(f) and 15d-15(f) of the Securities Exchange Act of 1934, as amended. Internal control over financial reporting, no matter
how well designed, has inherent limitations. Therefore, even those systems determined to be effective can provide only reasonable
assurance with respect to financial statement preparation and presentation. Further, because of changes in conditions, the effectiveness
of internal control over financial reporting may vary over time.
Under the supervision and with the participation of our management, including our chief executive officer and chief financial
officer, we conducted an evaluation to assess the effectiveness of our internal control over financial reporting as of December 31, 2013
based upon criteria set forth in the Internal Control—Integrated Framework (1992) issued by the Committee of Sponsoring
Organizations of the Treadway Commission. Based on our assessment, we believe that, as of December 31, 2013, our internal control
over financial reporting is effective.
The effectiveness of our internal control over financial reporting as of December 31, 2013 has been audited by KPMG LLP, an
independent registered public accounting firm, as stated in their report that is included herein.
F-2
Report of Independent Registered Public Accounting Firm
The Board of Directors and Stockholders
Kraton Performance Polymers, Inc.:
We have audited Kraton Performance Polymers, Inc.’s internal control over financial reporting as of December 31, 2013, based
on criteria established in Internal Control—Integrated Framework (1992) issued by the Committee of Sponsoring Organizations of the
Treadway Commission (COSO). Kraton Performance Polymers, Inc.’s management is responsible for maintaining effective internal
control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the
accompanying Management’s Annual Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion
on the Company’s internal control over financial reporting based on our audit.
We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States).
Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control
over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over
financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness
of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in
the circumstances. We believe that our audit provides a reasonable basis for our opinion.
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that
(1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the
assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial
statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being
made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance
regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a
material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also,
projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of
changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
In our opinion, Kraton Performance Polymers, Inc. maintained, in all material respects, effective internal control over financial
reporting as of December 31, 2013, based on criteria established in Internal Control—Integrated Framework (1992) issued by COSO.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the
consolidated balance sheets of Kraton Performance Polymers, Inc. and subsidiaries as of December 31, 2013 and 2012, and the related
consolidated statements of operations, comprehensive income (loss), changes in equity, and cash flows for each of the years in the
three-year period ended December 31, 2013, and our report dated February 27, 2014 expressed an unqualified opinion on those
consolidated financial statements.
/s/ KPMG LLP
Houston, Texas
February 27, 2014
F-3
Report of Independent Registered Public Accounting Firm
The Board of Directors and Stockholders
Kraton Performance Polymers, Inc.:
We have audited the accompanying consolidated balance sheets of Kraton Performance Polymers, Inc. and subsidiaries as of
December 31, 2013 and 2012, and the related consolidated statements of operations, comprehensive income (loss), changes in equity,
and cash flows for each of the years in the three-year period ended December 31, 2013. These consolidated financial statements are
the responsibility of Kraton Performance Polymers, Inc.’s management. Our responsibility is to express an opinion on these
consolidated financial statements based on our audits.
We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States).
Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial
statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and
disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made
by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable
basis for our opinion.
In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial
position of Kraton Performance Polymers, Inc. and subsidiaries as of December 31, 2013 and 2012, and the results of their operations
and their cash flows for each of the years in the three-year period ended December 31, 2013, in conformity with U.S. generally
accepted accounting principles.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States),
Kraton Performance Polymers, Inc.’s internal control over financial reporting as of December 31, 2013, based on criteria established
in Internal Control—Integrated Framework (1992) issued by the Committee of Sponsoring Organizations of the Treadway
Commission (COSO), and our report dated February 27, 2014 expressed an unqualified opinion on the effectiveness of Kraton
Performance Polymers, Inc.’s internal control over financial reporting.
/s/ KPMG LLP
Houston, Texas
February 27, 2014
F-4
KRATON PERFORMANCE POLYMERS, INC.
CONSOLIDATED BALANCE SHEETS
(In thousands, except par value)
December 31,
2013
December 31,
2012
ASSETS
Current assets:
Cash and cash equivalents ................................................................................................................ $
Receivables, net of allowances of $315 and $401 ............................................................................
Inventories of products .....................................................................................................................
Inventories of materials and supplies ...............................................................................................
Deferred income taxes ......................................................................................................................
Other current assets ..........................................................................................................................
Total current assets .................................................................................................................
Property, plant and equipment, less accumulated depreciation of $353,428 and $311,779 .......................
Intangible assets, less accumulated amortization of $78,784 and $68,531 ................................................
Investment in unconsolidated joint venture ...............................................................................................
Debt issuance costs ....................................................................................................................................
Deferred income taxes ...............................................................................................................................
Other long-term assets ...............................................................................................................................
223,166
124,635
340,323
10,331
7,869
28,363
734,687
381,205
63,393
13,582
10,846
79
25,397
Total assets ....................................................................................................................................... $ 1,194,797 $ 1,229,189
175,872 $
129,356
328,772
10,947
7,596
20,665
673,208
414,257
57,488
14,074
9,213
1,326
25,231
LIABILITIES AND EQUITY
Current liabilities:
Current portion of long-term debt .................................................................................................... $
Accounts payable-trade ....................................................................................................................
Other payables and accruals .............................................................................................................
Deferred income taxes ......................................................................................................................
Due to related party ..........................................................................................................................
Total current liabilities ............................................................................................................
Long-term debt, net of current portion .......................................................................................................
Deferred income taxes ...............................................................................................................................
Other long-term liabilities ..........................................................................................................................
Total liabilities ........................................................................................................................
0 $
115,736
54,539
182
24,603
195,060
350,989
18,359
75,991
640,399
15,074
99,167
50,978
513
16,080
181,812
432,943
22,273
99,946
736,974
Commitments and contingencies (note 11)
Equity:
Kraton stockholders’ equity:
Preferred stock, $0.01 par value; 100,000 shares authorized; none issued .............................
Common stock, $0.01 par value; 500,000 shares authorized; 32,547 shares issued and
0
0
outstanding at December 31, 2013; 32,277 shares issued and outstanding at
December 31, 2012 ............................................................................................................
Additional paid in capital ........................................................................................................
Retained earnings ....................................................................................................................
Accumulated other comprehensive loss ..................................................................................
Total Kraton stockholders’ equity .................................................................................
Noncontrolling interest .....................................................................................................................
Total equity ...................................................................................................................
323
354,957
171,445
(34,510 )
492,215
0
492,215
Total liabilities and equity ................................................................................................................ $ 1,194,797 $ 1,229,189
325
363,590
170,827
(21,252 )
513,490
40,908
554,398
See Notes to Consolidated Financial Statements
F-5
KRATON PERFORMANCE POLYMERS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share data)
Years ended December 31,
2012
2011
2013
Sales revenue .................................................................................................................... $ 1,292,121 $ 1,423,122 $ 1,437,479
1,121,293
Cost of goods sold .............................................................................................................
Gross profit .......................................................................................................................
316,186
Operating expenses:
1,066,289
225,832
1,191,680
231,442
Research and development ......................................................................................
Selling, general and administrative .........................................................................
Depreciation and amortization ................................................................................
Impairment of long-lived assets ..............................................................................
Total operating expenses................................................................................
Loss on extinguishment of debt ........................................................................................
Earnings of unconsolidated joint venture ..........................................................................
Interest expense, net ..........................................................................................................
Income (loss) before income taxes ....................................................................................
Income tax expense (benefit) ............................................................................................
Consolidated net income (loss) .........................................................................................
Net loss attributable to noncontrolling interest ........................................................
Net income (loss) attributable to Kraton ........................................................................... $
Earnings (loss) per common share:
32,014
105,558
63,182
0
200,754
0
530
30,470
(4,862 )
(3,887 )
(975 )
(357 )
(618 ) $
31,011
98,555
64,554
5,434
199,554
0
530
29,303
3,115
19,306
(16,191 )
0
(16,191 ) $
27,996
101,606
62,735
0
192,337
(2,985 )
529
29,884
91,509
584
90,925
0
90,925
Basic ........................................................................................................................ $
Diluted ..................................................................................................................... $
(0.02 ) $
(0.02 ) $
(0.50 ) $
(0.50 ) $
2.85
2.81
Weighted average common shares outstanding:
Basic ........................................................................................................................
Diluted .....................................................................................................................
32,096
32,096
31,939
31,939
31,786
32,209
See Notes to Consolidated Financial Statements
F-6
KRATON PERFORMANCE POLYMERS, INC.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
(In thousands)
2013
Years ended December 31,
2012
(16,191 ) $
(618 ) $
(4,198 )
837
0
(490 )
17,109
13,258
12,640
(722 )
11,918 $
(2,594 )
0
(28 )
(2,335 )
(11,935 )
(16,892 )
(33,083 )
0
(33,083 ) $
2011
90,925
(20,851 )
1,073
(809 )
0
(17,926 )
(38,513 )
52,412
0
52,412
Net income (loss) attributable to Kraton .......................................................................... $
Other comprehensive income (loss):
Foreign currency translation adjustments, net of tax of $0 .....................................
Reclassification of loss on interest rate swap, net of tax of $0 ...............................
Unrealized loss on interest rate swaps, net of tax of $0 ..........................................
Unrealized loss on net investment hedge, net of tax of $0 .....................................
(Increase) decrease in benefit plans liability, net of tax of $10,065, $0, and $0 .....
Other comprehensive income (loss), net of tax .............................................
Comprehensive income (loss) attributable to Kraton .......................................................
Comprehensive loss attributable to noncontrolling interest ...................................
Consolidated comprehensive income (loss) ..................................................................... $
See Notes to Consolidated Financial Statements
F-7
KRATON PERFORMANCE POLYMERS, INC.
CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
(In thousands)
Common
Stock
Additional
Paid in
Capital
Retained
Earnings
Accumulated
Other
Comprehensive
Income (Loss)
Total Kraton
Equity
Noncontrolling
Interest
Total
Equity
Balance at January 1, 2011 ........................... $
Net income ....................................................
Other comprehensive loss .............................
Exercise of stock options ..............................
Non-cash compensation related to equity
awards ......................................................
Balance at December 31, 2011 ..................... $
Net loss .........................................................
Other comprehensive loss .............................
Exercise of stock options ..............................
Non-cash compensation related to equity
awards ......................................................
Balance at December 31, 2012 ..................... $
Net loss .........................................................
Other comprehensive income (loss) ..............
Consolidation of variable interest entity .......
Exercise of stock options ..............................
Non-cash compensation related to equity
awards ......................................................
Balance at December 31, 2013 ..................... $
314 $ 334,457 $ 96,711 $
0
0
7,539
90,925
0
0
0
0
7
20,895 $ 452,377 $
0
(38,513 )
0
90,925
(38,513 )
7,546
0
5,459
0
0
5,459
321 $ 347,455 $ 187,636 $
0
0
931
(16,191 )
0
0
0
0
2
(17,618 ) $ 517,794 $
0
(16,892 )
0
(16,191 )
(16,892 )
933
0
6,571
0
0
6,571
323 $ 354,957 $ 171,445 $
0
0
0
739
(618 )
0
0
0
0
0
0
2
(34,510 ) $ 492,215 $
0
13,258
0
0
(618 )
13,258
0
741
0 $ 452,377
90,925
0
(38,513 )
0
7,546
0
0
5,459
0 $ 517,794
(16,191 )
0
(16,892 )
0
933
0
6,571
0
0 $ 492,215
(975 )
12,893
41,630
741
(357 )
(365 )
41,630
0
0
7,894
0
0
7,894
325 $ 363,590 $ 170,827 $
(21,252 ) $ 513,490 $
0
7,894
40,908 $ 554,398
See Notes to Consolidated Financial Statements
F-8
KRATON PERFORMANCE POLYMERS, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
CASH FLOWS FROM OPERATING ACTIVITIES
Consolidated net income (loss) ............................................................................... $
Adjustments to reconcile consolidated net income (loss) to net cash provided by
(975 ) $
(16,191 ) $
90,925
operating activities:
Years ended December 31,
2012
2011
2013
Depreciation and amortization .......................................................................
Amortization of debt premium .......................................................................
Amortization of debt issuance costs...............................................................
(Gain) loss on property, plant and equipment ................................................
Impairment of long-lived assets .....................................................................
Loss on extinguishment of debt .....................................................................
Earnings from unconsolidated joint venture, net of dividends received ........
Deferred income tax expense (benefit) ..........................................................
Share-based compensation .............................................................................
Decrease (increase) in:
Accounts receivable .............................................................................
Inventories of products, materials and supplies ....................................
Other assets ..........................................................................................
Increase (decrease) in:
Accounts payable-trade ........................................................................
Other payables and accruals .................................................................
Other long-term liabilities ....................................................................
Due to related party ..............................................................................
Net cash provided by operating activities ...................................
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property, plant, and equipment ............................................................
Purchase of software and other intangibles .............................................................
Settlement of net investment hedge .........................................................................
Net cash used in investing activities ...........................................
CASH FLOWS FROM FINANCING ACTIVITIES
63,182
(153 )
7,389
(52 )
0
0
(108 )
(15,546 )
7,894
(1,158 )
11,246
179
14,944
934
3,384
14,296
105,456
(81,080 )
(5,125 )
(2,490 )
(88,695 )
Proceeds from debt ..................................................................................................
Repayments of debt .................................................................................................
Capital lease payments ............................................................................................
Contribution from noncontrolling interest ...............................................................
Proceeds from the exercise of stock options............................................................
Proceeds from insurance note payable ....................................................................
Repayments of insurance note payable ...................................................................
Debt issuance costs ..................................................................................................
Net cash provided by (used in) financing activities ....................
Effect of exchange rate differences on cash ............................................................
Net increase (decrease) in cash and cash equivalents .................
Cash and cash equivalents, beginning of period ......................................................
Cash and cash equivalents, end of period ................................................................ $
Supplemental disclosures
40,000
(136,875 )
(2,950 )
41,630
741
0
0
(4,794 )
(62,248 )
(1,807 )
(47,294 )
223,166
175,872 $
64,554
(108 )
2,986
415
5,434
0
(130 )
9,948
6,571
16,646
53,615
(1,695 )
8,680
(6,481 )
(1,534 )
3,623
146,333
(65,006 )
(4,603 )
(335 )
(69,944 )
101,250
(45,626 )
0
0
933
0
0
(3,156 )
53,401
4,797
134,587
88,579
223,166 $
Cash paid during the period for income taxes, net of refunds received ......... $
Cash paid during the period for interest, net of capitalized interest ............... $
Capitalized interest ........................................................................................ $
8,885 $
23,543 $
4,180 $
14,241 $
24,402 $
2,648 $
Supplemental non-cash disclosures .........................................................................
Capital accruals .............................................................................................. $
Capital lease liability ..................................................................................... $
8,757 $
1,565 $
7,512 $
950 $
62,735
0
6,722
90
0
2,985
(14 )
(10,461 )
5,459
(7,704 )
(74,965 )
7,841
3,418
(12,025 )
(4,120 )
(6,111 )
64,775
(60,311 )
(4,129 )
0
(64,440 )
400,000
(393,160 )
0
0
8,271
4,734
(4,734 )
(15,231 )
(120 )
(4,386 )
(4,171 )
92,750
88,579
6,817
22,829
2,259
7,832
0
See Notes to Consolidated Financial Statements
F-9
KRATON PERFORMANCE POLYMERS, INC.
Notes to Consolidated Financial Statements
INDEX
1. Description of Business, Basis of Presentation, and Significant Accounting Policies ...............................................................
2. New Accounting Pronouncements .............................................................................................................................................
3. Share-Based Compensation .......................................................................................................................................................
4. Detail of Certain Balance Sheet Accounts .................................................................................................................................
5. Earnings per Share (“EPS”) .......................................................................................................................................................
6. Long-Term Debt ........................................................................................................................................................................
7. Debt Issuance Costs ...................................................................................................................................................................
8. Fair Value Measurements, Financial Instruments and Credit Risk ............................................................................................
9. Impairment Charges ...................................................................................................................................................................
10. Income Taxes ...........................................................................................................................................................................
11. Commitments and Contingencies.............................................................................................................................................
12. Employee Benefits ...................................................................................................................................................................
13. Industry Segment and Foreign Operations ...............................................................................................................................
14. Related Party Transactions .......................................................................................................................................................
15. Variable Interest Entity ............................................................................................................................................................
16. Supplemental Guarantor Information .......................................................................................................................................
17. Selected Quarterly Financial Data (Unaudited) .......................................................................................................................
18. Subsequent Events ...................................................................................................................................................................
PAGE
F-11
F-15
F-15
F-18
F-19
F-21
F-22
F-22
F-25
F-25
F-28
F-29
F-35
F-37
F-37
F-37
F-49
F-50
F-10
1. Description of Business, Basis of Presentation and Significant Accounting Policies
Description of Business. We are a leading global producer of styrenic block copolymers (“SBCs”) and other engineered
polymers. We market our products under the Kraton®, Cariflex™, and NEXAR™ brands. SBCs are highly-engineered synthetic
elastomers, which we invented and commercialized almost 50 years ago, that enhance the performance of numerous end use products
by imparting greater flexibility, resilience, strength, durability and processability.
Our polymers are typically formulated or compounded with other products to achieve improved, customer-specific performance
characteristics in a variety of applications. We seek to maximize the value of our product portfolio by emphasizing complex or
specialized polymers and innovations that yield higher margins than more commoditized products. We sometimes refer to these
complex or specialized polymers or innovations as being more “differentiated.”
Our products are found in many everyday applications, including personal care products such as disposable diapers and the
rubberized grips of toothbrushes, razor blades and power tools. Our products are also used to impart tack and shear properties in a
wide variety of adhesive products and to impart characteristics such as, flexibility and durability in sealants and corrosion resistance in
coatings. Our paving and roofing applications provide durability, extending road and roof life.
We also produce Cariflex isoprene rubber and isoprene rubber latex. Our Cariflex products are highly-engineered, non-SBC
synthetic substitutes for natural rubber and natural rubber latex. Our Cariflex products, which have not been found to contain the
proteins present in natural rubber latex and are, therefore, not known to cause allergies, are used in applications such as surgical gloves
and condoms. We believe the versatility of Cariflex provides opportunities for new, high margin applications.
We have a portfolio of innovations at various stages of development and commercialization, including
•
•
•
polyvinyl chloride alternatives for wire and cable, and medical applications;
polymers and compounds for soft skin and coated fabric applications for transportation and consumer markets;
our NEXAR family of membrane polymers for water filtration, heating, ventilation, air conditioning and breathable fabrics;
and
•
synthetic cement formulations and other oilfield applications.
We manufacture our polymers at five manufacturing facilities globally, including our flagship facility in Belpre, Ohio, as well as
facilities in Germany, France, Brazil and Japan. The facility in Japan is operated by an unconsolidated manufacturing joint venture.
The terms “Kraton,” “our company,” “we,” “our,” “ours” and “us” as used in this report refer collectively to Kraton Performance
Polymers, Inc. and its consolidated subsidiaries.
Basis of Presentation. The accompanying consolidated financial statements presented herein are for us and our consolidated
subsidiaries, each of which is a wholly-owned subsidiary, except our 50% investment in our joint venture, Kraton Formosa Polymers
Corporation (“KFPC”), located in Mailiao, Taiwan. KFPC is a variable interest entity for which we have determined that we are the
primary beneficiary and, therefore, have consolidated into our financial statements. Our 50% investment in our joint venture located in
Kashima, Japan is accounted for under the equity method of accounting. All significant intercompany transactions have been
eliminated.
Significant Accounting Policies. These financial statements reflect all normal recurring adjustments that are, in the opinion of
management, necessary to fairly present our results of operations and financial position.
Use of Estimates. The preparation of consolidated financial statements in conformity with accounting principles generally
accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of
assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the
reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
Significant items subject to such estimates and assumptions include
•
•
•
the useful lives of fixed assets;
allowances for doubtful accounts and sales returns;
the valuation of derivatives, deferred tax assets, property, plant and equipment, inventory, investments and share-based
compensation; and
•
liabilities for employee benefit obligations, asset retirement obligations, income tax uncertainties and other contingencies.
F-11
Cash and Cash Equivalents. It is our policy to invest our excess cash in investment instruments whose value is not subject to
market fluctuations, such as bank deposits or certificates of deposit. Other permitted investments include commercial paper of major
U.S. corporations with ratings of A1 by Standard & Poor’s Ratings Group or P1 by Moody’s Investor Services, Inc., loan
participations of major U.S. corporations with a short term credit rating of A1/P1 and direct obligations of the U.S. government or its
agencies. We consider all investments having a remaining maturity, at the time of purchase, of three months or less to be cash
equivalents.
Receivables. Receivables are recorded at the invoiced amount and do not bear interest. The allowance for doubtful accounts is
our best estimate of the amount of probable credit losses in our existing receivables and is determined based on our assessment of the
credit worthiness of individual customers, historical write-off experience and global economic data. We review the allowance for
doubtful accounts quarterly. Account balances are charged off against the allowance after all means of collection have been exhausted
and the potential for recovery is considered remote. We do not have significant off-balance sheet credit exposure related to our
customers.
Inventories. Our inventory is principally comprised of finished goods inventory. Inventories are stated at the lower of cost or
market as primarily determined on a first-in, first-out basis. We evaluate the carrying cost of our inventory on a quarterly basis for this
purpose. If the cost of the inventories exceeds their market value, provisions are made for the differences between the cost and the
market value.
Derivative Instruments and Hedging Activities. We account for derivatives and hedging activities in accordance with ASC 815,
“Derivatives and Hedging,” which requires entities to recognize all derivative instruments as either assets or liabilities in the balance
sheet at their respective fair values. For derivatives designated in cash flow hedging relationships, changes in the fair value are either
offset through earnings against the change in fair value of the hedged item attributable to the risk being hedged or recognized in
accumulated other comprehensive income (loss), to the extent the derivative is effective at offsetting the changes in cash flows being
hedged until the hedged item affects earnings.
For all hedging relationships, we formally document the hedging relationship and our risk-management objective and strategy
for undertaking the hedge, the hedging instrument, the hedged transaction, the nature of the risk being hedged, how the hedging
instrument’s effectiveness in offsetting the hedged risk will be assessed prospectively and retrospectively, and a description of the
method used to measure ineffectiveness. We also formally assess both at the inception of the hedging relationship and on an ongoing
basis, whether the derivatives that are used in hedging relationships are highly effective in offsetting changes in cash flows of hedged
transactions. For derivative instruments that are designated and qualify as part of a cash flow hedging relationship, the effective
portion of the gain or loss on the derivative is reported as a component of other comprehensive income (loss) and reclassified into
earnings in the same period or periods during which the hedged transaction affects earnings. Gains and losses on the derivative
representing either hedge ineffectiveness or hedge components excluded from the assessment of effectiveness are recognized in
current earnings.
We discontinue hedge accounting prospectively when we determine that the derivative is no longer effective in offsetting cash
flows attributable to the hedged risk, the derivative expires or is sold, terminated, or exercised, and the cash flow hedge is de-
designated because a forecasted transaction is not probable of occurring, or we remove the designation of the cash flow hedge.
In all situations in which hedge accounting is discontinued and the derivative remains outstanding, we continue to carry the
derivative at its fair value on the balance sheet and recognize any subsequent changes in its fair value in earnings. When it is probable
that a forecasted transaction will not occur, we discontinue hedge accounting and recognize immediately in earnings gains and losses
that were accumulated in other comprehensive income (loss) related to the hedging relationship.
Property, Plant and Equipment. Property, plant and equipment are recorded at cost. Major renewals and improvements which
extend the useful lives of equipment are capitalized. Repair and maintenance costs are expensed as incurred. Disposals are removed at
carrying cost less accumulated depreciation with any resulting gain or loss reflected in earnings. We capitalize interest costs which are
incurred as part of the cost of constructing major facilities and equipment. Depreciation is recognized using the straight-line method
over the following estimated useful lives:
Machinery and equipment .....................................................................................................................................................
Building and land improvements ..........................................................................................................................................
Manufacturing control equipment .........................................................................................................................................
Office equipment ..................................................................................................................................................................
Research equipment and facilities .........................................................................................................................................
Vehicles ................................................................................................................................................................................
Computer hardware and information systems .......................................................................................................................
20 years
20 years
10 years
5 years
5 years
5 years
3 years
F-12
Major Maintenance Activities. Major maintenance or turnaround costs are expensed as incurred.
Asset Retirement Obligations (“ARO”). We account for ARO’s pursuant to the provisions of ASC 410-20, “Asset Retirement
Obligations.” ASC 410-20 requires us to record the fair value of an ARO as a liability in the period in which we have a legal
obligation associated with the retirement of tangible long-lived assets that result from the acquisition, construction, development,
and/or normal use of the assets. The ARO is also capitalized as part of the carrying cost of the asset and is depreciated over the life of
the asset. The recognition of an ARO requires us to make numerous estimates, assumptions and judgments regarding such factors as
the existence of a legal obligation for an ARO; estimated probabilities, amounts and timing of settlements; the credit-adjusted risk-free
rate to be used; discount rate and inflation rates. Subsequent to the initial measurement of the ARO, the obligation is to be adjusted at
the end of each period to reflect accretion of the liability to its non-discounted amount and changes in either the timing or the amount
of the original estimated future cash flows underlying the obligation. Revisions also result in increases or decreases in the carrying
cost of these assets. Increases in the ARO liability due to accretion is charged to depreciation and amortization expense. The related
capitalized cost, including revisions thereto, is charged to depreciation and amortization expense.
We have no assets that are legally restricted for purposes of settling ARO’s. We have determined that we have contractual or
regulatory requirements to decommission and perform other remediation for many of our manufacturing facilities and other assets
upon retirement. These manufacturing facilities have historically been profitable, and we plan to continue to upgrade these assets and
expand the manufacturing capacity in conjunction with the growing market for our products. We plan to operate our manufacturing
facilities for the foreseeable future and there are no current plans to close or convert these assets for use in the manufacture of
fundamentally different products. Unlike our manufacturing assets in the United States and Brazil, our manufacturing assets in Europe
are all located on leased land. For these assets, we used the lease termination dates as the estimate for when our ARO’s related to those
assets will be settled.
Long-Lived Assets. In accordance with the Impairment or Disposal of Long-Lived Assets Subsections of ASC 360-10,
“Property, Plant, and Equipment—Overall,” long-lived assets, such as property, plant, and equipment, and purchased intangible
assets subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying
amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group be tested for possible
impairment, we first compare undiscounted cash flows expected to be generated by that asset or asset group to its carrying value. If the
carrying value of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, impairment is recognized
to the extent that the carrying value exceeds its fair value. Fair value is determined through various valuation techniques including
discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary.
Intangible Assets. We have intangible assets related to technology, tradenames/trademarks, customer relationships and software
as detailed in Note 4 Detail of Certain Balance Sheet Accounts to the consolidated financial statements. Intangible assets are
amortized on the straight-line method over the estimated useful lives of the assets. The estimated useful life of technology,
tradenames/trademarks and customer relationships is 15 years, while the estimated useful life of software is 10 years.
Pension and Other Postretirement Plans. We sponsor a noncontributory defined benefit pension plan, a non-qualified defined
benefit pension plan, and an additional post-retirement benefit plan. We annually evaluate significant assumptions related to the
benefits and obligations of these plans. Our estimation of the projected benefit obligations and related benefit expense requires that
certain assumptions be made regarding such variables as expected return on plan assets, discount rates, rates of future compensation
increases, estimated future employee turnover rates and retirement dates, distribution election rates, mortality rates, retiree utilization
rates for health care services and health care cost trend rates. The determination of the appropriate assumptions requires considerable
judgment concerning future events and has a significant impact on the amount of the obligations and expense recorded. We rely in part
on actuarial studies when determining the appropriateness of certain of the assumptions used in determining the benefit obligations
and the annual expenses for these plans.
Investment in Unconsolidated Joint Venture. Our 50% equity investment in a manufacturing joint venture at our Kashima site is
accounted for under the equity method with our share of the operating results of the joint venture classified within earnings of
unconsolidated joint venture.
We evaluate our equity method investment for impairment when events or changes in circumstances indicate, in our judgment,
that the carrying value of such investment may have experienced an other-than-temporary decline in value. When evidence of loss in
value has occurred, we compare the estimated fair value of the investment to the carrying value of the investment to determine
whether impairment has occurred. We assess the fair value of our equity method investment using commonly accepted techniques, and
may use more than one method, including, but not limited to, recent third party comparable sales, internally developed analysis and
analysis from outside advisors. If the estimated fair value is less than the carrying value and we consider the decline in value to be
other than temporary, the excess of the carrying value over the estimated fair value is recognized in the financial statements as an
impairment.
F-13
Debt Issuance Costs. We capitalize financing fees and other costs related to issuing long-term debt. We amortize these costs
using the effective interest method, except for costs related to revolving debt, which are amortized using the straight-line method. The
amortization of debt issuance costs are recorded in interest expense.
Contingencies . We are routinely involved in litigation, claims and disputes incidental to our business. Professional judgment is
required to classify the likelihood of these contingencies occurring. All relevant information that can be acquired concerning the
uncertain set of circumstances needs to be obtained and used to determine the probability classification. A contingency is categorized
as probable, reasonably possible, or remote. A contingency is classified as probable if the future event or events are likely to occur.
For the probable contingencies, a loss is accrued and disclosed as of the date of the financial statements if it is both probable that an
asset has been impaired or a liability has been incurred at the date of the financial statements and the amount of loss can be reasonably
estimated. A reasonably possible contingency occurs if the chance of the future event or events happening is more than remote but less
than likely (reasonably possible but not probable). We disclose the loss contingencies in the footnotes to the financial statements but
do not recognize any liability. A remote contingency is one where the chance of the future event or events occurring is slight. We
neither accrue for nor disclose the liability in the notes to the financial statements.
Environmental Costs. Environmental costs are expensed as incurred unless the expenditures extend the economic useful life of
the relevant assets. Costs that extend the economic useful life of assets are capitalized and depreciated over the remaining life of those
assets. Liabilities are recorded when environmental assessments, or remedial efforts are probable, and the cost can be reasonably
estimated.
Disclosures about Fair Value of Financial Instruments. For cash and cash equivalents, receivables, accounts payable and certain
accrued expenses the carrying amount approximates fair value due to the short maturities of these instruments. For long-term debt
instruments and the interest rate swap agreements fair value is estimated based upon market values (if applicable) or on the current
interest rates available to us for debt with similar terms and remaining maturities. Considerable judgment is required in developing
these estimates.
Revenue Recognition. Sales revenue is recognized in accordance with the provisions of ASC 605, “Revenue Recognition—
Overall,” when the revenue is realized or realizable, and has been earned. Revenue for product sales is recognized when risk and title
to the product transfer to the customer, which usually occurs at the time shipment is made. Our products are generally sold free on
board shipping point or, with respect to countries other than the United States, an equivalent basis. As such, title to the product passes
when the product is delivered to the freight carrier. Our standard terms of delivery are included in our contracts of sale, order
confirmation documents and invoices. Shipping and other transportation costs charged to customers are recorded in both sales and cost
of sales.
We have entered into agreements with some of our customers whereby they earn rebates from us when the volume of their
purchases of our product reach certain agreed upon levels. We recognize the rebate obligation ratably, as a reduction of revenue.
Research and Development Expenses. Research and development expenses are expensed as incurred.
Share-Based Compensation. Share-based compensation cost is measured at the grant date based on the fair value of the award.
We recognize these costs using the straight-line method over the requisite service period. The Kraton Performance Polymers, Inc.
Equity Incentive Plan (the “Equity Plan”) allows for the grant to key employees, independent contractors, and eligible non-employee
directors of incentive stock options (for employees only), non-qualified stock options (which together with the incentive stock options,
are referred to herein as (“Options”)), stock appreciation rights, restricted stock awards and restricted stock unit awards, in addition to
other equity or equity-based awards (including performance-based awards) as our board determines from time to time. We estimate
the fair value of stock options using the Black-Scholes valuation model. Since our equity interests were privately held prior to our
initial public offering we have limited publicly traded stock history, and as a result our estimated volatility is based on a combination
of our historical volatility and similar companies’ stock that are publicly traded. Until such time that we have enough publicly traded
stock history to estimate volatility based solely on our stock, we expect to estimate volatility of options granted based on a
combination of our historical volatility and similar companies’ stock that are publicly traded. The expected term of options represents
the period of time that options granted are expected to be outstanding. For all periods presented, we used the simplified method to
calculate the expected term of options. The risk free interest rate for the periods within the contractual life of the option is based on the
U.S. Treasury yield curve in effect at the time of grant. For all periods presented, the dividend yield is assumed to be zero based on
historical and expected dividend activity. Forfeitures are based substantially on the history of cancellations of similar awards granted
in prior years. See Note 3 Share-Based Compensation to the consolidated financial statements.
F-14
Leases. Our leases entered into as of December 31, 2013 are classified as either operating or capital leases. A lease is deemed a
capital lease when one of the following conditions is met: (1) ownership of the asset is transferred to the lessee at the end of the lease
term, (2) the lease contains a bargain purchase option, (3) the lease term is 75% or more of the asset’s useful life, or (4) the net present
value of minimum lease payments is equal to 90% or more of the asset’s fair market value. All other leases are classified as an
operating lease. The capital lease obligation is classified as either a current liability or long term liability based on the lease payment
schedule, and is offset by an asset purchased pursuant to the lease and depreciated in accordance with the our depreciation policy.
Generally, operating lease payments are paid on a straight-line basis. For those leases which contain escalating rent payment clauses,
we use the straight-line method to record lease expense.
Income Taxes. We conduct operations in separate legal entities in different jurisdictions. As a result, income tax amounts are
reflected in these consolidated financial statements for each of those jurisdictions.
Income taxes are recorded utilizing an asset and liability approach. This method gives consideration to the future tax
consequences associated with the differences between the financial accounting and tax basis of the assets and liabilities as well as the
ultimate realization of any deferred tax asset resulting from such differences. Valuation allowances are recorded to reduce deferred tax
assets when it is more likely than not that a tax benefit will not be realized.
In assessing the realizability of deferred tax assets, we consider whether it is more likely than not that some portion or all of the
deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future
taxable income during the periods in which those temporary differences become deductible. We consider the scheduled reversal of
deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Based upon the level of
historical taxable income and projections for future taxable income over the periods in which the deferred tax assets are deductible, we
believe it is more likely than not that we will realize the benefits of these deductible differences, net of the existing valuation
allowances.
Foreign Currency Translation and Foreign Currency Exchange Rates. Financial statements of our operations outside the United
States where the local currency is considered to be the functional currency are translated into U.S. dollars using the exchange rate at
each balance sheet date for assets and liabilities and the average exchange rate for each period for revenue, expenses, gains, losses and
cash flows. The effects of translating such operations into U.S. dollars are included as a component of accumulated other
comprehensive income (loss).
2. New Accounting Pronouncements
Adoption of Accounting Standards. We have implemented all new accounting pronouncements that are in effect and that
management believes would materially impact our financial statements and do not believe that there are any other new accounting
pronouncements that have been issued that might have a material impact on our financial position or results of operations.
3. Share-Based Compensation
We account for share-based awards under the provisions of ASC 718, “Share-Based Payment,” which established the
accounting for share-based awards exchanged for employee services. Accordingly, share-based compensation cost is measured at the
grant date based on the fair value of the award and we expense these costs using the straight-line method over the requisite service
period. Share-based compensation expense was approximately $7.9 million, $6.6 million and $5.5 million, net of tax effects of $0.0
million for the years ended December 31, 2013, 2012 and 2011, respectively. We have historically recorded these costs in selling,
general and administrative expenses; however, beginning in the second quarter of 2013, a portion of these costs were recorded in cost
of goods sold and research and development expenses. At December 31, 2013, there was approximately $3.5 million of unrecognized
compensation expense related to non-vested option awards to be recognized over a weighted-average period of 1.38 years, and $4.4
million of unrecognized compensation expense related to awards of restricted stock, restricted share units and performance share units
expected to be recognized over a weighted-average period of 1.87 years.
Kraton Performance Polymers, Inc. 2009 Equity Incentive Plan. On November 30, 2009, our board of directors and our
stockholders approved the Kraton Performance Polymers, Inc. Equity Incentive Plan (the “Equity Plan”) and on May 25, 2011, our
board of directors and stockholders approved the amendment and restatement of the Equity Plan. The Equity Plan allows for the grant
to key employees, independent contractors, and eligible non-employee directors of incentive stock options (to employees only), non-
qualified stock options (which together with the incentive stock options, are referred to herein as (“Options”)), stock appreciation
rights, restricted stock awards and restricted stock unit awards, in addition to other equity or equity-based awards (including
performance-based awards) as our board determines from time to time.
F-15
Under this plan, there are a total of 4,350,000 shares of common stock reserved for issuance. As of December 31, 2013 and
2012 there were 2,304,949 and 2,730,598 shares of common stock available for issuance, respectively.
Stock Option Activity
Option activities for the year ended December 31, 2013 are as follows:
Outstanding at December 31, 2012 ............................................................................................................
Granted .............................................................................................................................................
Exercised ..........................................................................................................................................
Forfeited ...........................................................................................................................................
Expired .............................................................................................................................................
Outstanding at December 31, 2013. ...........................................................................................................
Exercisable at December 31, 2013 .............................................................................................................
Options
(in thousands)
1,536 $
131
53
16
3
1,595
922 $
Weighted
Average
Exercise
Price
23.23
23.84
14.01
22.75
36.93
23.56
22.14
We granted 131,321; 348,502; and 432,155 options to our employees during the years ended December 31, 2013, 2012 and
2011, respectively. These options have a ten year term and vest in equal installments over three years. The weighted-average grant-
date fair value of options granted during the years ended December 31, 2013, 2012 and 2011 were $12.30, $13.23 and $17.15,
respectively. There were 52,971; 65,352; and 555,619 options exercised during the years ended December 31, 2013, 2012 and 2011,
respectively. The total intrinsic value of the options exercised was $0.5 million, $0.7 million and $11.3 million for the years ended
December 31, 2013, 2012 and 2011, respectively.
The following table summarizes additional information regarding the outstanding and exercisable options at December 31,
2013.
Outstanding options ................................................................................
Exercisable options .................................................................................
Options
(in thousands)
1,595 $
922 $
Weighted
Average
Exercise
Price
Aggregate
Intrinsic
Value(1)
(in thousands)
6,283
4,885
23.56 $
22.14 $
Weighted
Average
Remaining
Contractual
Term
(in years)
6.55
5.77
(1) The intrinsic value of a stock option is the amount by which the market value of the underlying stock exceeds the exercise price
of the option as of December 31, 2013.
Weighted-Average Assumptions for Option Pricing
2013
2012
2011
Risk-free interest rate ......................................................................................................
Expected dividend yield ..................................................................................................
Expected volatility ..........................................................................................................
Expected term ................................................................................................................. 6.0 years 6.0 years 6.0 years
1.01 %
0.00 %
55.0 %
1.11 %
0.00 %
54.0 %
2.46 %
0.00 %
47.0 %
Since our equity interests were privately held prior to our initial public offering we have limited publicly traded stock history,
and as a result our estimated volatility is based on a combination of our historical volatility and similar companies’ stock that are
publicly traded. Until such time that we have enough publicly traded stock history to estimate volatility based solely on our stock, we
expect to estimate volatility of options granted based on a combination of our historical volatility and similar companies’ stock that are
publicly traded. The expected term of options represents the period of time that options granted are expected to be outstanding. For all
periods presented, we used the simplified method to calculate the expected term of options. The risk free interest rate for the periods
within the contractual life of the option is based on the U.S. Treasury yield curve in effect at the time of grant. For all periods
presented, the dividend yield is assumed to be zero based on historical and expected dividend activity.
F-16
Restricted stock awards, Restricted share units and Performance share units
We may grant to certain employees time-vested restricted stock awards and time-vested restricted share units. In addition, we
may grant performance share units, which vest after the achievement of performance criteria established at grant. Holders of restricted
share units and performance share units do not have any beneficial ownership in the common stock underlying the restricted share
units or performance share units, and the grant represents an unsecured promise to deliver common stock on a future date. Actual
shares of common stock underlying the restricted share units will not be issued until the earlier of the passage of the vesting period, a
change in control that also results in the termination of the grantee’s employment, or the death / disability of the participant. The
performance share units vest at the end of a three-year period assuming continued employment and assuming our company’s
achievement of the performance measures established by our Compensation Committee when the performance share units were
initially granted. When performance share units vest, a number of shares of common stock equal to 0% to 200% of the initial grant
amount will be issued, depending on the level of achievement of such performance measures. We awarded 203,027 and 116,982
shares of restricted stock to our employees, which are subject to a three-year cliff vesting, during the years ended December 31, 2013
and 2012, respectively. We issued 26,424 and 19,394 shares of restricted stock to members of the board of directors during the years
ended December 31, 2013 and 2012, respectively, which vested on the grant date. We granted 28,976 restricted share units and 67,585
performance share units to our employees during the year ended December 31, 2013.
The following table represents the non-vested restricted stock awards, restricted share units and performance share units granted,
vested and forfeited during 2013.
Non-vested shares at December 31, 2012 ..................................................................................................
Granted .............................................................................................................................................
Vested ...............................................................................................................................................
Forfeited ...........................................................................................................................................
Non-vested shares at December 31, 2013 ..................................................................................................
Weighted-
average
Grant-date
Fair Value
Shares
(in thousands)
248 $
326
49
12
513 $
29.88
23.78
19.09
28.75
27.05
The total fair value of shares vested during the years ended December 31, 2013, 2012 and 2011 was $0.9 million, $1.2 million,
and $0.8 million, respectively.
F-17
4. Detail of Certain Balance Sheet Accounts
Inventories of products:
Finished products............................................................................................................................. $
Work in progress .............................................................................................................................
Raw materials ..................................................................................................................................
Total inventories of products .................................................................................................................... $
Property, plant and equipment:
Land ................................................................................................................................................. $
Buildings .........................................................................................................................................
Plant and equipment ........................................................................................................................
Construction in progress(1) .............................................................................................................
Property, plant and equipment ..................................................................................................................
Less accumulated depreciation ........................................................................................................
Property, plant and equipment, net of accumulated depreciation .............................................................. $
Intangible assets:
December 31,
2013
2012
(in thousands)
246,758 $
5,384
76,630
328,772 $
260,510
6,759
73,054
340,323
11,191 $
47,340
650,034
59,120
767,685
353,428
414,257 $
Technology ...................................................................................................................................... $
Customer relationships ....................................................................................................................
Tradenames/trademarks ...................................................................................................................
Software...........................................................................................................................................
Intangible assets...............................................................................................................................
44,202 $
35,145
24,445
32,480
136,272
Less accumulated amortization:
Technology ...................................................................................................................................... $
Customer relationships ....................................................................................................................
Tradenames/trademarks ...................................................................................................................
Software...........................................................................................................................................
Total accumulated amortization ......................................................................................................
Intangible assets, net of accumulated amortization ................................................................................... $
29,870 $
23,470
15,488
9,956
78,784
57,488 $
(1)
Construction in progress includes $4.5 million and $1.0 million of assets financed with short term capital leases as of
December 31, 2013 and 2012, respectively.
11,326
47,072
569,369
65,217
692,984
311,779
381,205
44,726
35,145
23,149
28,904
131,924
26,897
21,134
13,942
6,558
68,531
63,393
Other payables and accruals:
Employee related .............................................................................................................................. $
Other(1) ............................................................................................................................................
Total other payables and accruals .............................................................................................................. $
Other long-term liabilities:
Pension and other postretirement benefits ........................................................................................ $
Other .................................................................................................................................................
Total other long-term liabilities ................................................................................................................. $
Accumulated other comprehensive loss:
December 31,
2013
2012
(in thousands)
16,066 $
38,473
54,539 $
13,423
37,555
50,978
57,924 $
18,067
75,991 $
84,005
15,941
99,946
Foreign currency translation adjustments ......................................................................................... $
Net unrealized loss on interest rate swaps ........................................................................................
Net unrealized loss on net investment hedge ....................................................................................
Benefit plans liability .......................................................................................................................
Total accumulated other comprehensive loss ............................................................................................ $
22,758 $
0
(1,926 )
(42,084 )
(21,252 ) $
26,956
(837 )
(1,436 )
(59,193 )
(34,510 )
(1)
Included in other payables and accruals is $1.0 million due under a short term capital lease as of December 31, 2012.
Aggregate depreciation expense for property, plant and equipment was approximately $52.4 million, $54.6 million and $54.3
million for the years ended December 31, 2013, 2012 and 2011, respectively.
F-18
Aggregate amortization expense for intangible assets was approximately $10.3 million, $10.0 million and $8.4 million for the
years ended December 31, 2013, 2012 and 2011, respectively. Estimated amortization expense for each of the next five years is as
follows:
December 31:
2014 ........................................................................................................................................................................... $
2015 ........................................................................................................................................................................... $
2016 ........................................................................................................................................................................... $
2017 ........................................................................................................................................................................... $
2018 ........................................................................................................................................................................... $
Amortization
Expense
(in thousands)
10,816
10,663
9,869
9,474
9,338
5. Earnings per Share (“EPS”)
Basic EPS is computed by dividing net income by the weighted-average number of shares outstanding during the period.
Diluted EPS is computed by dividing net income by the diluted weighted-average number of shares outstanding during the
period and, accordingly, reflects the potential dilution that could occur if securities or other agreements to issue common stock, such
as stock options, were exercised, settled or converted into common stock and were dilutive. The diluted weighted-average number of
shares used in our diluted EPS calculation is determined using the treasury stock method.
Unvested awards of share-based payments with rights to receive dividends or dividend equivalents, such as our restricted stock
awards are considered to be participating securities and therefore the two-class method is used for purposes of calculating EPS. Under
the two-class method, a portion of net income is allocated to these participating securities and therefore is excluded from the
calculation of EPS allocated to common stock. Restricted stock awards outstanding totaled 416,662, 248,097 and 199,615 at
December 31, 2013, 2012 and 2011, respectively. These shares are subject to forfeiture and restrictions on transfer until vested and
have identical voting, income and distribution rights to the unrestricted common shares outstanding. Our weighted average restricted
stock awards outstanding were 392,329, 286,879 and 171,101 for the years ended December 31, 2013, 2012 and 2011, respectively.
Restricted share units of 58,467, 29,491 and 29,491 were outstanding at December 31, 2013, 2012 and 2011, respectively,
including vested and non-vested restricted share units. For the years ended December 31, 2013 and 2012, the weighted average
restricted share units of 52,784 and 29,491 are not included as a component of diluted EPS as they are anti-dilutive. The weighted
average restricted share units of 31,089 are included in the computation of our diluted EPS for the year ended December 31 2011.
Performance share units of 67,585 were outstanding at December 31, 2013. The weighted average performance share units of
55,920 are not included as a component of diluted EPS as they are anti-dilutive for the year ended December 31, 2013.
Stock options of 1,594,581, 1,535,655 and 1,292,751 were outstanding at December 31, 2013, 2012 and 2011, respectively. The
computation of diluted earnings per share excludes the effect of the potential exercise of stock options that are anti-dilutive. The
number of stock options excluded from the computation was 1,594,581, 1,535,655 and 418,662 for the years ended December 31,
2013, 2012 and 2011, respectively.
F-19
The effects of share-based compensation awards on the diluted weighted average number of shares outstanding used in
calculating diluted EPS are as follows:
Net
Loss
attributable to
Kraton
Year ended December 31, 2013
Weighted
Average
Shares
Outstanding
Loss
Per
Share
Basic:
As reported ........................................................................................................................ $
Amounts allocated to unvested restricted shares ...............................................................
Amounts available to common stockholders .................................................................... $
Diluted:
Amounts allocated to unvested restricted shares ...............................................................
Non participating share units ............................................................................................
Stock options added under the treasury stock method ......................................................
Amounts reallocated to unvested restricted shares ............................................................
Amounts available to stockholders and assumed conversions .......................................... $
(in thousands, except per share data)
(618 )
7
(611 )
(7 )
7
(611 )
32,488
(392 )
32,096 $
392
0
0
(392 )
32,096 $
(0.02 )
(0.02 )
Net
Loss
attributable to
Kraton
Year ended December 31, 2012
Weighted
Average
Shares
Outstanding
Loss
Per
Share
Basic:
As reported ....................................................................................................................... $
Amounts allocated to unvested restricted shares ..............................................................
Amounts available to common stockholders ................................................................... $
Diluted:
Amounts allocated to unvested restricted shares ..............................................................
Non participating share units ...........................................................................................
Stock options added under the treasury stock method .....................................................
Amounts reallocated to unvested restricted shares ...........................................................
Amounts available to stockholders and assumed conversions ......................................... $
(in thousands, except per share data)
(16,191 )
144
(16,047 )
32,226
(287 )
31,939 $
(0.50 )
(144 )
144
(16,047 )
287
0
0
(287 )
31,939 $
(0.50 )
Net
Income
attributable to
Kraton
Year ended December 31, 2011
Weighted
Average
Shares
Outstanding
Earnings
Per
Share
Basic:
As reported ........................................................................................................................ $
Amounts allocated to unvested restricted shares ...............................................................
Amounts available to common stockholders .................................................................... $
Diluted:
Amounts allocated to unvested restricted shares ...............................................................
Non participating share units ............................................................................................
Stock options added under the treasury stock method ......................................................
Amounts reallocated to unvested restricted shares ............................................................
Amounts available to stockholders and assumed conversions .......................................... $
(in thousands, except per share data)
90,925
(487 )
90,438
31,957
(171 )
31,786 $
2.85
487
(480 )
90,445
171
31
392
(171 )
32,209 $
2.81
F-20
6. Long-Term Debt
Long-term debt consists of the following:
Term loans ................................................................................................................................................. $
6.75% unsecured notes ...............................................................................................................................
Total long-term debt...................................................................................................................................
Less current portion of long-term debt .............................................................................................
Long-term debt, less current portion .......................................................................................................... $
December 31,
2013
2012
(in thousands)
0 $
350,989
350,989
0
350,989 $
96,875
351,142
448,017
15,074
432,943
Senior Secured Credit Facilities. In March 2013, we entered into an asset-based revolving credit facility consisting of a $150.0
million U.S. senior secured revolving credit facility and a $100.0 million Dutch senior secured revolving credit facility (the “Senior
Secured Credit Facilities”). The Senior Secured Credit Facilities replaced our then existing senior secured credit facility, and we
repaid in full all outstanding amounts payable under the previously existing indebtedness. Borrowing under the Senior Secured Credit
Facilities is subject to borrowing base limitations based on the level of receivables and inventory available for security.
We may request up to an aggregate of $100.0 million of additional revolving facility commitments of which up to an aggregate
of $40.0 million may be additional Dutch revolving facility commitments, provided that we satisfy additional conditions described in
the Senior Secured Credit Facilities, and provided further that the U.S. revolver commitment is at least 60% of the commitments after
giving effect to such increase.
Kraton Polymers U.S. LLC and Kraton Polymers Nederland B.V. are the borrowers under the Senior Secured Credit Facilities,
and Kraton Performance Polymers, Inc., Kraton Polymers LLC, Elastomers Holdings LLC and Kraton Polymers Capital Corporation
are guarantors. The Senior Secured Credit Facilities are secured by receivables and inventory. The Senior Secured Credit Facilities
terminate on March 27, 2018; however, we may from time to time request that the lenders extend the maturity of their commitments.
Availability under the Senior Secured Credit Facilities is limited to the lesser of the borrowing base and total commitments (less
certain reserves).
U.S. borrowings under the Senior Secured Credit Facilities (other than swingline loans) bear interest at a rate equal to, at the
applicable borrower’s option, either (a) a base rate determined by reference to the greater of (1) the prime rate of Bank of America,
N.A., (2) the federal funds rate plus 0.50% and (3) LIBOR plus 1.0%, or (b) a rate based on LIBOR, in each case plus an applicable
margin. U.S. swingline loans shall bear interest at a base rate determined by reference to the greater of (1) the prime rate of Bank of
America, N.A., (2) the federal funds rate plus 0.50% or (3) LIBOR plus 1.0%, in each case plus an applicable margin.
Dutch borrowings under the Senior Secured Credit Facilities bear interest at a rate equal to, at the applicable borrower’s option,
either (a) a fluctuating rate, with respect to Euros, Pounds Sterling and Dollars outside of the U.S. and Canada, equal to the rate
announced by the European Central Bank and used as a base rate by the local branch of Bank of America in the jurisdiction in which
such currency is funded, or (b) a rate based on LIBOR, in each case plus an applicable margin.
The applicable margin is subject to a minimum of 0.5% and a maximum of 1.0% with respect to U.S. base rate loans, and a
minimum of 1.5% and maximum of 2.0% for foreign base rate borrowings and LIBOR loans and is subject to adjustment based on the
borrowers’ excess availability of the applicable facility for the most recent fiscal quarter.
In addition to paying interest on outstanding principal amounts under the Senior Secured Credit Facilities, the borrowers will be
required to pay a commitment fee in respect of the unutilized commitments at an annual rate of 0.375%.
The Senior Secured Credit Facilities contain a financial covenant that if either (a) excess availability is less than the greater of
(i) 12.5% of the lesser of the commitments and the borrowing base and (ii) $31,250,000 or (b) U.S. availability is less than the greater
of (i) 12.5% of the lesser of the U.S. commitments and U.S. borrowing base and (ii) $18,750,000, then following such event, Kraton
and its restricted subsidiaries must maintain a fixed charge coverage ratio of at least 1.0 to 1.0 for four fiscal quarters (or for a shorter
duration if certain financial conditions are met). The Senior Secured Credit Facilities contain certain customary events of default,
including, without limitation, a failure to make payments under the facility, cross-default and cross-judgment default, certain
bankruptcy events and certain change of control events.
As of December 31, 2013, our available borrowing capacity was $186.9 million of which $0.0 million was drawn. As of the date
of this filing, our available borrowing capacity was $192.1 million, of which $0.0 million was drawn.
F-21
6.75% Senior Notes due 2019. Kraton Polymers LLC and its wholly-owned financing subsidiary Kraton Polymers Capital
Corporation issued $350.0 million aggregate principal amount of 6.75% senior notes that mature on March 1, 2019 pursuant to an
indenture, dated February 11, 2011 ($250.0 million senior notes) and supplemental indenture thereto dated March 20, 2012 ($100.0
million senior notes). The indenture provides that the notes are general unsecured, senior obligations and will be unconditionally
guaranteed on a senior unsecured basis. We pay interest on the notes at 6.75% per annum, semi-annually in arrears on March 1 and
September 1 of each year.
Debt Maturities. The principal payments on our outstanding total debt as of December 31, 2013, are as follows:
Principal
Payments
(in thousands)
350,000
350,000
December 31:
2019 ...........................................................................................................................................................................
Total debt ......................................................................................................................................................... $
See Note 8 Fair Value Measurements, Financial Instruments and Credit Risk to the consolidated financial statements.
7. Debt Issuance Costs
We capitalize the debt issuance costs related to issuing long-term debt and amortize these costs using the effective interest
method, except for costs related to revolving debt, which are amortized using the straight-line method. We had net debt issuance costs
of $11.4 million and $13.9 million (of which $2.2 million and $3.1 million were included in other current assets) as of December 31,
2013 and December 31, 2012, respectively. In connection with the March 2013 refinancing of our indebtedness, we charged to interest
expense $5.0 million of unamortized debt issuance costs related to our previously existing indebtedness and we capitalized $4.8
million of debt issuance costs related to our new indebtedness. We amortized $2.4 million (which excludes the $5.0 million of
accelerated amortization), $3.0 million and $2.5 million (which excludes the $4.2 million of accelerated amortization) of debt issuance
costs for the years ended December 31, 2013, 2012 and 2011, respectively.
8. Fair Value Measurements, Financial Instruments and Credit Risk
ASC 820, “Fair Value Measurements and Disclosures” defines fair value, establishes a consistent framework for measuring fair
value and expands disclosure requirements about fair value measurements. ASC 820 requires entities to, among other things,
maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.
ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price)
in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the
measurement date.
ASC 820 specifies a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable
or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect our
market assumptions.
In accordance with ASC 820, these two types of inputs have created the following fair value hierarchy:
• Level 1—Inputs that are quoted prices (unadjusted) for identical assets or liabilities in active markets;
• Level 2—Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either
directly or indirectly, for substantially the full term of the asset or liability, including:
•
•
•
•
Quoted prices for similar assets or liabilities in active markets
Quoted prices for identical or similar assets or liabilities in markets that are not active
Inputs other than quoted prices that is observable for the asset or liability
Inputs that are derived principally from or corroborated by observable market data by correlation or other means;
and
• Level 3—Inputs that are unobservable and reflect our assumptions used in pricing the asset or liability based on the best
information available under the circumstances (e.g., internally derived assumptions surrounding the timing and amount of
expected cash flows).
F-22
Recurring Fair Value Measurements. The following tables set forth by level within the fair value hierarchy our financial assets
and liabilities that were accounted for at fair value on a recurring basis as of December 31, 2013 and December 31, 2012, respectively.
These financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value
measurement. Our assessment of the significance of a particular input to the fair value measurement requires judgment, and may affect
the valuation of their fair value and their placement within the fair value hierarchy levels.
Fair Value Measurements at Reporting Date Using
Quoted Prices
in Active
Markets for
Identical Assets
(Level 1)
December 31, 2013
Significant
Other
Observable
Inputs
(Level 2)
(in thousands)
Significant
Unobservable
Inputs
(Level 3)
Balance Sheet Location
Retirement plan asset—noncurrent ........ Other long-term assets
Total .......................................................
$
1,908
1,908 $
1,908
1,908 $
0
0 $
0
0
Fair Value Measurements at Reporting Date Using
Quoted Prices
in Active
Markets for
Identical Assets
(Level 1)
December 31, 2012
Significant
Other
Observable
Inputs
(Level 2)
(in thousands)
Significant
Unobservable
Inputs
(Level 3)
Balance Sheet Location
Derivative asset—current ....................... Other current assets
Retirement plan asset—noncurrent ........ Other long-term assets
$
Derivative liability—current ..................
Derivative liability—noncurrent ............ Other long-term liabilities
$
Total .......................................................
Other payables and
accruals
34 $
860
(578 )
(258 )
58 $
0 $
860
0
0
860 $
34 $
(578 )
(258 )
(802 ) $
0
0
0
0
The use of derivatives creates exposure to credit risk relating to potential losses that could be recognized in the event that the
counterparties to these instruments fail to perform their obligations under the contracts. We seek to minimize this risk by limiting our
counterparties to major financial institutions with acceptable credit ratings and monitoring the total value of positions with individual
counterparties. In the event of a default by one of our counterparties, we may not receive payments provided for under the terms of our
derivatives.
Nonrecurring Fair Value Measurements. Our long-lived assets, such as property, plant, and equipment, and purchased
intangible assets subject to amortization are reviewed for impairment whenever events or changes in circumstances indicate that their
carrying value may not be recoverable. When impairment has occurred, such long-lived assets are written down to fair value. For the
year ended December 31, 2013 we determined that there was no impairment related to our long-lived assets.
The following table sets forth by level within the fair value hierarchy our fair value measurements with respect to non-financial
assets that are measured at fair value on a nonrecurring basis. Our assessment of the significance of a particular input to the fair value
measurement requires judgment, and may affect the valuation of their fair value and their placement within the fair value hierarchy
levels. See Note 9 Impairment Charges, for further discussion.
Fair Value Measurements as of Reporting Date
Quoted Prices
in Active
Markets for
Identical Assets
(Level 1)
Significant
Other
Observable
Inputs
(Level 2)
Significant
Unobservable
Inputs
(Level 3)
(in thousands)
December 31,
2012
Total
Impairment
Charges
Long-lived assets ........................................................... $
Total ............................................................................... $
0 $
0 $
0 $
0 $
14,284 $
14,284 $
14,284 $
14,284 $
5,434
5,434
F-23
The following table presents the carrying values and approximate fair values of our long-term debt as of December 31, 2013 and
December 31, 2012:
Term Loans (significant unobservable input – level 3) .......................... $
6.75% unsecured notes (quoted prices in active market for identical
December 31, 2013
December 31, 2012
Carrying
Value
Fair
Value
Carrying
Value
Fair
Value
0 $
(in thousands)
0 $
96,875 $
96,875
assets – level 1) ................................................................................. $
350,989 $
369,250 $
351,142 $
364,000
The term loans were variable interest rate instruments, and as such, the fair value approximated their carrying value.
Financial Instruments
Interest Rate Swap Agreements. Periodically, we enter into interest rate swap agreements to hedge or otherwise protect against
interest rate fluctuations on a portion of our variable rate debt. These interest rate swap agreements are designated as cash flow hedges
on our exposure to the variability of future cash flows.
In June 2011, we entered into a $75.0 million notional amount interest rate swap agreement with respect to a portion of our
outstanding term loans. This agreement was effective on July 15, 2011 and was set to expire on June 15, 2014. However, on
March 27, 2013, in connection with the refinancing of our credit facility, we terminated and settled the interest rate swap agreement,
and as a result, recognized $0.7 million of interest expense for the year ended December 31, 2013. We recorded an unrealized loss of
$0.1 million in accumulated other comprehensive loss related to the effective portion of this interest rate swap agreement for the year
ended December 31, 2012.
In June 2010, we entered into a $215.0 million notional amount interest rate swap agreement. This agreement was effective on
January 3, 2011 and was set to expire on January 3, 2012. However, on February 10, 2011, in connection with the refinancing of our
previously existing indebtedness, we terminated and settled the interest rate swap agreement, and as a result, recognized $1.0 million
of interest expense.
Fair Value Hedges. In April 2012, we entered into a series of non-deliverable forward contracts to reduce our exposure to
fluctuations in the Canadian dollar (“CAD”) against the U.S. dollar associated with the funding of certain capital expenditures. These
non-deliverable forward contracts qualified for hedge accounting and were designated as fair value hedges in accordance with ASC
815-25 “Fair Value Hedges.” These hedges were effective in offsetting our exposure to the CAD, and therefore the $0.1 million gain
on these hedges was offset by the $0.1 million loss on the exposure associated with the funding of our semi-works facility for the year
ended December 31, 2013. Similarly, for the year ended December 31, 2012, the $0.1 million loss on these hedges was offset by the
$0.1 million gain on the exposure to the CAD.
Net Investment Hedges. During 2012, we entered into a series of non-deliverable forward and foreign currency option contracts
to protect our net investment in our European subsidiaries against adverse changes in exchange rates by fixing the U.S. dollar/Euro
exchange rate. The notional amounts of these contracts ranged from €50.0 million to €100.0 million with all contracts expiring after
thirty days. In June 2013, we entered into a TWD 450.0 million notional amount non-deliverable forward contract to protect our net
investment in our subsidiary in Taiwan against adverse changes in exchange rates by fixing the New Taiwan Dollar/Euro exchange
rate. These contracts qualify for hedge accounting and were designated as net investment hedges in accordance with ASC 815-35 “Net
Investment Hedges.” For the years ended December 31, 2013 and 2012, we recorded in accumulated other comprehensive loss an
aggregate $0.5 million and $2.3 million loss related to the settlement of the effective portion of these contracts, respectively.
Foreign Currency Hedges. Periodically, we enter into foreign currency agreements to hedge or otherwise protect against
fluctuations in foreign currency exchange rates. These agreements typically do not qualify for hedge accounting and gains/losses
resulting from both the up-front premiums and/or settlement of the hedges at expiration of the agreements are recognized in the period
in which they are incurred. During the years ended December 31, 2013 and 2012, we entered into a series of foreign currency option
and forward contracts to reduce our exposure to exchange rate volatility. The contracts were structured such that the underlying
foreign currency exchange gains/losses would be offset by the mark-to-market impact of the hedging instruments and reduce the
impact of foreign currency exchange movements throughout the period. These contracts did not qualify for hedge accounting. For the
years ended December 31, 2013 and 2012, we recorded an aggregate loss of $1.8 million and an aggregate gain of $1.6 million,
respectively. In all periods, the gains or losses on settlement of these hedges offset the underlying foreign currency exchange gains and
losses recorded in cost of goods sold.
F-24
Credit Risk
Our customers are diversified by industry and geography with more than 800 customers in over 60 countries. We analyze the
counterparties’ financial condition prior to extending credit and we establish credit limits and monitor the appropriateness of those
limits on an ongoing basis. We also obtain cash, letters of credit or other acceptable forms of security from customers to provide credit
support, where appropriate, based on our financial analysis of the customer and the contractual terms and conditions applicable to each
transaction.
9. Impairment Charges
During 2012 we determined that we had impaired long-lived assets and, as a result, recorded pre-tax impairment charges
aggregating $5.4 million, for the year ended December 31, 2012 . The $18.1 million carrying value of the long-lived assets was
reduced to fair market value of $12.7 million. We used internally developed assumptions in determining the fair value of these long-
lived assets, which are classified within level 3 of the fair value hierarchy.
10. Income Taxes
Income taxes are recorded utilizing an asset and liability approach. This method gives consideration to the future tax
consequences associated with the differences between the financial accounting and tax basis of the assets and liabilities as well as the
ultimate realization of any deferred tax asset resulting from such differences.
Our income tax provision was a $3.9 million benefit, and a $19.3 million and $0.6 million expense for the years ended
December 31, 2013, 2012 and 2011, respectively. Our effective tax rates for the years ended December 31, 2013, 2012 and 2011 were
79.9%, 619.8% and 0.6%, respectively. Our effective tax rates differed from the U.S. corporate statutory tax rate of 35.0%, primarily
due to the mix of pre-tax income or loss earned in certain jurisdictions and the change in our valuation allowance. Excluding the
change in our valuation allowance, our effective tax rates would have been an 81.4% and 366.1% benefit, and a 19.5% expense for the
years ended December 31, 2013, 2012 and 2011, respectively.
The provision for income taxes is comprised of the following:
2013
Years ended December 31,
2012
(in thousands)
2011
Current tax provision (benefit):
U.S. ........................................................................................................................ $
Foreign...................................................................................................................
Total current tax provision ...........................................................................
(49 ) $
11,708
11,659
(50 ) $
9,408
9,358
228
10,817
11,045
Deferred tax provision (benefit):
U.S. ........................................................................................................................
Foreign...................................................................................................................
Total deferred tax provision (benefit) ..........................................................
Total income tax expense (benefit) ................................................................................. $
(10,065 )
(5,481 )
(15,546 )
(3,887 ) $
9,211
737
9,948
19,306 $
(9,211 )
(1,250 )
(10,461 )
584
Income (loss) before income taxes is comprised of the following:
Income (loss) before income taxes:
U.S. ......................................................................................................................... $
Foreign....................................................................................................................
Total income (loss) before income taxes .......................................................................... $
(39,445 ) $
34,583
(4,862 ) $
(46,930 ) $
50,045
3,115 $
5,860
85,649
91,509
2013
Years ended December 31,
2012
(in thousands)
2011
F-25
The provision for income taxes differs from the amount computed by applying the U.S. corporate statutory income tax rate to
income (loss) before income taxes for the reasons set forth below:
Income taxes at the statutory rate ..................................................................................... $
Foreign tax rate differential ..............................................................................................
State taxes, net of federal benefit .....................................................................................
Permanent differences ......................................................................................................
Deferred adjustments .......................................................................................................
Tax credits ........................................................................................................................
Uncertain tax positions .....................................................................................................
Valuation allowance .........................................................................................................
Other ................................................................................................................................
Income tax expense (benefit) .................................................................................. $
Income taxes at the statutory rate .....................................................................................
Foreign tax rate differential ..............................................................................................
State taxes, net of federal benefit .....................................................................................
Permanent differences ......................................................................................................
Deferred adjustments .......................................................................................................
Tax credits ........................................................................................................................
Uncertain tax positions .....................................................................................................
Valuation allowance .........................................................................................................
Other ................................................................................................................................
Effective tax rate.....................................................................................................
2013
Years ended December 31,
2012
(in thousands)
2011
(1,702 ) $
(4,278 )
(285 )
1,145
0
0
1,020
72
141
(3,887 ) $
1,090 $
(20,931 )
2,010
1,158
2,847
92
2,214
30,709
117
19,306 $
32,028
(13,683 )
84
(1,552 )
0
(140 )
(1,083 )
(17,303 )
2,233
584
Years ended December 31,
2012
2011
2013
35.0 %
88.0
5.9
(23.6 )
0.0
0.0
(21.0 )
(1.5 )
(2.9 )
79.9 %
35.0 %
(671.9 )
64.5
37.2
91.4
3.0
71.1
985.8
3.7
619.8 %
35.0 %
(15.0 )
0.1
(1.7 )
0.0
(0.2 )
(1.2 )
(18.9 )
2.5
0.6 %
Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities
for financial reporting purposes and the amounts used for income tax purposes, as well as net operating loss and tax credit
carryforwards. The tax effects of temporary differences are comprised of the following:
Deferred tax assets:
Net operating loss carryforwards ...................................................................................................... $
Inventory ..........................................................................................................................................
Benefit plans accrual ........................................................................................................................
Other accruals and reserves ..............................................................................................................
Valuation allowance for deferred tax assets .....................................................................................
Total deferred tax assets .......................................................................................................... $
Deferred tax liabilities:
December 31,
2013
2012
(in thousands)
121,644 $
7,308
15,961
17,975
162,888
(89,994 )
72,894 $
105,709
10,556
25,513
14,791
156,569
(90,414 )
66,155
Property, plant and equipment .......................................................................................................... $
Intangible assets................................................................................................................................
Total deferred tax liabilities ....................................................................................................
Net deferred tax liabilities ....................................................................................................... $
(75,467 ) $
(7,046 )
(82,513 )
(9,619 ) $
(74,216 )
(6,777 )
(80,993 )
(14,838 )
F-26
December 31
2013
2012
(in thousands)
Net deferred tax liabilities consist of:
Current deferred tax assets ............................................................................................................... $
Non-current deferred tax assets ........................................................................................................
Current deferred tax liabilities ..........................................................................................................
Non-current deferred tax liabilities ...................................................................................................
Net deferred tax liabilities .......................................................................................................................... $
7,596 $
1,326
(182 )
(18,359 )
(9,619 ) $
7,869
79
(513 )
(22,273 )
(14,838 )
As of December 31, 2013, we had $344.8 million of net operating loss carryforwards, of which $73.3 million relates to foreign
jurisdictions and $271.5 million relates to the United States, which will expire beginning in 2024 through 2033, if not utilized. We
expect to generate sufficient taxable income in future years that will allow utilization of the portion of the net operating loss
carryforwards for which no valuation allowance has been provided.
We record a valuation allowance when it is more likely than not that some portion or all of the deferred tax assets will not be
realized. As of December 31, 2013 and December 31, 2012, a valuation allowance of $90.0 million and $90.4 million, respectively,
has been provided for net operating loss carryforwards and other deferred tax assets. For the year ended December 31, 2013, we have
recorded changes in the valuation allowance for deferred tax assets as a result of our assessed ability to realize the tax benefit of our
net operating loss carryforwards in certain jurisdictions, primarily in the United States. We decreased our valuation allowance by $0.4
million in 2013, which includes a $0.5 million decrease due to changes in other comprehensive income, partially offset by a $0.1
million increase to the income tax provision. The $0.1 million is comprised of $10.2 million of current year operating losses, offset by
a $10.1 million benefit related to the tax effect of unrealized pension gains. We increased our valuation allowance by $36.2 million in
2012, of which $30.7 million was included in the income tax provision and $5.5 million represents changes in equity. The $30.7
million increase in the valuation allowance is comprised of $13.5 million related to the reversal of the benefit recorded for prior year’s
net operating losses and $17.2 million related to current year operating losses. We consider the reversal of deferred tax liabilities
within the net operating loss carryforward period, projected future taxable income and tax planning strategies in making this
assessment.
For the period ending December 31, 2013, the unremitted earnings of our foreign subsidiaries are permanently reinvested in the
corresponding country of origin. Accordingly, we have not provided deferred taxes for the differences between the book basis and
underlying tax basis in those subsidiaries or on the foreign currency translation adjustment amounts related to such operations.
We file income tax returns in the U.S. federal jurisdiction and in various state and foreign jurisdictions. For our U.S. federal
income tax returns, the statute of limitations has expired through the tax year ended December 31, 2003. As a result of net operating
loss carryforwards from 2004, the statute remains open for all years subsequent to 2003. In addition, open tax years for state and
foreign jurisdictions remain subject to examination.
We recognize the tax impact of certain tax positions only when it is more likely than not those such positions are sustainable.
The taxes are recorded in accordance with ASC 740-10, “Accounting for Uncertainty in Income Taxes,” which prescribes the
minimum recognition threshold.
As of January 1, 2013, we had total unrecognized tax benefits of approximately $5.1 million. During the year ended
December 31, 2013, we had an increase of $1.3 million primarily related to uncertain tax positions in Europe. We recorded interest
and penalties related to unrecognized tax benefits within the provision for income taxes. As of December 31, 2013, we had $6.4
million of unrecognized tax benefits related to uncertain foreign tax positions, all of which, if recognized, would impact the effective
tax rate. We believe that no current tax positions that have resulted in unrecognized tax benefits will significantly increase or decrease
within one year.
F-27
The following presents a rollforward of our unrecognized tax benefits and associated interest and penalties.
Balance at December 31, 2011 ........................................................................................ $
Increase in prior year tax positions ........................................................................
Increase in current year tax positions ....................................................................
Balance at December 31, 2012 ........................................................................................ $
Increase in prior year tax positions ........................................................................
Increase in current year tax positions ....................................................................
Balance at December 31, 2013 ........................................................................................ $
2,792 $
125
1,930
4,847 $
365
622
5,834 $
18 $
191
0
209 $
380
0
589 $
2,810
316
1,930
5,056
745
622
6,423
Unrecognized
Tax Benefits
Interest and
Penalties
(in thousands)
Total
11. Commitments and Contingencies
(a) Lease Commitments
We have entered into various long-term non-cancelable operating leases. Future minimum lease commitments at December 31,
2013, are as follows: 2014—$9.7 million; 2015—$8.5 million; 2016—$5.7 million; 2017—$5.1 million; 2018—$4.7 million; and
2019 and thereafter—$10.4 million. For the years ended December 31, 2013, 2012, and 2011, we recorded $11.2 million, $12.8
million, and $9.7 million in rent expense, respectively.
(b) Environmental and Safety Matters
Our finished products are not generally classified as hazardous under U.S. environmental laws. However, our operations involve
the handling, transportation, treatment, and disposal of potentially hazardous materials that are extensively regulated by
environmental, health and safety laws, regulations and permit requirements. Environmental permits required for our operations are
subject to periodic renewal and can be revoked or modified for cause or when new or revised environmental requirements are
implemented. Changing and increasingly strict environmental requirements can affect the manufacturing, handling, processing,
distribution and use of our chemical products and the raw materials used to produce such products and, if so affected, our business and
operations may be materially and adversely affected. In addition, changes in environmental requirements can cause us to incur
substantial costs in upgrading or redesigning our facilities and processes, including waste treatment, disposal, and other waste
handling practices and equipment.
We conduct environmental management programs designed to maintain compliance with applicable environmental requirements
at all of our facilities. We routinely conduct inspection and surveillance programs designed to detect and respond to leaks or spills of
regulated hazardous substances and to correct identified regulatory deficiencies. However, a business risk inherent with chemical
operations is the potential for personal injury and property damage claims from employees, contractors and their employees, and
nearby landowners and occupants. While we believe our business operations and facilities generally are operated in compliance, in all
material respects, with all applicable environmental and health and safety requirements, we cannot be sure that past practices or future
operations will not result in material claims or regulatory action, require material environmental expenditures, or result in exposure or
injury claims by employees, contractors and their employees, and the public. Some risk of environmental costs and liabilities are
inherent in our operations and products, as it is with other companies engaged in similar businesses.
Our Paulinia, Brazil and Belpre, Ohio facilities are subject to a number of actual and/or potential environmental liabilities
primarily relating to contamination caused by former operations at those facilities. Some environmental laws could impose on us the
entire costs of cleanup regardless of fault, legality of the original disposal, or ownership of the disposal site. In some cases, the
governmental entity with jurisdiction could seek an assessment for damage to the natural resources caused by contamination from
those sites. Shell Chemicals has agreed, subject to certain limitations, in time and amounts, to indemnify us against most
environmental liabilities related to the acquired facilities that arise from conditions existing prior to the closing.
We had no material operating expenditures for environmental fines, penalties, government imposed remedial or corrective
actions in each of the years ended December 31, 2013, 2012, and 2011.
F-28
(c) Asset Retirement Obligations (“ARO”)
The changes in the aggregate carrying amount of our ARO liability are as follows:
Beginning balance ...................................................................................................................................... $
Additional accruals ....................................................................................................................................
Accretion expense ......................................................................................................................................
Obligations settled .....................................................................................................................................
Revisions in estimated cash flows .............................................................................................................
Foreign currency translation ......................................................................................................................
Ending balance ........................................................................................................................................... $
9,837 $
0
505
(0 )
0
155
10,497 $
8,978
897
576
(1,850 )
1,236
0
9,837
2013
2012
(in thousands)
(d) Legal Proceedings
We received notice from the tax authorities in Brazil assessing R$5.9 million in connection with tax credits that were generated
from the purchase of certain goods. The credits were subsequently applied against taxes owed. The tax authorities assert that the goods
purchased were not eligible to earn a credit. We have appealed this assessment and contend that the tax credits were earned. While the
outcome of this proceeding cannot be predicted with certainty, we do not expect this matter to have a material adverse effect upon our
financial position, results of operations or cash flows.
We and certain of our subsidiaries, from time to time, are parties to various other legal proceedings, claims and disputes that
have arisen in the ordinary course of business. These claims may involve significant amounts, some of which would not be covered by
insurance. While the outcome of these proceedings cannot be predicted with certainty, our management does not expect any of these
other existing matters, individually or in the aggregate, to have a material adverse effect upon our financial position, results of
operations or cash flows. Furthermore, Shell Chemicals has agreed, subject to certain limitations, to indemnify us for certain claims
brought with respect to matters occurring before February 28, 2001. As of the date of this Form 10-K, we have not been named as
parties in any of these claims. Our right to indemnification from Shell Chemicals is subject to certain time limitations. A substantial
settlement payment or judgment in excess of our accruals could have a material adverse effect on our financial position, results of
operations or cash flows.
12. Employee Benefits
(a) U.S. Retirement Benefit Plan. We have a U.S. noncontributory defined benefit pension plan (“Pension Plan”) which covers
all salaried and hourly wage employees in the United States, who were employed by us on or before December 31, 2005. Employees
who began their employment with us after December 31, 2005 are not covered by our Pension Plan. The benefits under the Pension
Plan are based primarily on years of service and employees’ pay near retirement. For our employees who were employed as of
March 1, 2001 and who: (1) were previously employed by Shell Chemicals; and (2) elected to transfer their pension assets to us, we
consider the total combined Shell Chemicals and Kraton service when calculating the employee’s pension benefit. For those
employees who: (1) elected to retire from Shell Chemicals; or (2) elected not to transfer their pension benefit, only Kraton service
(since March 1, 2001) is considered when calculating benefits.
The 2013 measurement date of the Pension Plan’s assets and obligations was December 31, 2013. Based on the funded status of
our defined benefit pension plan as of December 31, 2013 and 2012, we reported a decrease in our accumulated other comprehensive
loss of approximately $22.4 million and an increase of $10.3 million, respectively, and a related change in accrued pension
obligations.
F-29
Information concerning the pension obligation, plan assets, amounts recognized in our financial statements and underlying
actuarial and other assumptions are as follows:
Change in benefit obligation:
Benefit obligation at beginning of year .............................................................................................
Service cost ........................................................................................................................................
Interest cost ........................................................................................................................................
Benefits paid ......................................................................................................................................
Actuarial (gain) / loss ........................................................................................................................
Benefit obligation at end of year .......................................................................................................
Change in plan assets:
Fair value at beginning of year ..........................................................................................................
Actual return on plan assets ...............................................................................................................
Employer contributions .....................................................................................................................
Benefits paid ......................................................................................................................................
Fair value at end of year ....................................................................................................................
Funded status at end of year ..............................................................................................................
December 31,
2013
2012
(in thousands)
133,727 $
3,332
5,506
(3,641 )
(16,702 )
122,222 $
81,364 $
8,776
6,210
(3,641 )
92,709 $
(29,513 ) $
111,948
3,130
5,510
(3,184 )
16,323
133,727
67,177
9,346
8,025
(3,184 )
81,364
(52,363 )
$
$
$
$
$
Amounts recognized on balance sheet:
Noncurrent liabilities .........................................................................................................................
$
(29,513 ) $
(52,363 )
Amounts recognized in accumulated other comprehensive loss:
Prior service cost ...............................................................................................................................
Net actuarial loss ...............................................................................................................................
Amounts recognized in accumulated other comprehensive loss .................................................................
$
$
0 $
24,021
24,021 $
0
46,467
46,467
The accumulated benefit obligation for the Pension Plan was $112.7 million and $119.9 million at December 31, 2013, and
2012, respectively.
Estimated Future Benefit Payments.
The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid:
2014 .................................................................................................................................................................................... $
2015 ....................................................................................................................................................................................
2016 ....................................................................................................................................................................................
2017 ....................................................................................................................................................................................
2018 ....................................................................................................................................................................................
Years 2019-2023 .................................................................................................................................................................
$
(in thousands)
3,997
4,323
4,652
5,072
5,452
34,369
57,865
Net periodic pension costs consist of the following components:
Service cost benefits earned during the period ................................................................ $
Interest on prior year’s projected benefit obligation .......................................................
Expected return on plan assets ........................................................................................
Amortization of net actuarial loss ...................................................................................
Net periodic pension costs ..................................................................................... $
3,332 $
5,506
(6,608 )
3,576
5,806 $
3,130 $
5,510
(5,936 )
2,617
5,321 $
2,605
5,135
(5,239 )
916
3,417
2013
Years ended December 31,
2012
(in thousands)
2011
F-30
Discount rates are determined annually and are based on rates of return of high-quality long-term fixed income securities
currently available and expected to be available during the maturity of the pension benefits.
Weighted average assumptions used to determine benefit obligations:
December 31,
2013
2012
Measure date .................................................................................................................................. 12/31/2013 12/31/2012
Discount rate ..................................................................................................................................
Rates of increase in salary compensation level .............................................................................
5.02 %
3.00 %
4.21 %
3.00 %
Weighted average assumptions used to determine net periodic benefit cost:
Discount rate ..................................................................................................................................
Rates of increase in salary compensation level .............................................................................
Expected long-term rate of return on plan assets ...........................................................................
4.21 %
3.00 %
8.50 %
4.83 %
3.00 %
8.50 %
Our management relied in part on actuarial studies in establishing the expected long-term rate of return on assets
assumption. The study includes a review of anticipated future long-term performance of individual asset classes and consideration of
the appropriate asset allocation strategy given the anticipated requirements of the Pension Plan to determine the average rate of
earnings expected on the funds invested to provide for the Pension Plan benefits. While the study gives appropriate consideration to
recent fund performance and historical returns, the assumption is primarily a long-term, prospective rate. Based on our most recent
study, the expected long-term return assumption for our Pension Plan effective for 2014 will remain at 8.5%.
Pension Plan Assets. We maintain target allocation percentages among various asset classes based on an investment policy
established for the pension plan. The target allocation is designed to achieve long term objectives of return, while mitigating downside
risk and considering expected cash flows. The plan’s strategic target allocation as of December 31, 2013 was 50% equity, 30% debt
and 20% consisting of real estate funds, hedge funds and commodity funds. The latter was assumed to behave similar to debt
securities and therefore we included this 20% asset allocation as bonds in the model. Our investment policy is reviewed from time to
time to ensure consistency with our long term objective.
Our Pension Plan asset allocations at December 31, 2013 and 2012 by asset category are as follows:
Percentage of Plan
Assets
at December 31,
2013
2012
Equity securities .........................................................................................................................................
Debt securities ............................................................................................................................................
Real estate ..................................................................................................................................................
Other ..........................................................................................................................................................
Total .................................................................................................................................................
57.6 %
33.8 %
4.0 %
4.6 %
100.0 %
55.3 %
36.5 %
4.1 %
4.1 %
100.0 %
No pension assets were invested in debt or equity securities of Kraton at December 31, 2013 and 2012.
The inputs and methodology used for valuing securities are not an indication of the risk associated with investing in those
securities. The following is a description of the primary valuation methodologies used for assets measured at fair value:
• Common/Collective Trust Funds: Valued at the net asset value per unit held at year end as quoted by the funds.
• Mutual Funds, Real Estate and Other: Valued at the net asset value of shares held at year end as quoted in the active
market.
F-31
A summary of total investments for our pension plan assets measured at fair value is presented below. See Note 8 Fair Value
Measurements, Financial Instruments and Credit Risk to the consolidated financial statements for a detailed description of fair value
measurements and the hierarchy established for Level 1, 2 and 3 valuation inputs.
Pension Plan Assets
Fair Value Measurements at
December 31, 2013
Quoted Prices
In Active Markets
Identical Assets
(Level 1)
Significant
Observable
Inputs
(Level 2)
Significant
Unobservable
Inputs
(Level 3)
Total
Cash and Cash Equivalents ................................................................... $
Common/Collective Trust Funds(a):
472 $
(in thousands)
472 $
0 $
Equity Funds ................................................................................
Debt Funds ..................................................................................
30,547
19,094
0
0
30,547
19,094
Mutual Funds:
Equity Funds ................................................................................
Debt Funds ..................................................................................
Real Estate ............................................................................................
Other .....................................................................................................
Total ................................................................................... $
22,899
12,262
3,668
3,767
92,709 $
22,899
12,262
3,668
3,767
43,068 $
0
0
0
0
49,641 $
0
0
0
0
0
0
0
0
Pension Plan Assets
Fair Value Measurements at
December 31, 2012
Quoted Prices
In Active Markets
Identical Assets
(Level 1)
Significant
Observable
Inputs
(Level 2)
Significant
Unobservable
Inputs
(Level 3)
Total
Cash and Cash Equivalents ................................................................... $
Common/Collective Trust Funds(a):
64 $
(in thousands)
64 $
0 $
Equity Funds ................................................................................
Debt Funds ..................................................................................
24,864
16,788
0
0
24,864
16,788
Mutual Funds:
Equity Funds ................................................................................
Debt Funds ..................................................................................
Real Estate ............................................................................................
Other .....................................................................................................
Total ................................................................................... $
20,082
12,876
3,364
3,326
81,364 $
20,082
12,876
3,364
3,326
39,712 $
0
0
0
0
41,652 $
0
0
0
0
0
0
0
0
(a) Strategies are generally to invest in equity or debt securities, or a combination thereof, that match or outperform certain
predefined indices.
(b) Other Retirement Benefit Plans. Certain employees are eligible to participate in a non-qualified defined benefit restoration
plan (“BRP”) which are intended to restore certain benefits under the Pension Plan in the United States and the Kraton Savings Plan in
the United States, which would otherwise be lost due to certain limitations imposed by law on tax-qualified plans. We did not make
any contributions for the years ended December 31, 2013 and 2011, respectively, and we made $1.6 million in contributions to the
BRP for the year ended December 31, 2012. As of December 31, 2013 and 2012, amounts recognized as a component of other long-
term liabilities for the benefit restoration plans were $1.3 million and $1.9 million, respectively.
(c) Postretirement Benefits Other Than Pensions. Health and welfare benefits are provided to benefit eligible employees in the
United States who retire from Kraton and were employed by us prior to January 1, 2006. Retirees under the age of 65 are eligible for
the same medical, dental, and vision plans as active employees, but with an annual cap on premiums that vary based on years of
service and ranges from $7,000 to $10,000 per employee. Our subsidy schedule for medical plans is based on accredited service at
retirement. Retirees are responsible for the full cost of premiums for postretirement dental and vision coverage. In general, the plans
stipulate that health and welfare benefits are paid as covered expenses as incurred. We accrue the cost of these benefits during the
period in which the employee renders the necessary service.
F-32
Employees who were retirement eligible as of February 28, 2001, have the option to participate in either Shell Chemicals or
Kraton postretirement health and welfare plans.
ASC 715, “Compensation-Retirement Benefits,” requires that we measure the plans’ assets and obligations that determine our
funded status at the end of each fiscal year and the 2013 measurement date of the plans’ assets and obligations was December 31,
2013. We are also required to recognize as a component of accumulated other comprehensive loss the changes in funded status that
occurred during the year that are not recognized as part of new periodic benefit cost.
Based on the funded status of our postretirement benefit plan as of December 31, 2013 and 2012, we reported a decrease in our
accumulated other comprehensive loss of approximately $3.9 million and an increase of $1.4 million, respectively, and a related
change in accrued pension obligations.
Information concerning the plan obligation, the funded status and amounts recognized in our financial statements and
underlying actuarial and other assumptions are as follows:
December 31,
2013
2012
(in thousands)
Change in benefit obligation:
Benefit obligation at beginning of period ......................................................................................... $
Service cost .......................................................................................................................................
Interest cost .......................................................................................................................................
Benefits and expenses paid (premiums) ...........................................................................................
Actuarial (gain) loss .........................................................................................................................
Benefit obligation at end of period ................................................................................................... $
29,437 $
557
1,155
(1,052 )
(3,204 )
26,893 $
26,684
493
1,206
(955 )
2,009
29,437
Reconciliation of plan assets(1):
Employer contributions .................................................................................................................... $
Benefits paid .....................................................................................................................................
$
Funded status at end of year ............................................................................................................. $
1,052 $
(1,052 )
0 $
(26,893 ) $
955
(955 )
0
(29,437 )
(1) Shell Chemicals has committed to a future cash payment related to retiree medical expenses based on a specified dollar amount
per employee, if certain contractual commitments are met. We have recorded an asset of approximately $9.0 million and $9.2
million as our estimate of the present value of this commitment as of December 31, 2013 and 2012, respectively.
Amounts recognized in the balance sheet:
Current liabilities ....................................................................................................................................... $
Noncurrent liabilities..................................................................................................................................
$
Amounts recognized in accumulated other comprehensive loss:
Prior service cost ........................................................................................................................................ $
Net actuarial loss ........................................................................................................................................
$
December 31,
2013
2012
(in thousands)
(1,173 ) $
(25,720 )
(26,893 ) $
(1,076 )
(28,361 )
(29,437 )
0 $
7,554
7,554 $
0
11,466
11,466
F-33
Net periodic benefit costs consist of the following components:
2013
Years ended December 31,
2012
(in thousands)
2011
Service cost ..................................................................................................................... $
Interest cost .....................................................................................................................
Amortization of net actuarial loss ...................................................................................
Net periodic benefit costs ................................................................................................ $
557 $
1,155
708
2,420 $
493 $
1,206
566
2,265 $
414
1,246
412
2,072
Weighted average assumptions used to determine benefit obligations:
December 31,
2013
2012
Measurement date ........................................................................................................................... 12/31/2013 12/31/2012
Discount rate ...................................................................................................................................
Rates of increase in salary compensation level ..............................................................................
4.86 %
N/A
4.02 %
N/A
Weighted average assumptions used to determine net periodic benefit cost:
Discount rate ...................................................................................................................................
Rates of increase in salary compensation level ..............................................................................
Expected long-term rate of return on plan assets ............................................................................
4.02 %
N/A
N/A
4.65 %
N/A
N/A
December 31,
2013
2012
Assumed health care cost trend rates:
Health care cost trend rate assumed for next year ..........................................................................
Rate to which the cost trend rate is assumed to decline (the ultimate trend rate) ...........................
Year that the rate reaches the ultimate trend rate ............................................................................
7.50 %
5.00 %
2020
8.00 %
5.00 %
2020
Discount rates are determined annually and are based on rates of return of high-quality long-term fixed income securities
currently available and expected to be available during the maturity of the postretirement benefit plan.
Assumed health care cost trend rates have a significant effect on the amounts reported for the health care plans. A 1% change in
assumed health care cost trend rates would have the following effect (in thousands):
Effect on total of service and interest cost components ............................................................................. $
Effect on postretirement benefit obligation ................................................................................................
1% Increase 1% Decrease
(65 )
46 $
(998 )
766
(d) Kraton Savings Plan. The Kraton Savings Plan, as adopted on March 1, 2001, covers substantially all U.S. employees,
including executive officers. Through automatic payroll deduction, participants have the option to defer up to 60% of eligible earnings
in any combination of pretax and/or post-tax contributions, subject to annual dollar limitations set forth in the Internal Revenue Code.
Under this plan, we have two types of employer contributions:
(1) For our standard contributions, we make matching contributions of 50% of the first 6% contributed by the employee
after completing one year of service, and we make matching contributions of 100% of the first 6% contributed by the employee
after completing five years of service.
(2) For our enhanced contributions, we make employer contributions of 3% for employees who have less than five years
of service and a 4% contribution for employees who have five or more years of service.
For our employees who were employed as of February 28, 2001, and who were previously employed by Shell Chemicals, we
recognize their Shell Chemicals years of service for purposes of determining employer contributions under our Plan. Our contributions
to the plan for the years ended December 31, 2013, 2012, and 2011, were $3.7 million, $3.4 million, and $3.2 million, respectively.
F-34
13. Industry Segment and Foreign Operations
We operate in one segment for the manufacturing and marketing of engineered polymers. In accordance with the provisions of
ASC 280, “Segment Reporting,” our chief operating decision-maker has been identified as the President and Chief Executive Officer,
who regularly reviews operating results to make decisions about allocating resources and assessing performance for the entire
company. Since we operate in one segment and in one group of similar products, all financial segment and product line information
required by ASC 280 can be found in the consolidated financial statements.
We manufacture our products along the following primary product lines based upon polymer chemistry and process
technologies:
•
•
un-hydrogenated SBCs (“USBCs”);
hydrogenated SBCs (“HSBCs”);
• Cariflex™ isoprene rubber and isoprene rubber latex; and
•
compounds.
Sales revenue for our four primary product lines is as follows:
2013
Years ended December 31,
2012
(in thousands)
2011
USBCs .............................................................................................................................. $
HSBCs ..............................................................................................................................
Cariflex .............................................................................................................................
Compounds .......................................................................................................................
Other .................................................................................................................................
753,087 $
392,131
116,003
29,730
1,170
852,070
454,835
99,412
26,578
4,584
$ 1,292,121 $ 1,423,122 $ 1,437,479
841,437 $
443,869
105,898
29,716
2,202
During the years ended December 31, 2013, 2012, and 2011, no single customer accounted for 10.0% or more of our total sales
revenue.
For geographic reporting, sales revenue is attributed to the geographic location in which the customers’ facilities are located.
Long-lived assets consist primarily of property, plant, and equipment, which are attributed to the geographic location in which they are
located and presented at historical cost.
F-35
Sales revenue and long-lived assets by geographic region are as follows:
Sales revenue:
2013
Years ended December 31,
2012
(in thousands)
2011
United States ........................................................................................................... $
Germany .................................................................................................................
Japan .......................................................................................................................
China ......................................................................................................................
Brazil ......................................................................................................................
France .....................................................................................................................
Italy .........................................................................................................................
Thailand ..................................................................................................................
Belgium ..................................................................................................................
United Kingdom .....................................................................................................
Netherlands .............................................................................................................
Malaysia .................................................................................................................
Turkey ....................................................................................................................
Mexico ....................................................................................................................
Sweden ...................................................................................................................
Taiwan ....................................................................................................................
Canada ....................................................................................................................
Argentina ................................................................................................................
Poland .....................................................................................................................
South Korea ............................................................................................................
Austria ....................................................................................................................
Australia .................................................................................................................
All other countries ..................................................................................................
399,547 $
172,625
81,056
72,103
55,549
47,443
43,321
42,402
39,825
36,736
29,146
26,353
23,403
17,710
17,269
17,182
16,187
15,672
13,751
12,923
12,863
10,248
88,807
490,373
212,079
91,788
61,039
50,777
46,233
49,484
32,209
43,339
40,644
36,991
16,592
25,004
11,437
15,830
17,378
22,703
13,502
19,084
13,742
21,498
13,146
92,607
$ 1,292,121 $ 1,423,122 $ 1,437,479
466,496 $
191,636
89,131
76,283
49,735
48,352
44,490
40,959
45,599
37,993
32,110
19,208
29,777
13,188
17,467
19,914
18,856
14,833
21,945
15,489
16,811
17,396
95,454
December 31,
2013
2012
(in thousands)
Long-lived assets, at cost:
United States ..................................................................................................................................... $
France ...............................................................................................................................................
Brazil ................................................................................................................................................
Germany ...........................................................................................................................................
Netherlands .......................................................................................................................................
Taiwan ..............................................................................................................................................
China ................................................................................................................................................
Japan .................................................................................................................................................
All other countries ............................................................................................................................
$
453,157 $
123,804
76,524
64,258
27,865
12,935
7,226
1,696
220
767,685 $
411,969
118,275
79,585
55,581
15,255
0
5,906
1,978
4,435
692,984
F-36
14. Related Party Transactions
We own a 50% equity investment in a SBC manufacturing joint venture with JSR Corporation (“JSR”) under the name of
Kraton JSR Elastomers K.K. (“KJE”) located in Kashima, Japan. We and JSR separately, but with equal rights, participate in
distributions in the sales of the thermoplastic rubber produced by KJE.
The aggregate amounts of related-party transactions were as follows:
Purchases from related party ........................................................................................... $
50,728 $
48,370 $
34,610
Our due to related party is solely related to our commercial arrangement with KJE, which requires payment by each party within
Years ended December 31,
2012
2011
2013
150 days of invoice.
15. Variable Interest Entity
In February 2013, we executed definitive agreements providing for a 50/50 joint venture with FPCC to build, own and operate a
30 kiloton HSBC plant at FPCC’s petrochemical site in Mailiao, Taiwan. The joint venture company, Kraton Formosa Polymers
Corporation (“KFPC”), is a Taiwan entity with each of Kraton and FPCC having equal representation on the board. Both Kraton and
FPCC made an initial investment of approximately $15.2 million at inception, with additional Kraton contributions of $15.0 million
and $11.4 million in August and October 2013, respectively. As a result, the total investment by each of us and FPCC amounted to
$41.6 million as of December 31, 2013. We have exclusive rights to purchase all production from KFPC. Additionally, we will be
obligated to purchase a minimum volume each year, with the minimum obligation increasing over the first three years the plant is
operational. As such, we have determined that we are the primary beneficiary of this variable interest entity and, therefore, have
consolidated KFPC in our 2013 financial statements and have reflected FPCC’s ownership as a noncontrolling interest.
The following table summarizes the fair value of KFPC assets and liabilities as of February 27, 2013 recorded upon initial
consolidation in our consolidated balance sheet and the carrying amounts of such assets and liabilities as of December 31, 2013,
before intercompany eliminations.
December 31,
2013
February 27,
2013
(In thousands)
Cash and cash equivalents ......................................................................................................................... $
Other current assets ...................................................................................................................................
Property, plant and equipment ..................................................................................................................
Intangible assets ........................................................................................................................................
Other long-term assets ..............................................................................................................................
Total assets ...................................................................................................................................... $
Current liabilities ......................................................................................................................................
Total liabilities ................................................................................................................................. $
66,816 $
256
12,912
10,094
462
90,540 $
8,724
8,724 $
30,348
0
0
0
0
30,348
0
0
16. Supplemental Guarantor Information
Kraton Polymers LLC and Kraton Polymers Capital Corporation, a financing subsidiary, collectively, the Issuers, are co-issuers
of the 6.75% senior notes due March 1, 2019. Kraton Performance Polymers, Inc. and Elastomers Holdings LLC, a U.S. holding
company and wholly-owned subsidiary of Kraton Polymers LLC, collectively, the Guarantors, fully and unconditionally guarantee on
a joint and several basis, the Issuers’ obligations under the 6.75% senior notes. Our remaining subsidiaries are not guarantors of the
6.75% senior notes. We do not believe that separate financial statements and other disclosures concerning the Guarantor Subsidiaries
would provide any additional information that would be material to investors in making an investment decision.
F-37
KRATON PERFORMANCE POLYMERS, INC.
CONSOLIDATING BALANCE SHEET
December 31, 2013
(In thousands, except par value)
Kraton
Kraton
Polymers
LLC(1)
Guarantor
Subsidiaries
Non-
Guarantor
Subsidiaries Eliminations Consolidated
ASSETS
Current assets:
Cash and cash equivalents ...................................................... $
Receivables, net of allowances of $315 ..................................
Inventories of products ...........................................................
Inventories of materials and supplies .....................................
Deferred income taxes ............................................................
Other current assets ................................................................
Total current assets .....................................................
Property, plant and equipment, less accumulated depreciation of
$353,428 ......................................................................................
Intangible assets, less accumulated amortization of $78,784 .............
Investment in consolidated subsidiaries .............................................
Investment in unconsolidated joint venture ........................................
Debt issuance costs ............................................................................
Deferred income taxes .......................................................................
Other long-term assets .......................................................................
Total assets ................................................................. $
LIABILITIES AND STOCKHOLDERS’ AND MEMBER’S
EQUITY
Current liabilities:
Accounts payable-trade ..........................................................
Other payables and accruals ...................................................
Due to related party ................................................................
Deferred income taxes ............................................................
Total current liabilities ...............................................
Long-term debt, net of current portion ...............................................
Deferred income taxes .......................................................................
Other long-term liabilities ..................................................................
Total liabilities ...........................................................
Commitments and contingencies (note 11)
Stockholders’ and member’s equity:
Preferred stock, $.01 par value; 100,000 shares authorized;
0 $
0
0
0
0
0
0
0 $
80
0
0
0
2,071
2,151
11,792 $
45,971
176,823
8,898
3,952
1,541
248,977
164,080 $
83,305
151,949
2,049
3,644
17,053
422,080
0 $
0
0
0
0
0
0
175,872
129,356
328,772
10,947
7,596
20,665
673,208
0
0
47,157
34,208
534,742 1,325,811
813
6,000
536
612
241,650
23,280
0
0
1,874
0
563,305
534,742 $ 1,417,288 $ 1,079,086 $
0
0
0
0
414,257
0
125,450
57,488
0
0
0
(1,860,553 )
0
14,074
0
13,261
9,213
0
1,339
1,326
0
790
108,393
25,231
(647,079 )
671,313 $ (2,507,632 ) $ 1,194,797
0
0
0
0
0
0
0
0
0
104
7,875
0
0
7,979
350,989
10,553
513,560
883,081
48,259
25,970
0
0
74,229
0
3,953
64,394
142,576
67,373
20,694
24,603
182
112,852
0
3,853
145,116
261,821
0
0
0
0
0
0
0
(647,079 )
(647,079 )
115,736
54,539
24,603
182
195,060
350,989
18,359
75,991
640,399
none issued .......................................................................
0
0
0
0
0
0
Common stock, $.01 par value; 500,000 shares authorized;
32,547 shares issued and outstanding ...............................
Additional paid in capital .......................................................
Member’s equity ....................................................................
Retained earnings ...................................................................
Accumulated other comprehensive income (loss) ..................
Kraton stockholders’ and member’s equity ................
Noncontrolling interest ...............................................
Total stockholders’ and member’s equity ...................
Total liabilities and stockholders’ and member’s equity ........ $
0
0
325
0
0
363,590
972,485
534,742
0
0
0
170,827
(35,975 )
(535 )
0
936,510
534,207
534,742
0
0
0
534,742
936,510
534,207
534,742 $ 1,417,288 $ 1,079,086 $
325
0
0
363,590
0
0
0
(1,860,553 )
353,326
170,827
0
0
(21,252 )
0
15,258
513,490
(1,860,553 )
368,584
40,908
0
40,908
409,492
554,398
(1,860,553 )
671,313 $ (2,507,632 ) $ 1,194,797
(1) Kraton Polymers LLC and Kraton Polymers Capital Corporation, a financing subsidiary, collectively, the Issuers, are co-issuers
of the 6.75% senior notes due March 1, 2019. Kraton Polymers Capital Corporation has minimal assets and income. We do not
believe that separate financial information concerning the Issuers would provide additional information that would be material
to investors in making an investment decision.
F-38
KRATON PERFORMANCE POLYMERS, INC.
CONSOLIDATING BALANCE SHEET
December 31, 2012
(In thousands, except par value)
Kraton
Kraton
Polymers
LLC(1)
Guarantor
Subsidiaries
Non-
Guarantor
Subsidiaries Eliminations Consolidated
ASSETS
Current assets:
Cash and cash equivalents ...................................................... $
Receivables, net of allowances of $401 ..................................
Inventories of products ...........................................................
Inventories of materials and supplies .....................................
Deferred income taxes ............................................................
Other current assets ................................................................
Total current assets .....................................................
Property, plant and equipment, less accumulated depreciation of
$311,779 ......................................................................................
Intangible assets, less accumulated amortization of $68,531 .............
Investment in consolidated subsidiaries .............................................
Investment in unconsolidated joint venture ........................................
Debt issuance costs ............................................................................
Deferred income taxes .......................................................................
Other long-term assets .......................................................................
Total assets ................................................................. $
LIABILITIES AND STOCKHOLDERS’ AND MEMBER’S
EQUITY
Current liabilities:
Current portion of long-term debt ..........................................
Accounts payable-trade ..........................................................
Other payables and accruals ...................................................
Due to related party ................................................................
Deferred income taxes ............................................................
Total current liabilities ...............................................
Long-term debt, net of current portion ...............................................
Deferred income taxes .......................................................................
Other long-term liabilities ..................................................................
Total liabilities ...........................................................
Commitments and contingencies (note 12)
Stockholders’ and member’s equity:
Preferred stock, $.01 par value; 100,000 shares authorized;
0 $
0
0
0
0
0
0
0 $
426
0
0
0
3,787
4,213
80,903 $
44,728
180,776
8,013
5,768
691
320,879
142,263 $
79,481
159,547
2,318
2,101
23,885
409,595
0 $
0
0
0
0
0
0
223,166
124,635
340,323
10,331
7,869
28,363
734,687
0
0
222,956
56,626
22,337
41,056
0
526,725 1,258,814
0
813
0
10,846
0
0
480,756
1,500
526,725 $ 1,373,868 $ 1,046,928 $
0
0
0
0
381,205
0
101,623
63,393
0
0
0
(1,785,539 )
0
13,582
0
12,769
10,846
0
0
79
0
79
193,141
25,397
(650,000 )
717,207 $ (2,435,539 ) $ 1,229,189
0
0
0
0
0
0
0
0
0
0
15,074
2,072
8,995
0
0
26,141
432,943
12,206
377,032
848,322
0
44,304
21,744
0
0
66,048
0
5,768
89,825
161,641
0
52,791
20,239
16,080
513
89,623
0
4,299
283,089
377,011
0
0
0
0
0
0
0
0
(650,000 )
(650,000 )
15,074
99,167
50,978
16,080
513
181,812
432,943
22,273
99,946
736,974
none issued .......................................................................
0
0
0
0
0
0
Common stock, $.01 par value; 500,000 shares authorized;
32,277 shares issued and outstanding ...............................
Additional paid in capital .......................................................
Member’s equity ....................................................................
Retained earnings ...................................................................
Accumulated other comprehensive income (loss) ..................
Total stockholders’ and member’s equity ...................
Total liabilities and stockholders’ and member’s equity ........ $
0
0
323
0
0
354,957
938,374
526,725
0
0
0
171,445
(53,087 )
(1,179 )
0
885,287
525,546
526,725
526,725 $ 1,373,868 $ 1,046,928 $
323
0
0
354,957
0
0
0
(1,785,539 )
320,440
171,445
0
0
(34,510 )
0
19,756
492,215
(1,785,539 )
340,196
717,207 $ (2,435,539 ) $ 1,229,189
(1) Kraton Polymers LLC and Kraton Polymers Capital Corporation, a financing subsidiary, collectively, the Issuers, are co-issuers
of the 6.75% senior notes due March 1, 2019. Kraton Polymers Capital Corporation has minimal assets and income. We do not
believe that separate financial information concerning the Issuers would provide additional information that would be material
to investors in making an investment decision.
F-39
KRATON PERFORMANCE POLYMERS, INC.
CONSOLIDATING STATEMENT OF OPERATIONS
Year Ended December 31, 2013
(In thousands)
Sales revenue .................................................... $
Cost of goods sold .............................................
Gross profit (loss) .............................................
Operating expenses ...........................................
Research and development ......................
Selling, general and administrative .........
Depreciation and amortization ................
Total operating expenses................
Earnings in consolidated subsidiaries ...............
Earnings of unconsolidated joint venture ..........
Interest expense (income), net ..........................
Income (loss) before income taxes ....................
Income tax expense (benefit) ............................
Consolidated net income (loss) .........................
Net loss attributable to noncontrolling
0 $
0
0
0
0
0
0
(975 )
0
0
(975 )
0
(975 )
Kraton
Kraton
Polymers
LLC(1)
Guarantor
Subsidiaries
Non-
Guarantor
Subsidiaries Eliminations Consolidated
0 $ 635,456 $ 812,412 $ (155,747 ) $ 1,292,121
(155,747 ) 1,066,289
225,832
708,828
103,584
511,220
124,236
0
1,988
(1,988 )
0
154
16,317
16,471
58,772
0
43,477
(3,164 )
(2,189 )
(975 )
17,372
73,202
32,049
122,623
0
0
(14,490 )
16,103
(10,114)
26,217
14,642
32,202
14,816
61,660
0
530
1,483
40,971
8,416
32,555
0
0
0
0
(57,797 )
0
0
(57,797 )
0
(57,797 )
32,014
105,558
63,182
200,754
0
530
30,470
(4,862 )
(3,887 )
(975 )
interest ..........................................................
Net income (loss) attributable to Kraton ........... $
0
(975 ) $
0
(975 ) $
0
26,217 $
(357 )
32,912 $
0
(57,797 ) $
(357 )
(618 )
(1) Kraton Polymers LLC and Kraton Polymers Capital Corporation, a financing subsidiary, collectively, the Issuers, are co-issuers
of the 6.75% senior notes due March 1, 2019. Kraton Polymers Capital Corporation has minimal assets and income. We do not
believe that separate financial information concerning the Issuers would provide additional information that would be material
to investors in making an investment decision.
F-40
KRATON PERFORMANCE POLYMERS, INC.
CONSOLIDATING STATEMENT OF OPERATIONS
Year Ended December 31, 2012
(In thousands)
Sales revenue .................................................... $
Cost of goods sold .............................................
Gross profit .......................................................
Operating expenses ...........................................
Research and development ......................
Selling, general and administrative .........
Depreciation and amortization ................
Impairment of long-lived assets ..............
Total operating expenses................
Earnings (loss) in consolidated subsidiaries .....
Earnings of unconsolidated joint venture ..........
Interest expense (income), net ..........................
Income (loss) before income taxes ....................
Income tax expense (benefit) ............................
Net income (loss) .............................................. $
Kraton
Kraton
Polymers
LLC(1)
Guarantor
Subsidiaries
Non-
Guarantor
Subsidiaries Eliminations Consolidated
0 $ 708,666 $ 870,810 $ (156,354 ) $ 1,423,122
(156,354 ) 1,191,680
231,442
753,652
117,158
596,078
112,588
0
(1,696 )
1,696
0 $
0
0
0
0
0
0
0
(16,191 )
0
0
(16,191 )
0
(16,191 ) $
0
54
16,317
0
16,371
33,451
0
38,405
(19,629 )
(3,438 )
(16,191 ) $
19,024
68,320
34,860
5,434
127,638
0
0
(15,111 )
61
10,289
(10,228 ) $
11,987
30,181
13,377
0
55,545
0
530
6,009
56,134
12,455
43,679 $
0
0
0
0
0
(17,260 )
0
0
(17,260 )
0
(17,260 ) $
31,011
98,555
64,554
5,434
199,554
0
530
29,303
3,115
19,306
(16,191 )
(1) Kraton Polymers LLC and Kraton Polymers Capital Corporation, a financing subsidiary, collectively, the Issuers, are co-issuers
of the 6.75% senior notes due March 1, 2019. Kraton Polymers Capital Corporation has minimal assets and income. We do not
believe that separate financial information concerning the Issuers would provide additional information that would be material
to investors in making an investment decision.
F-41
KRATON PERFORMANCE POLYMERS, INC.
CONSOLIDATING STATEMENT OF OPERATIONS
Year Ended December 31, 2011
(In thousands)
Sales revenue ................................................... $
Cost of goods sold ............................................
Gross profit (loss) ............................................
Operating expenses ..........................................
Research and development .....................
Selling, general and administrative ........
Depreciation and amortization ...............
Total operating expenses...............
Loss on extinguishment of debt .......................
Earnings in consolidated subsidiaries ..............
Earnings of unconsolidated joint venture .........
Interest expense (income), net .........................
Income before income taxes ............................
Income tax expense (benefit) ...........................
Net income ....................................................... $
Kraton
Kraton
Polymers
LLC(1)
Guarantor
Subsidiaries
Non-
Guarantor
Subsidiaries Eliminations Consolidated
0 $ 718,700 $ 862,885 $ (144,106 ) $ 1,437,479
(144,106 ) 1,121,293
316,186
708,933
153,952
554,881
163,819
0
1,585
(1,585 )
0 $
0
0
0
0
0
0
0
90,925
0
0
90,925
0
90,925 $
0
(178 )
16,383
16,205
(2,985 )
148,674
0
38,096
89,803
(1,122 )
90,925 $
17,537
69,954
32,973
120,464
0
0
0
(14,987 )
58,342
(9,954 )
68,296 $
10,459
31,830
13,379
55,668
0
0
529
6,775
92,038
11,660
80,378 $ (239,599 ) $
0
0
0
0
0
(239,599 )
0
0
(239,599 )
0
27,996
101,606
62,735
192,337
(2,985 )
0
529
29,884
91,509
584
90,925
(1) Kraton Polymers LLC and Kraton Polymers Capital Corporation, a financing subsidiary, collectively, the Issuers, are co-issuers
of the 6.75% senior notes due March 1, 2019. Kraton Polymers Capital Corporation has minimal assets and income. We do not
believe that separate financial information concerning the Issuers would provide additional information that would be material
to investors in making an investment decision.
F-42
KRATON PERFORMANCE POLYMERS, INC.
CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME (LOSS)
Year Ended December 31, 2013
(In thousands)
Net income (loss) attributable to Kraton ............. $
Other comprehensive income (loss):
(975 ) $
(975 ) $
26,217 $
Kraton
Kraton
Polymers
LLC (1)
Guarantor
Subsidiaries
Non-
Guarantor
Subsidiaries Eliminations Consolidated
(618)
(57,797 ) $
32,912 $
Foreign currency translation
adjustments, net of tax of $0 .......
Reclassification of loss on interest
rate swap, net of tax of $0 ...........
Unrealized loss on net investment
hedge, net of tax of $0 .................
(Increase) decrease in benefit plans
liability, net of tax of $10,065 .....
Other comprehensive income
(loss), net of tax .................
0
0
0
0
0
(4 )
0
(4,194 )
0
(4,198 )
837
(189 )
0
0
0
(301 )
0
0
837
(490 )
0
17,112
(3 )
0
17,109
644
17,112
(4,498 )
0
13,258
Comprehensive income (loss) attributable to
Kraton .............................................................
(975 )
(331 )
43,329
28,414
(57,797 )
12,640
Comprehensive loss attributable to
noncontrolling interest ..........................
Consolidated comprehensive income (loss) ........ $
0
(975 ) $
0
(331 ) $
0
43,329 $
(722 )
27,692 $
0
(57,797 ) $
(722 )
11,918
(1) Kraton Polymers LLC and Kraton Polymers Capital Corporation, a financing subsidiary, collectively, the Issuers, are co-issuers
of the 6.75% senior notes due March 1, 2019. Kraton Polymers Capital Corporation has minimal assets and income. We do not
believe that separate financial information concerning the Issuers would provide additional information that would be material
to investors in making an investment decision.
F-43
KRATON PERFORMANCE POLYMERS, INC.
CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME (LOSS)
Year Ended December 31, 2012
(In thousands)
Kraton
Kraton
Polymers
LLC (1)
Guarantor
Subsidiaries
Non-
Guarantor
Subsidiaries Eliminations Consolidated
(16,191 )
(17,260 ) $
43,679 $
(10,228 ) $
Net income (loss) attributable to Kraton .............. $ (16,191 ) $
Other comprehensive income (loss):
(16,191 ) $
Foreign currency translation adjustments, net
of tax of $0 .............................................
Unrealized loss on interest rate swaps, net of
tax of $0 .................................................
Unrealized loss on net investment hedge, net
0
0
263
(28 )
of tax of $0 .............................................
0
(2,335 )
0
(2,857 )
0
(2,594 )
0
0
0
0
0
(28 )
0
(2,335 )
(Increase) decrease in benefit plans liability,
net of tax of $0 .......................................
Other comprehensive loss, net of tax ....
0
0
Consolidated comprehensive income (loss) ......... $ (16,191 ) $
0
(2,100 )
(18,291 ) $
(12,088 )
(12,088 )
(22,316 ) $
153
(2,704 )
40,975 $
0
0
(17,260 ) $
(11,935 )
(16,892 )
(33,083 )
(1) Kraton Polymers LLC and Kraton Polymers Capital Corporation, a financing subsidiary, collectively, the Issuers, are co-issuers
of the 6.75% senior notes due March 1, 2019. Kraton Polymers Capital Corporation has minimal assets and income. We do not
believe that separate financial information concerning the Issuers would provide additional information that would be material
to investors in making an investment decision.
F-44
KRATON PERFORMANCE POLYMERS, INC.
CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME
Year Ended December 31, 2011
(In thousands)
Net income attributable to Kraton ..................... $
Other comprehensive income (loss):
Foreign currency translation
90,925 $
90,925 $
Kraton
Kraton
Polymers
LLC (1)
Guarantor
Subsidiaries
Non-
Guarantor
Subsidiaries Eliminations Consolidated
90,925
80,378 $ (239,599 ) $
68,296 $
adjustments, net of tax of $0 ...............
0
(68 )
4,803
(25,586 )
0
(20,851 )
Reclassification of loss on interest rate
swap, net of tax of $0 ..........................
Unrealized loss on interest rate swap, net
of tax of $0..........................................
(Increase) decrease in benefit plans
liability, net of tax of $0 .....................
Other comprehensive income
(loss), net of tax .........................
0
0
0
Consolidated comprehensive income ................ $
90,925 $
1,073
1,073
(809 )
0
0
0
(809 )
0
(18,445 )
519
0
(17,926 )
196
91,121 $
(13,642 )
54,654 $
(25,067 )
55,311 $ (239,599 ) $
0
(38,513 )
52,412
(1) Kraton Polymers LLC and Kraton Polymers Capital Corporation, a financing subsidiary, collectively, the Issuers, are co-issuers
of the 6.75% senior notes due March 1, 2019. Kraton Polymers Capital Corporation has minimal assets and income. We do not
believe that separate financial information concerning the Issuers would provide additional information that would be material
to investors in making an investment decision.
F-45
KRATON PERFORMANCE POLYMERS, INC.
CONSOLIDATING STATEMENT OF CASH FLOWS
Year Ended December 31, 2013
(In thousands)
Cash flows provided by (used in) operating
activities ....................................................... $
0 $
29,662 $
(46,569 ) $ 122,363 $
0 $ 105,456
Kraton
Kraton
Polymers
LLC(1)
Guarantor
Subsidiaries
Non-
Guarantor
Subsidiaries
Eliminations Consolidated
Cash flows provided by (used in) investing
activities:
Proceeds from intercompany loans ..........
Purchase of property, plant and
equipment, net of proceeds from
sales.....................................................
Purchase of software and other
intangibles ...........................................
Settlement of net investment hedge .........
Net cash provided by (used in)
0
68,962
0
0
(68,962 )
0
0
0
0
0
(40,048 )
(41,032 )
0
(81,080 )
0
(2,490 )
(5,125 )
0
0
0
0
0
(5,125 )
(2,490 )
investing activities .....................
0
66,472
(45,173 )
(41,032 )
(68,962 )
(88,695 )
Cash flows provided by (used in) financing
activities:
Proceeds from debt ..................................
Repayments of debt .................................
Capital lease payments ............................
Cash contribution from member ..............
Cash distribution to member ....................
Contribution from noncontrolling
interest .................................................
Proceeds from the exercise of stock
options .................................................
Debt issuance costs ..................................
Proceeds from (payments on)
intercompany loans .............................
Net cash provided by (used in)
financing activities ....................
Effect of exchange rate differences on cash ......
Net increase (decrease) in cash
and cash equivalents ..................
Cash and cash equivalents, beginning of
period ............................................................
Cash and cash equivalents, end of period .......... $
0
0
0
0
(741 )
0
741
0
0
0
0
0
0
0 $
0
(96,875 )
0
741
0
40,000
(40,000 )
(2,950 )
(741 )
741
0
0
0
0
0
0
0
0
0
0
40,000
(136,875 )
(2,950 )
0
0
0
0
0
0
41,630
0
41,630
0
(3,310 )
0
(1,484 )
0
0
741
(4,794 )
0
28,891
(97,853 )
68,962
0
(96,134 )
0
22,631
0
(57,707 )
(1,807 )
68,962
0
(62,248 )
(1,807 )
0
(69,111 )
21,817
0
(47,294 )
0
0 $
80,903
11,792 $ 164,080 $
142,263
223,166
0
0 $ 175,872
(1) Kraton Polymers LLC and Kraton Polymers Capital Corporation, a financing subsidiary, collectively, the Issuers, are co-issuers
of the 6.75% senior notes due March 1, 2019. Kraton Polymers Capital Corporation has minimal assets and income. We do not
believe that separate financial information concerning the Issuers would provide additional information that would be material
to investors in making an investment decision.
F-46
KRATON PERFORMANCE POLYMERS, INC.
CONSOLIDATING STATEMENT OF CASH FLOWS
Year Ended December 31, 2012
(In thousands)
Cash flows provided by (used in) operating
activities ............................................................ $
0 $
(46,544 ) $
99,059 $
93,818 $
0 $ 146,333
Kraton
Kraton
Polymers
LLC(1)
Guarantor
Subsidiaries
Non-
Guarantor
Subsidiaries Eliminations Consolidated
Cash flows used in investing activities:
Repayments of intercompany loans .............
Purchase of property, plant and equipment,
net of proceeds from sales .......................
Purchase of software and other
intangibles ..............................................
Settlement of net investment hedge..............
Net cash used in investing
0
(6,522 )
0
0
6,522
0
0
0
0
0
(51,516 )
(13,490 )
0
(65,006 )
0
(335 )
(4,603 )
0
0
0
0
0
(4,603 )
(335 )
activities .........................................
0
(6,857 )
(56,119 )
(13,490 )
6,522
(69,944 )
Cash flows provided by (used in) financing
activities:
Proceeds from debt .......................................
Repayments of debt ......................................
Cash contribution from member ..................
Cash distribution to member ........................
Proceeds from the exercise of stock options
Debt issuance costs ......................................
Proceeds from (payments on) intercompany
loans ........................................................
Net cash provided by (used in)
financing activities .........................
Effect of exchange rate differences on cash ..........
Net increase in cash and cash
equivalents .....................................
Cash and cash equivalents, beginning of period ....
Cash and cash equivalents, end of period .............. $
0
0
0
(933 )
933
0
101,250
(45,626 )
933
0
0
(3,156 )
0
0
0
0
0
0
0
0
0
0
0
0
0
0
(933 )
933
0
0
101,250
(45,626 )
0
0
933
(3,156 )
0
0
0
0
0
0 $
0
31,933
(25,411 )
(6,522 )
0
53,401
0
31,933
0
(25,411 )
4,797
(6,522 )
0
53,401
4,797
0
0
0 $
74,873
6,030
80,903 $ 142,263 $
59,714
82,549
134,587
0
0
88,579
0 $ 223,166
(1) Kraton Polymers LLC and Kraton Polymers Capital Corporation, a financing subsidiary, collectively, the Issuers, are co-issuers
of the 6.75% senior notes due March 1, 2019. Kraton Polymers Capital Corporation has minimal assets and income. We do not
believe that separate financial information concerning the Issuers would provide additional information that would be material
to investors in making an investment decision.
F-47
KRATON PERFORMANCE POLYMERS, INC.
CONSOLIDATING STATEMENT OF CASH FLOWS
Year Ended December 31, 2011
(In thousands)
Cash flows provided by (used in) operating
activities ......................................................
$
0 $
(26,158 ) $
16,973 $
73,960 $
0 $
64,775
Kraton
Kraton
Polymers
LLC(1)
Guarantor
Subsidiaries
Non-
Guarantor
Subsidiaries Eliminations Consolidated
Cash flows provided by (used in) investing
activities:
Proceeds from intercompany loans ........
Purchase of property, plant and
equipment, net of proceeds from
sales ...................................................
Purchase of software and other
intangibles .........................................
Net cash provided by (used in)
investing
activities...................................
Cash flows provided by (used in) financing
activities:
Proceeds from debt ................................
Repayments of debt ...............................
Cash contribution from member ............
Cash distribution to member ..................
Proceeds from the exercise of stock
options ...............................................
Proceeds from insurance note payable ...
Repayments of insurance note payable ..
Debt issuance costs ................................
Proceeds from (payments on)
intercompany loans ...........................
Net cash provided by (used in)
0
26,278
0
0
(26,278 )
0
0
0
0
(44,591 )
(15,720 )
0
(60,311 )
0
(4,072 )
(57 )
0
(4,129 )
0
26,278
(48,663 )
(15,777 )
(26,278 )
(64,440 )
0
0
0
(8,271 )
400,000
(393,160 )
8,271
0
8,271
0
0
0
0
4,734
(4,734 )
(15,231 )
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
(8,271 )
8,271
400,000
(393,160 )
0
0
0
0
0
0
8,271
4,734
(4,734 )
(15,231 )
0
0
6,300
(32,578 )
26,278
0
financing
activities...................................
Effect of exchange rate differences on cash ....
Net increase (decrease) in cash
and cash equivalents ................
Cash and cash equivalents, beginning of
period ..........................................................
Cash and cash equivalents, end of period ........
$
0
0
0
0
0 $
(120 )
0
6,300
0
(32,578 )
(4,386 )
26,278
0
(120 )
(4,386 )
0
(25,390 )
21,219
0
(4,171 )
0
0 $
31,420
6,030 $
61,330
82,549 $
0
0 $
92,750
88,579
(1) Kraton Polymers LLC and Kraton Polymers Capital Corporation, a financing subsidiary, collectively, the Issuers, are co-issuers
of the 6.75% senior notes due March 1, 2019. Kraton Polymers Capital Corporation has minimal assets and income. We do not
believe that separate financial information concerning the Issuers would provide additional information that would be material
to investors in making an investment decision.
F-48
17. Selected Quarterly Financial Data (Unaudited)
The following table sets forth a summary of Kraton Performance Polymers, Inc.’s quarterly financial information for each of the
four quarters ended December 31, 2013 and December 31, 2012:
First
Second
Third
Fourth
Quarter(1)
Quarter(2)
Quarter(3)
Quarter(4)
Total
(in thousands, except per share data)
2013
Sales revenue ........................................................................... $ 340,107 $ 334,543 $ 327,109 $ 290,362 $ 1,292,121
225,832
Gross profit ..............................................................................
25,078
Operating income .....................................................................
Net income (loss) attributable to Kraton ..................................
(618 )
Earnings (loss) per common share
59,911
10,786
(3,748 )
47,450
1,793
(5,598 )
59,861
10,670
3,829
58,610
1,829
4,899
Basic ...............................................................................
Diluted ............................................................................
(0.12 )
(0.12 )
0.12
0.12
(0.17 )
(0.17 )
0.15
0.15
(0.02 )
(0.02 )
Weighted average common shares outstanding
Basic ...............................................................................
Diluted ............................................................................
32,062
32,062
32,073
32,378
32,073
32,073
32,111
32,439
32,096
32,096
2012
Sales revenue ........................................................................... $ 408,313 $ 375,756 $ 342,635 $ 296,418 $ 1,423,122
231,442
Gross profit ..............................................................................
31,888
Operating income (loss) ...........................................................
Net income (loss) attributable to Kraton ..................................
(16,191 )
Earnings (loss) per common share
42,753
(9,638 )
(15,499 )
39,690
(7,407 )
(29,452 )
75,519
25,647
16,353
73,480
23,286
12,407
Basic ...............................................................................
Diluted ............................................................................
0.51
0.50
0.38
0.38
(0.48 )
(0.48 )
(0.91 )
(0.91 )
(0.50 )
(0.50 )
Weighted average common shares outstanding
Basic ...............................................................................
Diluted ............................................................................
31,908
32,248
31,930
32,172
31,943
31,943
31,975
31,975
31,939
31,939
(1) During the first quarter of 2013, we charged $5.0 million to interest expense, related to the write-off of unamortized debt
issuance costs in connection with the refinancing of our credit facility and $0.7 million related to the termination and settlement
of our interest rate swap agreement. During the first quarter of 2012, we recognized charges of $6.2 million associated with a
property tax dispute in France, of which $5.6 million is recorded in cost of goods sold and $0.6 million is recorded in selling,
general and administrative expenses, offset by $6.8 million associated with the LBI settlement, which is recorded in cost of
goods sold.
(2) During the second quarter of 2013, we incurred charges of approximately $1.1 million, related to professional fees for our
proposed combination with the styrenic block copolymer (“SBC”) operations of LCY Chemical Corp., which are recorded in
selling, general and administrative expenses. During the second quarter of 2012, we recognized $2.8 million for storm related
charges and $1.0 million related to severance, which is included cost of goods sold.
(3) During the third quarter of 2013, we incurred charges of approximately $3.5 million, attributable to the MACT related
production downtime at our Belpre, Ohio facility, which is recorded in costs of goods sold, and charges of approximately $1.0
million, related to professional fees for our proposed combination with the SBC operations of LCY Chemical Corp., which are
recorded in selling, general and administrative expenses. During the third quarter of 2012, we recognized $5.4 million for
impairment related charges.
(4) During the fourth quarter of 2013, we incurred charges of approximately $7.1 million, related to professional fees for our
proposed combination with the SBC operations of LCY Chemical Corp., and charges of approximately $0.5 million, related to
restructuring costs, which are primarily recorded in selling, general and administrative expenses. During the fourth quarter of
2012, we recognized $1.1 million related to a retirement plan settlement charge associated with a disbursement from a benefit
plan upon the retirement of an employee, which is included in selling, general and administrative expenses.
Basic and diluted earnings per share are computed independently for each of the quarters presented. Therefore, the sum of
quarterly basic and diluted per share information may not equal annual basic and diluted earnings per share.
F-49
18. Subsequent Events
On January 28, 2014, we executed a definitive agreement to combine with the styrenic block copolymer (“SBC”) operations of
Taiwan-based LCY Chemical Corp. (“LCY”). The combination agreement calls for LCY to contribute its SBC business in exchange
for newly issued shares in the combined company, such that Kraton’s shareholders and LCY will each own 50% of the outstanding
shares of the combined enterprise. The combined company will be incorporated in the UK and the shares will be listed on the NYSE.
In the first quarter of 2014 we experienced weather-related downtime at our Belpre, Ohio facility. In addition, our facility in
Berre, France experienced an operating disruption resulting from a small fire which impacted one of the production lines at this
facility. The aggregate negative impact of these events is currently estimated to be approximately $12.0 million, comprised of
incremental expenses incurred to resume normal operations and the impact of under-absorbed fixed production costs.
We have evaluated significant events and transactions that occurred after the balance sheet date and determined that there were
no events or transactions other than those disclosed above that would require recognition or disclosure in our consolidated financial
statements for the period ended December 31, 2013.
F-50
Report of Independent Registered Public Accounting Firm
The Board of Directors and Stockholders
Kraton Performance Polymers, Inc.:
Under date of February 27, 2014, we reported on the consolidated balance sheets of Kraton Performance Polymers, Inc. and
subsidiaries as of December 31, 2013 and 2012, and the related consolidated statements of operations, comprehensive income (loss),
changes in equity, and cash flows for each of the years in the three-year period ended December 31, 2013, which are included in
Kraton Performance Polymers, Inc.’s annual report on Form 10-K. In connection with our audits of the aforementioned consolidated
financial statements, we also audited the related consolidated financial statement schedule II—Valuation and Qualifying Accounts and
Reserves (financial statement schedule) in Kraton Performance Polymers, Inc.’s annual report on Form 10-K. This financial statement
schedule is the responsibility of Kraton Performance Polymers, Inc.’s management. Our responsibility is to express an opinion on this
financial statement schedule based on our audits.
In our opinion, the financial statement schedule, when considered in relation to the basic consolidated financial statements taken
as a whole, presents fairly, in all material respects, the information set forth therein.
/s/ KPMG LLP
Houston, Texas
February 27, 2014
F-51
KRATON PERFORMANCE POLYMERS, INC.
SCHEDULE II—VALUATION AND QUALIFYING ACCOUNTS AND RESERVES
For the Years Ended December 31, 2013, 2012, and 2011
(In thousands)
Balance
at Beginning
of Period
Net
Expenses
Write-offs
Balance
at End of
Period
Allowance for doubtful accounts:
Year ended December 31, 2013 ............................................................. $
Year ended December 31, 2012 ............................................................. $
Year ended December 31, 2011 ............................................................. $
401 $
549 $
947 $
6 $
(23 ) $
(26 ) $
(92 ) $
(125 ) $
(372 ) $
315
401
549
Inventory reserves:
Year ended December 31, 2013 ............................................................. $
Year ended December 31, 2012 ............................................................. $
Year ended December 31, 2011 ............................................................. $
11,179 $
11,843 $
8,269 $
(693 ) $
(665 ) $
3,485 $
(10 ) $
1 $
89 $
10,476
11,179
11,843
Balance
at Beginning
of Period
Net
Expenses
Foreign
Currency
Balance
at End of
Period
F-52
Kraton At A Glance
Financial Highlights
(In thousands, except per share data)
2013
2012
2011
Year Ended December 31,
Operating revenues
Income from operations
Net income (loss) attributable to Kraton
EBITDA(1)
Adjusted EBITDA(1)
Adjusted EBITDA at ECRC(1)
Earnings (loss) per common share – diluted
Cash flows from operating activities
Capital expenditures
Working capital
Long-term debt, net of current portion
Total stockholders’ equity
$ 1,292,121
$ 25,078
$ (618)
$ 88,790
$ 110,169
$ 140,906
$ (0.02)
$ 105,456
$ 86,205
$ 478,148
$ 350,989
$ 554,398
$ 1,423,122
$ 31,888
$ (16,191)
$ 96,972
$ 113,309
$ 143,842
$ (0.50)
$ 146,333
$ 69,609
$ 552,875
$ 432,943
$ 492,215
$ 1,437,479
$ 123,849
$ 90,925
$ 184,128
$ 194,327
$ 127,995
2.81
$
$ 64,775
$ 64,440
$ 504,445
$ 385,000
$ 517,794
(1) EBITDA represents net income before interest, taxes, depreciation and amortization. Adjusted EBITDA at estimated current replacement cost (ECRC) is Adjusted EBITDA net of
the impact of the spread between the FIFO basis of accounting and ECRC. A reconciliation of net income or loss attributable to Kraton to EBITDA, Adjusted EBITDA and Adjusted
EBITDA at ECRC is presented in Item 6 of the Annual Report on Form 10-K for the year ended December 31, 2013 included in this annual report.
Corporate Profile
Kraton Performance Polymers, Inc. (NYSE: KRA) is a leading global producer of engineered polymers used to enhance
the performance of products that touch virtually every aspect of our lives. The original inventor of styrenic block copolymer
(SBC) chemistry in the 1960s, Kraton has a history of innovation dating back almost 50 years that drives growth for its
customers. The company has a broad portfolio of value-enhancing polymers that are used in a wide variety of appli cations
including consumer and personal care items, adhesives and coatings, electronics, medical supplies, automotive com-
ponents, and paving and roofing materials. Kraton offers its products to a diverse group of more than 800 customers
in over 60 countries worldwide and collaborates with customers on custom solutions to meet specific needs.
Our Mission
Our Vision
Our Core Values
Create exceptional value
by “Giving Innovators Their
Edge®” better than all others
in the industry we lead.
Guided by our Core Values,
we will be an admired
Fortune 500 specialty
chemical company with
consistent earnings per
share growth, a sustaining
Vitality Index, industry-
leading margins, delivering
returns above our cost
of capital.
The health of our people
Compliant, respectful and ethical behavior
Talented people, enthusiastic teams
Safety:
Integrity:
Verve:
Relationships: Our customers and all other stakeholders
Innovation:
Results:
Creative solutions
Making it happen...Safely!
Shareholder Information
Investor Relations, Form 10-K
and Other Information
We will furnish without charge to each
person whose proxy is being solicited,
upon request of any such person, a
copy of our Annual Report on Form
10-K for the year ended December 31,
2013, as filed with the Securities and
Exchange Commission, including the
consolidated financial statements and
schedules thereto, but not the exhibits.
Our Annual Report on Form 10-K as
filed with the Securities and Exchange
Commission is also available on our
website under the “Investor Relations”
tab at www.kraton.com. Information
on our website or any other website
is not incorporated by reference into
or otherwise made a part of this report.
Please contact:
Investor Relations
Kraton Performance Polymers, Inc.
15710 John F. Kennedy Boulevard
Suite 300
Houston, Texas 77032
Phone: 281-504-4700
E-mail: Investor.Relations@Kraton.com
Transfer Agent and Registrar
If you have any questions regarding
your stock certificate or changes
to your address, please contact:
Computershare Investor Services
250 Royall Street
Canton, Massachusetts 02021
Phone: 303-262-0678
Directors and Officers
Board of Directors
Dan F. Smith 2, 3*
Chairman,
Former Chairman, President
and Chief Executive Officer,
Lyondell Chemical Company
Richard C. Brown 2*, 3
Managing Director,
Sun Capital Partners, Inc.
Anna C. Catalano 2
Former Group Vice President, BP plc
Steven J. Demetriou 4*
Chairman and Chief Executive Officer,
Aleris International, Inc.
Kevin M. Fogarty 3
President and Chief Executive Officer,
Kraton Performance Polymers, Inc.
Dominique Fournier 4
Former Chief Executive Officer,
Infineum International, Limited
John J. Gallagher, III 1, 4
Chief Executive Officer,
Stellar CJS Holdings, LLC
Barry J. Goldstein 1*, 4
Retired Executive Vice President
and Chief Financial Officer,
Office Depot, Inc.
Francis S. Kalman 1
Former Executive Vice President,
McDermott International, Inc.
Karen A. Twitchell 1, 2
Former Executive Vice President
and Chief Financial Officer,
Landmark Aviation
Committees
1 Audit
2 Compensation
3 Executive
4 Nominating and Corporate Governance
* Denotes Chairperson
Corporate Officers
Kevin M. Fogarty
President and Chief Executive Officer
Thomas A. Abrey
Vice President, Health, Safety,
Environmental and Security
Damian T. Burke
Vice President, Corporate Development
Melinda S. Conley
Vice President, Human Resources
Stephen W. Duffy
Vice President, General Counsel
and Secretary
Lothar P.F. Freund
Vice President, Technology
Holger R. Jung
Vice President, Sales and Marketing
G. Scott Lee
Vice President, Operations
Stephen E. Tremblay
Vice President, Chief Financial Officer
Independent Auditors
KPMG
Suite 4500
811 Main Street
Houston, Texas 77002
Stock Exchange Listing
Kraton Performance Polymers, Inc.
Common Stock is listed on the
New York Stock Exchange under
the symbol KRA.
Annual Meeting
The company’s annual meeting
of shareholders is scheduled
for Tuesday, June 3, 2014, at
1:00 p.m. at:
Sheraton North Houston
15700 John F. Kennedy Boulevard
Houston, Texas 77032
X
T
,
N
O
T
S
U
O
H
,
S
D
N
A
R
B
E
G
A
V
A
S
:
I
N
G
S
E
D
Forward-looking Statements
Some of the statements in this annual report to stockholders contain forward-looking statements within the meaning of the Private Securities Litigation
Reform Act of 1995, including, without limitation, discussions of strategy, plans or intentions; anticipated benefits of or performance of our products;
beliefs regarding opportunities for new, high-margin applications and other innovations; our investment in the joint venture with Formosa Petrochemical
Corporation; our proposed combination with the Styrenic Block Copolymer (“SBC”) business of LCY Chemical Corp. (“LCY”), the expectation that such
combination will close in the fourth quarter of 2014 and expected synergies and other benefits therefrom and costs associated therewith; expectations
regarding high-margin applications; our plans and expectations regarding our planned Asia expansion project; and our expectations regarding the
startup of our semi-works facility in Belpre, Ohio, during the first quarter of 2014. Such forward-looking statements involve known and unknown risks,
uncertainties, assumptions and other important factors that could cause the actual results, performance or our achievements, or industry results, to differ
materially from historical results, any future results, or performance or achievements expressed or implied by such forward-looking statements. Please refer
to our Annual Report on Form 10-K included herewith for further identification of forward-looking statements, and discussion of associated risks and
important factors that could cause our actual results to differ materially from those expressed as forward-looking statements. Forward-looking statements
are based on current plans, estimates and projections, and, therefore, you should not place undue reliance on them. Forward-looking statements speak
only as of the date they are made, and we undertake no obligation to update them publicly in light of new information or future events.
Advancing Opportunity
Kraton Performance Polymers
2013 Annual Report
K
r
a
t
o
n
P
e
r
f
o
r
m
a
n
c
e
P
o
y
m
e
r
s
l
2
0
1
3
A
n
n
u
a
l
R
e
p
o
r
t
Kraton Performance Polymers, Inc.
15710 John F. Kennedy Boulevard
Suite 300
Houston, Texas 77032
Phone: 281-504-4700